bisoprolol has been researched along with Heart Failure in 300 studies
Bisoprolol: A cardioselective beta-1 adrenergic blocker. It is effective in the management of HYPERTENSION and ANGINA PECTORIS.
Heart Failure: A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Bisoprolol is commonly used to treat moderate or severe chronic stable heart failure, coronary heart disease, and hypertension." | 9.51 | The Efficacy and Safety of Bisoprolol in the Treatment of Myocardial Infarction with Cardiac Insufficiency. ( Wang, Y, 2022) |
| "Among patients with permanent atrial fibrillation and symptoms of heart failure treated with low-dose digoxin or bisoprolol, there was no statistically significant difference in quality of life at 6 months." | 9.34 | Effect of Digoxin vs Bisoprolol for Heart Rate Control in Atrial Fibrillation on Patient-Reported Quality of Life: The RATE-AF Randomized Clinical Trial. ( Bunting, KV; Calvert, MJ; Camm, AJ; Deeks, JJ; Gill, SK; Griffith, M; Haynes, S; Jones, JC; Kirchhof, P; Kotecha, D; Lip, GYH; Mehta, S; Rahimi, K; Stanbury, M; Steeds, RP; Strauss, VY; Townend, JN, 2020) |
| "The comparative tolerability, efficacy, and safety of bisoprolol and carvedilol have not been established in Japanese patients with heart failure and reduced ejection fraction (HFrEF)." | 9.30 | Tolerability, Efficacy, and Safety of Bisoprolol vs. Carvedilol in Japanese Patients With Heart Failure and Reduced Ejection Fraction - The CIBIS-J Trial. ( Kinugawa, S; Komuro, I; Masuyama, T; Momomura, SI; Murohara, T; Saito, Y; Tsutsui, H, 2019) |
| "TY-0201 (TY) is a transdermal formulation of bisoprolol that is the free base of bisoprolol fumarate (BO), a drug widely used to treat chronic heart failure (CHF)." | 9.24 | Efficacy and Safety of Switching From Oral Bisoprolol to Transdermal Patch in Japanese Patients With Chronic Heart Failure. ( Daimon, M; Dohi, N; Kinugawa, K; Komuro, I; Momomura, SI; Okamoto, H; Saito, Y; Sakata, Y; Yamamoto, K; Yasumura, Y, 2017) |
| "This study was designed to elucidate differences in effects of 2 beta blockers, bisoprolol and carvedilol, in patients with chronic heart failure." | 9.24 | Protective effects of bisoprolol against myocardial injury and pulmonary dysfunction in patients with chronic heart failure. ( Abe, S; Amano, H; Arikawa, T; Haruyama, A; Inami, S; Inoue, T; Node, K; Sakuma, M; Tanaka, A; Toyoda, S, 2017) |
| "We investigated bisoprolol pharmacokinetics, including longitudinal changes and importance of patient characteristics in chronic heart failure." | 9.22 | Bisoprolol pharmacokinetics and body composition in patients with chronic heart failure: a longitudinal study. ( Anker, SD; Cvan Trobec, K; Grabnar, I; Kerec Kos, M; Lainscak, M; Rosano, G; Trontelj, J; Vovk, T, 2016) |
| "Bisoprolol fumarate (bisoprolol) is a β-blocker widely used to treat chronic heart failure (CHF)." | 9.19 | Efficacy and safety of bisoprolol fumarate compared with carvedilol in Japanese patients with chronic heart failure: results of the randomized, controlled, double-blind, Multistep Administration of bisoprolol IN Chronic Heart Failure II (MAIN-CHF II) stud ( Hori, M; Izumi, T; Matsuzaki, M; Nagai, R, 2014) |
| "The aim of our study was to examine regional differences in the demographics, etiology, risk factors, comorbidities and treatment of female patients with heart failure (HF) in the Cardiac Insufficiency BIsoprolol Study in ELDerly (CIBIS-ELD) clinical trial." | 9.19 | Regional differences among female patients with heart failure from the Cardiac Insufficiency BIsoprolol Study in ELDerly (CIBIS-ELD). ( Apostolovic, S; Djordjevic-Radojkovic, D; Düngen, HD; Gelbrich, G; Inkrot, S; Jankovic-Tomasevic, R; Lainscak, M; Musial-Bright, L; Pavlovic, M; Putnikovic, B; Radovanovic, S; Salinger-Martinovic, S; Stanojevic, D; Tahirovic, E; Tomasevic, M; Waagstein, F, 2014) |
| "Ivabradine (IVA), a selective If current inhibitor decreasing the heart rate (HR) in patients with sinus rhythm, has been added to the most recent European Guidelines on heart failure." | 9.17 | Ivabradine improves quality of life in subjects with chronic heart failure compared to treatment with β-blockers: results of a multicentric observational APULIA study. ( Benvenuto, A; Buta, F; De Viti, D; Masciocco, L; Massari, F; Meliota, G; Riccioni, G; Saracino, P; Speziale, G, 2013) |
| "The aim of the study was to develop a population pharmacokinetic (PK) model for clearance of bisoprolol in patients with congestive heart failure (CHF)." | 9.17 | Population pharmacokinetics of bisoprolol in patients with chronic heart failure. ( Apostolović, S; Deljanin-Ilic, M; Ilic, S; Jankovic, SM; Jevtovic-Stoimenov, T; Marinkovic, D; Milovanovic, JR; Nikolic, VN; Pesic, S; Stanojevic, D; Stefanovic, N; Velickovic-Radovanović, R; Zecevic, DR; Zivanovic, S, 2013) |
| " carvedilol in 883 elderly heart failure patients with reduced or preserved left ventricular ejection fraction in 41 European centres." | 9.15 | Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial. ( Anker, SD; Apostolovic, S; Dietz, R; Doehner, W; Düngen, HD; Edelmann, F; Eschenhagen, T; Gelbrich, G; Herrmann-Lingen, C; Inkrot, S; Krotin, M; Lainscak, M; Mehrhof, F; Neskovic, AN; Prettin, C; Putnikovic, B; Rau, T; Sakac, D; Tahirovic, E; Töpper, A; Waagstein, F; Wachter, R, 2011) |
| "Carvedilol and bisoprolol reduce QT dispersion (QTD) in chronic heart failure (CHF)." | 9.14 | The comparative effects of long-term carvedilol versus bisoprolol therapy on QT dispersion in patients with chronic heart failure. ( Aygul, MU; Aygul, N; Duzenli, MA; Ozdemir, K, 2009) |
| "In CIBIS III, initiating chronic heart failure (CHF) treatment with bisoprolol (target dose 10 mg q." | 9.14 | The effect of treatment with bisoprolol-first versus enalapril-first on cardiac structure and function in heart failure. ( Goulder, M; Meyer, WR; van de Ven, LL; van Veldhuisen, DJ; Willenheimer, R; Zilahi, Z, 2010) |
| "To assess the clinical effects and safety profile of initial monotherapy with either bisoprolol or enalapril in elderly patients with heart failure (HF)." | 9.13 | Clinical effects of initial 6 months monotherapy with bisoprolol versus enalapril in the treatment of patients with mild to moderate chronic heart failure. Data from the CIBIS III Trial. ( Dobre, D; Goulder, MA; Krum, H; van Veldhuisen, DJ; Willenheimer, R, 2008) |
| "Body weight increased significantly in the carvedilol group (mean change + 2." | 9.13 | Effect of selective and non-selective beta-blockers on body weight, insulin resistance and leptin concentration in chronic heart failure. ( Gobec, L; Kovacić, D; Lainscak, M; Marinsek, M; Podbregar, M, 2008) |
| "To compare the effects of carvedilol and bisoprolol on lung function in patients with chronic heart failure (CHF)." | 9.12 | Lung function with carvedilol and bisoprolol in chronic heart failure: is beta selectivity relevant? ( Agostoni, P; Apostolo, A; Bussotti, M; Cattadori, G; Contini, M; Fiorentini, C; Palermo, P; Sciomer, S, 2007) |
| "To analyze the effect of bisoprolol in patients with stable congestive heart failure and who tolerated beta-blockers." | 9.11 | Effects of bisoprolol in patients with stable congestive heart failure. ( Bauters, C; Dagorn, J; de Groote, P; Delour, P; Lamblin, N; Millaire, A; Tison, E; Verkindère, C, 2004) |
| "Patients (n=54) with NYHA class III-IV heart failure and left ventricular ejection fraction < or =35% were randomized either to treatment with bisoprolol (1." | 9.10 | [Clinical, hemodynamic and neurohumoral effects of long-term therapy of patients with severe chronic heart failure with beta-adrenoblocker bisoprolol]. ( Baklanova, NA; Belenkov, IuN; Mareev, VIu; Masenko, VP; Narusov, OIu; Nasonova, SN; Skvortsov, AA; Sychev, AV, 2003) |
| "The addition of bisoprolol to the standart therapy in patients with mild to moderate heart failure is well tolerated and improves functional capacity." | 9.10 | [Assessment of the efficacy of bisoprolol administration by cardiopulmonary exercise testing in patients with heart failure]. ( Akbulut, T; Aksoy, S; Bilsel, T; Dağ, O; Dayi, SU; Köse, H; Satiroğlu, O; Sayar, N; Terzi, S; Yeşilçimen, K, 2003) |
| "To evaluate the effect of beta1-selective blocker bisoprolol on the QT and QTc dispersion in patients with chronic heart failure and to compare the responses to bisoprolol in patients with different etiologies." | 9.09 | Effect of bisoprolol on QT dispersion in patients with congestive heart failure--the etiology-dependent response. ( Chen, Y; Li, XP; Peng, DQ; Zhao, SP, 2001) |
| "Economic analysis of bisoprolol plus standard therapy versus placebo plus standard therapy in the treatment of chronic heart failure in Germany." | 9.09 | [Cost effectiveness of bisoprolol in treatment of heart failure in Germany. An analysis based on the CIBIS-II study]. ( Follath, F; Paschen, B; Schwenkglenks, M; Szucs, TD, 2000) |
| "The effect of beta-blockade on heart-rate variability was assessed at different heart rates in 52 patients with heart failure included in the randomized, placebo-controlled, Cardiac Insufficiency Bisoprolol Study (CIBIS)." | 9.08 | Effects of beta-blockade with bisoprolol on heart rate variability in advanced heart failure: analysis of scatterplots of R-R intervals at selected heart rates. ( Copie, X; Guize, L; Jaillon, P; Le Heuzey, JY; Lechat, P; Pousset, F, 1996) |
| "To further evaluate the mechanism of beta-blocker-induced benefits in heart failure, the relationships between bisoprolol-induced hemodynamic effects and survival were studied during the Cardiac Insufficiency BIsoprolol Study (CIBIS)." | 9.08 | Prognostic value of bisoprolol-induced hemodynamic effects in heart failure during the Cardiac Insufficiency BIsoprolol Study (CIBIS). ( Boissel, JP; Escolano, S; Golmard, JL; Henneman, JA; Hetzel, M; Jaillon, P; Lardoux, H; Lechat, P; Maisch, B; Mallet, A; Witchitz, S, 1997) |
| "The Cardiac Insufficiency Bisoprolol Study (CIBIS) demonstrates that, for patients with heart failure of different etiologies, the administration of the beta(1)-adrenoceptor blocker bisoprolol adjuvant to the standard therapy leads to a significant avoidance of hospital admissions." | 9.08 | [Cost effectiveness of bisoprolol in heart failure. Economic evaluation of the Cardiac Insufficiency Bisoprolol Study (CIBIS) for Germany]. ( Brecht, JG; Paschen, B; Schädlich, PK, 1997) |
| "To define the role of bisoprolol, a highly selective beta(1)-antagonist in congestive heart failure due to systolic dysfunction." | 8.84 | Bisoprolol for congestive heart failure. ( Gustafsson, F; Rosenberg, J, 2008) |
| "To the best of our knowledge, there is no study that has conducted a review investigating the clinical efficacy and safety of bisoprolol combined with trimetazidine on chronic heart failure (CHF) patients with chronic obstructive pulmonary disease (COPD)." | 8.02 | Effects of trimetazidine in combination with bisoprolol in patients with chronic heart failure and concomitant chronic obstructive pulmonary disease: A protocol for systematic review and meta-analysis. ( Fu, B; Ma, S; Zhang, X, 2021) |
| "To analyze the application effect of bisoprolol combined with sacubitril valsartan sodium tablets in the cardiac rehabilitation of patients with acute myocardial infarction combined with left heart failure after percutaneous coronary intervention (PCI)." | 8.02 | Study on the application effect of bisoprolol combined with sacubitril valsartan sodium tablets in the cardiac rehabilitation of patients with acute myocardial infarction combined with left heart failure after percutaneous coronary intervention (PCI). ( Chen, C; Li, Y; Peng, Y; Wu, X, 2021) |
| "Although bisoprolol has been established to prevent heart failure (HF), finding the optimal dose remains a challenge." | 7.96 | Association between bisoprolol plasma concentration and worsening of heart failure: (CVI ARO 6). ( Arita, T; Kano, H; Kato, Y; Matsuno, S; Nagashima, K; Oikawa, Y; Otsuka, T; Sagara, K; Semba, H; Suzuki, S; Tanabe, G; Uejima, T; Yagi, N; Yajima, J; Yamashita, T, 2020) |
| "The study aimed to investigate the effects of the sodium-glucose co-transporter 2 (SGLT2) inhibitor empagliflozin on chronic heart failure (HF) in normoglycemic rats." | 7.96 | Comparative efficacy of empagliflozin and drugs of baseline therapy in post-infarct heart failure in normoglycemic rats. ( Ivkin, D; Karpov, A; Kaschina, E; Krasnova, M; Kulikov, A; Okovityi, S; Smirnov, A, 2020) |
| "Although bisoprolol is used widely to treat patients with heart failure (HF), little information is available regarding the association between the dose of bisoprolol administered and the bisoprolol plasma concentration (Bis-PC) in real-world clinical practice." | 7.96 | Association Between Dose and Plasma Concentration of Bisoprolol in Patients with Heart Failure (CVI ARO 6). ( Arita, T; Kano, H; Kato, Y; Matsuno, S; Nagashima, K; Oikawa, Y; Otsuka, T; Sagara, K; Semba, H; Suzuki, S; Tanabe, G; Uejima, T; Yagi, N; Yajima, J; Yamashita, T, 2020) |
| "The work was aimed at studying the relationship between the efficiency of bisoprolol and the polymorphism of β1- and β2-adrenergic receptors (β-AR) genes in patients with heart failure." | 7.91 | [POLYMORPHISM OF THE BETA1- AND BETA2-ADRENORECEPTOR GENES AND BISOPROLOL EFFICIENCY IN PATIENTS WITH HEART FAILURE]. ( Bondar, T; Galchinskaya, V; Isayeva, G; Lozyk, T; Pyvovar, S; Rudyk, I, 2019) |
| "Whether the reduction of heart rate with ivabradine (IVA) could affect sympathetic activation and cardiac innervation in heart failure (HF) remains unknown." | 7.91 | Modulation of Sympathetic Activity and Innervation With Chronic Ivabradine and β-Blocker Therapies: Analysis of Hypertensive Rats With Heart Failure. ( Akiyama, T; Iwanaga, Y; Kakehi, K; Miyazaki, S; Shimizu, S; Sonobe, T; Watanabe, H; Yamamoto, H, 2019) |
| "Heart failure is a highly prevalent cardiovascular complication among patients receiving long-term hemodialysis, but the benefits of carvedilol, bisoprolol, and metoprolol controlled release/extended release on the outcomes of these patients remain unclear." | 7.83 | Prognostic Benefits of Carvedilol, Bisoprolol, and Metoprolol Controlled Release/Extended Release in Hemodialysis Patients with Heart Failure: A 10-Year Cohort. ( Chen, TH; Hong, CY; Sue, YM; Tang, CH; Wang, CC, 2016) |
| "Bisoprolol, an antagonist of β1-adrenergic receptors, is effective in reducing the morbidity and mortality in patients with heart failure (HF)." | 7.83 | β1-Adrenergic blocker bisoprolol reverses down-regulated ion channels in sinoatrial node of heart failure rats. ( Du, Y; Han, K; Huang, X; Ma, A; Wang, T; Wu, G; Xi, Y; Zhang, J, 2016) |
| "The objective of this study was to establish the benefit of bisoprolol up-titration toward recommended dosage targets, versus lower-dose maintenance, in heart failure (HF) patients with systolic dysfunction." | 7.83 | Beneficial Effect on Surrogate Markers of Heart Failure with Bisoprolol Up-Titration to Recommended Targets in Korean Patients with Heart Failure and Left Ventricular Systolic Dysfunction. ( Cha, TJ; Choi, DJ; Choi, SW; Han, SW; Hwang, KK; Jeon, H; Kim, HJ; Kim, JH; Kim, SH; Kim, YJ; Ryu, KH; Shim, WJ; Shin, MS; Yoo, BS, 2016) |
| "To identify the prevalence and characteristics of recently hospitalized chronic heart failure (CHF) patients in community care who meet the indication for ivabradine." | 7.81 | Characterizing patients with chronic heart failure in community care after hospitalization: a potential role for ivabradine. ( Charles, H; Cochrane, L; Elder, DH; Lang, CC; Mohan, M, 2015) |
| "Data were retrospectively collected from 23 patients with HF [age 57±18 years, left ventricular ejection fraction (LVEF) 33±15%] who could not increase the dosage of carvedilol because of dizziness or hypotension, defined as systolic blood pressure<90 mmHg." | 7.79 | Switching from carvedilol to bisoprolol ameliorates adverse effects in heart failure patients with dizziness or hypotension. ( Asano, Y; Ichibori, Y; Kanzaki, M; Komuro, I; Minamiguchi, H; Mizote, I; Ohtani, T; Sakata, Y; Taniguchi, T, 2013) |
| "In experimental PH, treatment with bisoprolol delays progression toward right heart failure, and partially preserves RV systolic and diastolic function." | 7.78 | Bisoprolol delays progression towards right heart failure in experimental pulmonary hypertension. ( Bogaards, SJ; de Man, FS; Handoko, ML; Paulus, WJ; Postmus, PE; Schalij, I; van Ballegoij, JJ; van der Velden, J; Vonk-Noordegraaf, A; Westerhof, N, 2012) |
| " We present a case where carvedilol was replaced with bisoprolol resulting in acute urinary retention." | 7.77 | Carvedilol for the treatment of benign prostatic hypertrophy in patients with heart failure? ( Lindenfeld, J; Page, RL; Rohrer, CK; Shakar, SF, 2011) |
| "Although carvedilol and bisoprolol are effective medicines for the treatment of patients with heart failure (HF), only a few reports have compared their effects." | 7.76 | Comparative effects of carvedilol vs bisoprolol for severe congestive heart failure. ( Hachiya, H; Haraguchi, G; Hirao, K; Inagaki, H; Isobe, M; Kawabata, M; Kimura, S; Konishi, M, 2010) |
| "At present only bisoprolol, metoprolol succinate, nebivolol, and carvedilol are considered to be beta adrenoblockers with proven efficacy relative to course and prognosis of chronic heart failure (CHF)." | 7.76 | [Clinical, hemodynamic and neurohumoral effects of switching patients with chronic heart failure from not recommended -adrenoblockers to bisoprolol in ambulatory practice]. ( Ageev, FT; Ovchinnikov, AG; Seredenina, EM; Zhubrina, ES, 2010) |
| "To assess the effects of bisoprolol on exercise capacity and ventricular function in patients with heart failure." | 7.74 | Effects of bisoprolol on cardiac function and exercise in patients with heart failure. ( Bacal, F; Bocchi, EA; Cruz, Fd; Ferreira, SM; Guimarães, GV; Issa, VS; Rezende, MV, 2007) |
| "Bisoprolol treatment in patients with chronic heart failure was effectively and safely carried out by primary care physicians." | 7.73 | Effects of bisoprolol treatment for chronic heart failure initiated and followed up by primary care physicians. ( Schuchert, A, 2005) |
| "The purpose of this study was to investigate the relation between the Arg389Gly polymorphism of the beta(1)-AR gene and chronic heart failure (CHF) and to evaluate the effect of this polymorphism on clinical response to beta-adrenoceptor blockade (bisoprolol) in patients with CHF." | 7.73 | [Beta1-adrenergic receptor (Arg389Gly) polymorphism and response to bisoprolol in patients with chronic heart failure]. ( Deng, B; Lou, M; Song, HM; Wang, HB; Yu, WP, 2006) |
| "We hypothesized that abnormal oxidative stress in chronic heart failure (CHF) could be related to endothelial damage and platelet activation, and that the vasodilating beta-blocker carvedilol would have beneficial effects on these processes compared with a selective non-vasodilating cardioselective beta-blocker, bisoprolol." | 7.72 | Neither carvedilol nor bisoprolol in maximally tolerated doses has any specific advantage in lowering chronic heart failure oxidant stress: implications for beta-blocker selection. ( Blann, AD; Chin, BS; Gibbs, CR; Lip, GY, 2003) |
| "This is the first study in Spain to show that bisoprolol can be used effectively at the maximum recommended doses, for the outpatient treatment of heart failure." | 7.72 | [Use of bisoprolol in heart failure. The BISOCOR observational study]. ( Alegría Ezquerra, E; Anguita Sánchez, M; Espinosa Caliani, JS; García Saavedra, V; González-Juanatey, JR; Pérez Ojeda, G; Ruiz Ros, JA, 2003) |
| "To elucidate effect of beta-blocker bisoprolol on hibernating myocardium in patients with congestive heart failure (CHF) of ischaemic etiology without concomitant use of angiotensin converting enzyme inhibitors." | 7.72 | [Effect of beta-Blocker Bisoprolol on Function of Hibernating Myocardium in Patients With Chronic Heart Failure of Ischemic Etiology]. ( Ivanenko, VV; Lopatin, IuM; Riazantseva, NV; Tarasov, DL, 2004) |
| "This study considers the cost-effectiveness of bisoprolol in heart failure patients as an adjunctive therapy to usual treatment." | 7.71 | A cost-effectiveness analysis of bisoprolol for heart failure. ( Varney, S, 2001) |
| "The beneficial effects of the beta-blocker bisoprolol on mortality and rate of hospitalisation as well as its safety in patients with chronic heart failure has been proven." | 7.71 | Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure. ( Erdmann, E; Lechat, P; Verkenne, P; Wiemann, H, 2001) |
| "To investigate the cost effectiveness of adding the beta-blocker bisoprolol to standard treatment in patients with congestive heart failure (CHF)." | 7.71 | Cost effectiveness of bisoprolol in the treatment of chronic congestive heart failure in Sweden: analysis using data from the Cardiac Insufficiency Bisoprolol Study II trial. ( Ekman, M; Jönsson, B; Zethraeus, N, 2001) |
| "The cardioprotective effects of bisoprolol were studied in a rat model of severe heart failure induced by autoimmune myocarditis." | 7.71 | Bisoprolol improves survival in rats with heart failure. ( Aizawa, Y; Fuse, K; Hanawa, H; Hasegawa, G; Inoue, M; Ito, M; Kato, K; Kodama, M; Ma, M; Naito, M; Nakazawa, M; Ohta, Y; Wahed, MI; Watanabe, K, 2001) |
| "The cost-effectiveness of adding the beta blocker bisoprolol to standard treatment in patients with congestive heart failure was investigated, based on data from the Cardiac Insufficiency Bisoprolol Study II (CIBIS II)." | 7.71 | [Cost-effectiveness of bisoprolol in chronic heart failure]. ( Dahlström, U; Ekman, M; Höglund, C; Zethraeus, N, 2002) |
| "Bisoprolol was started at 1." | 6.76 | Comparison of effectiveness of carvedilol versus bisoprolol for prevention of postdischarge atrial fibrillation after coronary artery bypass grafting in patients with heart failure. ( Arisi, G; Caminiti, G; Iellamo, F; Madonna, M; Marazzi, G; Massaro, R; Righi, D; Rosano, GM; Volterrani, M, 2011) |
| " We also assessed the relations between dose levels and baseline variables or adverse events." | 6.76 | Influence of order and type of drug (bisoprolol vs. enalapril) on outcome and adverse events in patients with chronic heart failure: a post hoc analysis of the CIBIS-III trial. ( Follath, F; Funck-Brentano, C; Goulder, M; van de Ven, LL; van Veldhuisen, DJ; Willenheimer, R, 2011) |
| "Chronic obstructive pulmonary disease (COPD) frequently coexists in patients with chronic heart failure (CHF) and is a key factor for beta blocker underprescription and underdosing." | 6.76 | Differences between bisoprolol and carvedilol in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized trial. ( Kovacic, D; Lainscak, M; Podbregar, M; Rozman, J; von Haehling, S, 2011) |
| "Heart failure (HF) and chronic obstructive pulmonary disease (COPD) frequently coexist." | 6.74 | Bisoprolol in patients with heart failure and moderate to severe chronic obstructive pulmonary disease: a randomized controlled trial. ( Carter, R; Chalmers, GW; Dunn, FG; Hawkins, NM; MacDonald, MR; McMurray, JJ; Petrie, MC, 2009) |
| "Whether all patients with congestive heart failure (CHF) need to reach the target dose of beta-blocker to obtain a benefit in terms of survival remains uncertain." | 6.71 | Bisoprolol dose-response relationship in patients with congestive heart failure: a subgroup analysis in the cardiac insufficiency bisoprolol study(CIBIS II). ( Funck-Brentano, C; Jaillon, P; Lechat, P; Mary-Krause, M; Simon, T, 2003) |
| "10, NYHA III-IV 29%) to treatment with either bisoprolol or carvedilol, in order to assess and compare the maximally achievable number of patients on treatment with these BB and the maximally achieved dosage during a minimum of 2 months attendance at our out patient heart failure clinic." | 6.71 | Tolerability of beta-blocker initiation and titration with bisoprolol and carvedilol in congestive heart failure -- a randomized comparison. ( Atar, D; Galatius, S; Gustafsson, F; Hildebrandt, PR, 2004) |
| "Bisoprolol-first treatment was noninferior to enalapril-first treatment if the upper limit of the 95% confidence interval (CI) for the absolute between-group difference was <5%, corresponding to a hazard ratio (HR) of 1." | 6.71 | Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. ( Erdmann, E; Follath, F; Krum, H; Lechat, P; Ponikowski, P; Silke, B; Skene, A; van de Ven, L; van Veldhuisen, DJ; Verkenne, P; Willenheimer, R, 2005) |
| "The bisoprolol daily dose was 5 mg once daily." | 6.68 | Effects of bisoprolol on heart rate variability in heart failure. ( Boissel, JP; Copie, X; Fillette, F; Guize, L; Hetzel, M; Jaillon, P; Le Heuzey, JY; Lechat, P; Pousset, F; Remme, W, 1996) |
| "The base of treatment of heart failure is the blockade of the neuro-hormonal system, which includes the use of angiotensin converting enzyme inhibitors (angiotensin receptor blockers in case of angiotensin converting enzyme inhibitors intolerance), beta receptor blockers and mineralocorticoid receptor antagonists." | 6.49 | [Epidemiology and treatment of chronic heart failure; use of bisoprolol]. ( Nagy, V, 2013) |
| "Bisoprolol fumarate is a highly selective beta-1 receptor blocker." | 6.44 | Bisoprolol in the treatment of chronic heart failure. ( de Groote, P; Ennezat, PV; Mouquet, F, 2007) |
| "Bisoprolol is a highly selective beta(1)-adrenoceptor antagonist." | 6.41 | Bisoprolol: a review of its use in chronic heart failure. ( Keating, GM; McGavin, JK, 2002) |
| "We conclude that the amplitude of benefit of the beta-blockers carvedilol, metoprolol and bisoprolol on mortality and morbidity is similar, regardless of the severity of chronic heart failure." | 6.20 | Beta-blocker benefit according to severity of heart failure. ( Bouzamondo, A; Hulot, JS; Lechat, P; Sanchez, P, 2003) |
| "However, orthostatic hypotension (OH) is sometimes caused by BBs." | 5.56 | Bisoprolol transdermal patch improves orthostatic hypotension in patients with chronic heart failure and hypertension. ( Dobashi, S; Fujii, T; Hisatake, S; Ikeda, T; Kabuki, T; Kiuchi, S; Oka, T; Sano, T, 2020) |
| "Bisoprolol is commonly used to treat moderate or severe chronic stable heart failure, coronary heart disease, and hypertension." | 5.51 | The Efficacy and Safety of Bisoprolol in the Treatment of Myocardial Infarction with Cardiac Insufficiency. ( Wang, Y, 2022) |
| "Thyroid storm is a life-threatening disorder that remains a therapeutic challenge." | 5.46 | Switching Therapy from Intravenous Landiolol to Transdermal Bisoprolol in a Patient with Thyroid Storm Complicated by Decompensated Heart Failure and Gastrointestinal Dysfunction. ( Fujita, M; Godo, S; Kawazoe, Y; Kudo, D; Kushimoto, S; Nomura, R; Ozaki, H; Shimokawa, H, 2017) |
| "The long-term use of β-blockers has been shown to improve clinical outcomes among patients with heart failure (HF)." | 5.46 | Older adults with heart failure treated with carvedilol, bisoprolol, or metoprolol tartrate: risk of mortality. ( Bouvier, M; de Denus, S; Deblois, D; Dorais, M; Dubé, MP; Haibe-Kains, B; Jenna, S; Leduc, R; Perreault, S; Rouleau, JL; Tardif, JC; White, M; White-Guay, B, 2017) |
| " After adjustment for age, sex, comorbidities, and severity of HF and COPD, bisoprolol use showed a dose-response survival benefit [low dose: adjusted hazard ratio (HR) = 0." | 5.43 | Carvedilol, Bisoprolol, and Metoprolol Use in Patients With Coexistent Heart Failure and Chronic Obstructive Pulmonary Disease. ( Chang, YS; Chen, TJ; Chou, KT; Hu, YW; Hung, MH; Lee, FY; Liu, CJ; Ou, SM; Perng, DW; Su, VY; Yang, KY, 2016) |
| "Treatment with bisoprolol reversed, to varying degrees, the expression of 10 of the 46 miRNAs whose expression was differentially expressed in the heart failure model." | 5.39 | Regulation by bisoprolol for cardiac microRNA expression in a rat volume-overload heart failure model. ( Chen, C; Geng, T; Jin, T; Li, S; Li, X; Ma, A; Sun, C; Wang, T; Yan, H; Zhang, J; Zhang, X, 2013) |
| "Among patients with permanent atrial fibrillation and symptoms of heart failure treated with low-dose digoxin or bisoprolol, there was no statistically significant difference in quality of life at 6 months." | 5.34 | Effect of Digoxin vs Bisoprolol for Heart Rate Control in Atrial Fibrillation on Patient-Reported Quality of Life: The RATE-AF Randomized Clinical Trial. ( Bunting, KV; Calvert, MJ; Camm, AJ; Deeks, JJ; Gill, SK; Griffith, M; Haynes, S; Jones, JC; Kirchhof, P; Kotecha, D; Lip, GYH; Mehta, S; Rahimi, K; Stanbury, M; Steeds, RP; Strauss, VY; Townend, JN, 2020) |
| "Bisoprolol has anti-arrhythmic effects, but its direct effect on I(Na) in cardiac cells remains unclear." | 5.34 | Bisoprolol inhibits sodium current in ventricular myocytes of rats with diastolic heart failure. ( Deng, CY; Kuang, SJ; Tang, HF; Wu, SL; Zhang, WC, 2007) |
| "Heart failure is characterized by limited exercise tolerance and by a skeletal muscle myopathy with atrophy and shift toward fast fibres." | 5.33 | Skeletal muscle myofibrillar protein oxidation in heart failure and the protective effect of Carvedilol. ( Angelini, A; Dalla Libera, L; Danieli Betto, D; Germinario, E; Gobbo, V; Ravara, B; Vescovo, G, 2005) |
| "The comparative tolerability, efficacy, and safety of bisoprolol and carvedilol have not been established in Japanese patients with heart failure and reduced ejection fraction (HFrEF)." | 5.30 | Tolerability, Efficacy, and Safety of Bisoprolol vs. Carvedilol in Japanese Patients With Heart Failure and Reduced Ejection Fraction - The CIBIS-J Trial. ( Kinugawa, S; Komuro, I; Masuyama, T; Momomura, SI; Murohara, T; Saito, Y; Tsutsui, H, 2019) |
| "Bisoprolol was administered orally at doses of 1." | 5.29 | [Clinical effects of bisoprolol in congestive heart failure due to dilated cardiomyopathy]. ( Li, L; Li, Z, 1995) |
| "To compare the hazard of all-cause, chronic obstructive pulmonary disease (COPD) and heart failure (HF) hospitalization in carvedilol vs." | 5.27 | Relationship between heart failure, concurrent chronic obstructive pulmonary disease and beta-blocker use: a Danish nationwide cohort study. ( Andersen, MP; Capuano, A; Enghusen-Poulsen, H; Gislason, G; Mascolo, A; Mortensen, RN; Rosano, GMC; Rossi, F; Sessa, M; Torp-Pedersen, C, 2018) |
| "The RAte control Therapy Evaluation in permanent Atrial Fibrillation (RATE-AF) trial will enrol 160 participants with a prospective, randomised, open-label, blinded end point design comparing initial rate control with digoxin or bisoprolol." | 5.24 | A review of rate control in atrial fibrillation, and the rationale and protocol for the RATE-AF trial. ( Calvert, M; Deeks, JJ; Griffith, M; Kirchhof, P; Kotecha, D; Lip, GY; Mehta, S; Slinn, G; Stanbury, M; Steeds, RP; Townend, JN, 2017) |
| "TY-0201 (TY) is a transdermal formulation of bisoprolol that is the free base of bisoprolol fumarate (BO), a drug widely used to treat chronic heart failure (CHF)." | 5.24 | Efficacy and Safety of Switching From Oral Bisoprolol to Transdermal Patch in Japanese Patients With Chronic Heart Failure. ( Daimon, M; Dohi, N; Kinugawa, K; Komuro, I; Momomura, SI; Okamoto, H; Saito, Y; Sakata, Y; Yamamoto, K; Yasumura, Y, 2017) |
| "This study was designed to elucidate differences in effects of 2 beta blockers, bisoprolol and carvedilol, in patients with chronic heart failure." | 5.24 | Protective effects of bisoprolol against myocardial injury and pulmonary dysfunction in patients with chronic heart failure. ( Abe, S; Amano, H; Arikawa, T; Haruyama, A; Inami, S; Inoue, T; Node, K; Sakuma, M; Tanaka, A; Toyoda, S, 2017) |
| "We investigated bisoprolol pharmacokinetics, including longitudinal changes and importance of patient characteristics in chronic heart failure." | 5.22 | Bisoprolol pharmacokinetics and body composition in patients with chronic heart failure: a longitudinal study. ( Anker, SD; Cvan Trobec, K; Grabnar, I; Kerec Kos, M; Lainscak, M; Rosano, G; Trontelj, J; Vovk, T, 2016) |
| "Bisoprolol fumarate (bisoprolol) is a β-blocker widely used to treat chronic heart failure (CHF)." | 5.19 | Efficacy and safety of bisoprolol fumarate compared with carvedilol in Japanese patients with chronic heart failure: results of the randomized, controlled, double-blind, Multistep Administration of bisoprolol IN Chronic Heart Failure II (MAIN-CHF II) stud ( Hori, M; Izumi, T; Matsuzaki, M; Nagai, R, 2014) |
| "The aim of our study was to examine regional differences in the demographics, etiology, risk factors, comorbidities and treatment of female patients with heart failure (HF) in the Cardiac Insufficiency BIsoprolol Study in ELDerly (CIBIS-ELD) clinical trial." | 5.19 | Regional differences among female patients with heart failure from the Cardiac Insufficiency BIsoprolol Study in ELDerly (CIBIS-ELD). ( Apostolovic, S; Djordjevic-Radojkovic, D; Düngen, HD; Gelbrich, G; Inkrot, S; Jankovic-Tomasevic, R; Lainscak, M; Musial-Bright, L; Pavlovic, M; Putnikovic, B; Radovanovic, S; Salinger-Martinovic, S; Stanojevic, D; Tahirovic, E; Tomasevic, M; Waagstein, F, 2014) |
| "Ivabradine (IVA), a selective If current inhibitor decreasing the heart rate (HR) in patients with sinus rhythm, has been added to the most recent European Guidelines on heart failure." | 5.17 | Ivabradine improves quality of life in subjects with chronic heart failure compared to treatment with β-blockers: results of a multicentric observational APULIA study. ( Benvenuto, A; Buta, F; De Viti, D; Masciocco, L; Massari, F; Meliota, G; Riccioni, G; Saracino, P; Speziale, G, 2013) |
| "The aim of the study was to develop a population pharmacokinetic (PK) model for clearance of bisoprolol in patients with congestive heart failure (CHF)." | 5.17 | Population pharmacokinetics of bisoprolol in patients with chronic heart failure. ( Apostolović, S; Deljanin-Ilic, M; Ilic, S; Jankovic, SM; Jevtovic-Stoimenov, T; Marinkovic, D; Milovanovic, JR; Nikolic, VN; Pesic, S; Stanojevic, D; Stefanovic, N; Velickovic-Radovanović, R; Zecevic, DR; Zivanovic, S, 2013) |
| " carvedilol is influenced by clinical and psychosocial factors in elderly patients with heart failure." | 5.17 | Determinants of change in quality of life in the Cardiac Insufficiency Bisoprolol Study in Elderly (CIBIS-ELD). ( Apostolović, S; Düngen, HD; Edelmann, F; Haverkamp, W; Herrmann-Lingen, C; Inkrot, S; Lashki, DJ; Loncar, G; Neskovic, A; Scherer, M; Tahirović, E; Wachter, R, 2013) |
| "This pharmacogenetic substudy of the prospective, double-blind, randomized CIBIS-ELD trial determined the impact of the β1-adrenoceptor Arg189Gly polymorphism on heart-rate responses to bisoprolol or carvedilol in elderly patients with heart failure (421 with sinus rhythm, 107 with atrial fibrillation)." | 5.16 | Impact of the β1-adrenoceptor Arg389Gly polymorphism on heart-rate responses to bisoprolol and carvedilol in heart-failure patients. ( Apostolović, S; Dimković, S; Düngen, HD; Edelmann, F; Eschenhagen, T; Gelbrich, G; Haverkamp, W; Lainščak, M; Nešković, AN; Rau, T; Waagstein, F, 2012) |
| " carvedilol in 883 elderly heart failure patients with reduced or preserved left ventricular ejection fraction in 41 European centres." | 5.15 | Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial. ( Anker, SD; Apostolovic, S; Dietz, R; Doehner, W; Düngen, HD; Edelmann, F; Eschenhagen, T; Gelbrich, G; Herrmann-Lingen, C; Inkrot, S; Krotin, M; Lainscak, M; Mehrhof, F; Neskovic, AN; Prettin, C; Putnikovic, B; Rau, T; Sakac, D; Tahirovic, E; Töpper, A; Waagstein, F; Wachter, R, 2011) |
| "Carvedilol and bisoprolol reduce QT dispersion (QTD) in chronic heart failure (CHF)." | 5.14 | The comparative effects of long-term carvedilol versus bisoprolol therapy on QT dispersion in patients with chronic heart failure. ( Aygul, MU; Aygul, N; Duzenli, MA; Ozdemir, K, 2009) |
| "In CIBIS III, initiating chronic heart failure (CHF) treatment with bisoprolol (target dose 10 mg q." | 5.14 | The effect of treatment with bisoprolol-first versus enalapril-first on cardiac structure and function in heart failure. ( Goulder, M; Meyer, WR; van de Ven, LL; van Veldhuisen, DJ; Willenheimer, R; Zilahi, Z, 2010) |
| "to evaluate of the effectiveness of switching from beta-adrenoblockers (BAB) non-included into the guidelines for the management of chronic heart failure (CHF) to nebivolol and bisoprolol for outpatients." | 5.14 | [Optimization of use of beta-adrenoblockers in the treatment of chronic heart failure in the outpatient setting]. ( Ageev, FT; Blankova, ZN; Kheĭmets, GI; Kuz'mina, AE; Ovchinnikov, AG; Patrusheva, IF; Seredenina, EM; Zhubrina, ES, 2009) |
| "To assess the clinical effects and safety profile of initial monotherapy with either bisoprolol or enalapril in elderly patients with heart failure (HF)." | 5.13 | Clinical effects of initial 6 months monotherapy with bisoprolol versus enalapril in the treatment of patients with mild to moderate chronic heart failure. Data from the CIBIS III Trial. ( Dobre, D; Goulder, MA; Krum, H; van Veldhuisen, DJ; Willenheimer, R, 2008) |
| "Body weight increased significantly in the carvedilol group (mean change + 2." | 5.13 | Effect of selective and non-selective beta-blockers on body weight, insulin resistance and leptin concentration in chronic heart failure. ( Gobec, L; Kovacić, D; Lainscak, M; Marinsek, M; Podbregar, M, 2008) |
| "to study the safety of switching from short-acting metoprolol to long-acting bisoprolol in patients with cardiac failure and postinfarction impaired left ventricular systolic function." | 5.13 | Switching beta-blocker therapy in chronic heart failure. ( Somlói, M; Toldy-Schedel, E; Tomcsányi, J; Wettstein, A, 2008) |
| "To assess effects of different variants of neurohormonal (NH) modulation with angiotensin converting enzyme (ACE-I) quinapril (Q), angiotensin-receptor blocker (ARB) valsartan (V) and their combination in addition to beta-adrenergic blocker bisoprolol (B) on functional status, quality of life (QOL), parameters of left ventricular (LV) remodeling, main indices of 24-h heart rate variability (HRV) and NH profile in patients with stable mild-to-moderate congestive heart failure (CHF)." | 5.12 | [Is triple combination of different neurohormonal modulators recommended for treatment of mild-to-moderate congestive heart failure patients? (Results of Sadko-CHF study)]. ( Arbolishvili, GN; Baklanova, NA; Belenkov, IuN; Mareev, VIu; Masenko, VP; Nasonova, SN; Skvortsov, AA; Sychev, AV, 2006) |
| "To compare the effects of carvedilol and bisoprolol on lung function in patients with chronic heart failure (CHF)." | 5.12 | Lung function with carvedilol and bisoprolol in chronic heart failure: is beta selectivity relevant? ( Agostoni, P; Apostolo, A; Bussotti, M; Cattadori, G; Contini, M; Fiorentini, C; Palermo, P; Sciomer, S, 2007) |
| "Our purpose was to evaluate the effect of a treatment over six months with bisoprolol on the surrogate parameters of N-Terminal-pro brain natriuretic peptide, subsequently to be described as brain natriuretic peptide, peak uptake of oxygen, and ventricular function assessed by magnetic resonance imaging in grown ups and adults who had undergone surgical correction of tetralogy of Fallot." | 5.12 | A prospective, randomized, double-blind, placebo controlled trial of beta-blockade in patients who have undergone surgical correction of tetralogy of Fallot. ( Alpers, V; Arnhold, JO; Bahlmann, J; Buchhorn, R; Geyer, S; Klimes, K; Kuehne, T; Norozi, K; Raab, B; Wessel, A; Zoege, M, 2007) |
| "Forty-four patients with chronic congestive heart failure were enrolled in the study to randomly receive carvedilol or bisoprolol in addition to background therapy." | 5.12 | Does NT-proBNP remain a sensitive biomarker for chronic heart failure after administration of a beta-blocker? ( Hua, C; Hua, L; Huang, J; Huang, Y; Jiang, W; Li, F; Li, N; Li, Y; Wang, F; Wu, Y; Xu, Z, 2007) |
| "To analyze the effect of bisoprolol in patients with stable congestive heart failure and who tolerated beta-blockers." | 5.11 | Effects of bisoprolol in patients with stable congestive heart failure. ( Bauters, C; Dagorn, J; de Groote, P; Delour, P; Lamblin, N; Millaire, A; Tison, E; Verkindère, C, 2004) |
| "The study was undertaken to evaluate the effects of long-term (6-month) therapy with the selective beta-blocker bisoprolol, the cytoprotector trimetazidine and their combination on the clinical course of disease, the morphofunctional parameters of the left ventricle (LV) and life quality in 71 patients with coronary heart disease (CHD) concurrent with functional classes (FC) III-IV chronic heart failure (CHF) (ejection fraction (EF) < 35%, as evidenced by echoCG)." | 5.11 | [Potentialities of cytoprotection in the treatment of chronic heart failure in patients with coronary heart disease]. ( Fedorova, TA; Il'ina, IuV; Rybakova, MK; Sotnikova, TI, 2004) |
| "Bisoprolol, carvedilol, enalapril are widely used for the treatment of patients with chronic heart failure." | 5.11 | [Effect of long-term therapy with contemporary drugs on diastolic cardiac function in patients with chronic heart failure]. ( Belousov, IuB; Khanina, NIu; Upnitskiĭ, AA, 2005) |
| "Patients (n=54) with NYHA class III-IV heart failure and left ventricular ejection fraction < or =35% were randomized either to treatment with bisoprolol (1." | 5.10 | [Clinical, hemodynamic and neurohumoral effects of long-term therapy of patients with severe chronic heart failure with beta-adrenoblocker bisoprolol]. ( Baklanova, NA; Belenkov, IuN; Mareev, VIu; Masenko, VP; Narusov, OIu; Nasonova, SN; Skvortsov, AA; Sychev, AV, 2003) |
| "The addition of bisoprolol to the standart therapy in patients with mild to moderate heart failure is well tolerated and improves functional capacity." | 5.10 | [Assessment of the efficacy of bisoprolol administration by cardiopulmonary exercise testing in patients with heart failure]. ( Akbulut, T; Aksoy, S; Bilsel, T; Dağ, O; Dayi, SU; Köse, H; Satiroğlu, O; Sayar, N; Terzi, S; Yeşilçimen, K, 2003) |
| "CIBIS-II was a multicentre bouble-blind randomized placebo-controlled trial which enrolled 2,647 class III-IV heart failure patients, with a left ventricular ejection fraction < or = 35%, receiving standard therapy with a diuretic and ACEI and randomly assigned to placebo (n = 1,320) or to bisoprolol (n = 1,327) 1." | 5.09 | [Clinical trial of the month. The CIBIS-II study]. ( Kulbertus, H, 1999) |
| " The purpose of this study was to examine the relations between baseline variables, the interactions between treatment, bisoprolol, or placebo, and the occurrence of critical events during the CIBIS trial, a mortality and morbidity trial of beta-blockade in patients with heart failure." | 5.09 | Predictors of medical events in patients enrolled in the cardiac insufficiency bisoprolol study (CIBIS): a study of the interactions between beta-blocker therapy and occurrence of critical events using analysis of competitive risks. ( Funck-Brentano, C; Lancar, R; Lardoux, H; Le Heuzey, JY; Lechat, P; Soubrié, C, 2000) |
| "To evaluate the effect of beta1-selective blocker bisoprolol on the QT and QTc dispersion in patients with chronic heart failure and to compare the responses to bisoprolol in patients with different etiologies." | 5.09 | Effect of bisoprolol on QT dispersion in patients with congestive heart failure--the etiology-dependent response. ( Chen, Y; Li, XP; Peng, DQ; Zhao, SP, 2001) |
| "Economic analysis of bisoprolol plus standard therapy versus placebo plus standard therapy in the treatment of chronic heart failure in Germany." | 5.09 | [Cost effectiveness of bisoprolol in treatment of heart failure in Germany. An analysis based on the CIBIS-II study]. ( Follath, F; Paschen, B; Schwenkglenks, M; Szucs, TD, 2000) |
| "The effect of beta-blockade on heart-rate variability was assessed at different heart rates in 52 patients with heart failure included in the randomized, placebo-controlled, Cardiac Insufficiency Bisoprolol Study (CIBIS)." | 5.08 | Effects of beta-blockade with bisoprolol on heart rate variability in advanced heart failure: analysis of scatterplots of R-R intervals at selected heart rates. ( Copie, X; Guize, L; Jaillon, P; Le Heuzey, JY; Lechat, P; Pousset, F, 1996) |
| "To further evaluate the mechanism of beta-blocker-induced benefits in heart failure, the relationships between bisoprolol-induced hemodynamic effects and survival were studied during the Cardiac Insufficiency BIsoprolol Study (CIBIS)." | 5.08 | Prognostic value of bisoprolol-induced hemodynamic effects in heart failure during the Cardiac Insufficiency BIsoprolol Study (CIBIS). ( Boissel, JP; Escolano, S; Golmard, JL; Henneman, JA; Hetzel, M; Jaillon, P; Lardoux, H; Lechat, P; Maisch, B; Mallet, A; Witchitz, S, 1997) |
| "The Cardiac Insufficiency Bisoprolol Study (CIBIS) demonstrates that, for patients with heart failure of different etiologies, the administration of the beta(1)-adrenoceptor blocker bisoprolol adjuvant to the standard therapy leads to a significant avoidance of hospital admissions." | 5.08 | [Cost effectiveness of bisoprolol in heart failure. Economic evaluation of the Cardiac Insufficiency Bisoprolol Study (CIBIS) for Germany]. ( Brecht, JG; Paschen, B; Schädlich, PK, 1997) |
| "Beta-blockers such as metoprolol, carvedilol, and bisoprolol are indicated for the treatment of patients with reduced ejection fraction heart failure." | 5.05 | Genetic Variation of Hepatic Enzymes Influence on β-Blocker Dose in Patients With Reduced Ejection Fraction Heart Failure. ( Ingram, A; Valente, M, 2020) |
| " Studies investigating any of three beta blockers (carvedilol, bisoprolol, and extended release metoprolol succinate) which are known to be effective in adult patients with heart failure were included." | 4.91 | Effects of beta-blockers for congestive heart failure in pediatric and congenital heart disease patients: a meta-analysis of published studies. ( Cho, MJ; Jung Kwak, M; Kim, HY; Kim, YM; Lee, HD; Lim, RK; Park, KH, 2015) |
| "The historical choice of angiotensin-converting enzyme (ACE) inhibition as first-line therapy in heart failure is challenged by early activation of the sympathetic system and multiple ways beta blockade (in particular, unselective agents such as carvedilol) may affect cardiac remodeling, its underlying mechanisms, and, hence, progression of heart failure, compared with ACE inhibition." | 4.84 | Beta blockers or angiotensin-converting-enzyme inhibitor/angiotensin receptor blocker: what should be first? ( Remme, WJ, 2007) |
| "To define the role of bisoprolol, a highly selective beta(1)-antagonist in congestive heart failure due to systolic dysfunction." | 4.84 | Bisoprolol for congestive heart failure. ( Gustafsson, F; Rosenberg, J, 2008) |
| "There is overwhelming evidence that beta blocker therapy in the form of metoprolol, bisoprolol, and carvedilol can have positive outcomes on morbidity, mortality, and quality of life in patients who have been diagnosed with mild to severe heart failure." | 4.82 | Emerging trends in the management of heart failure: Beta blocker therapy. ( Rone, T; Sauls, JL, 2005) |
| "The Carvedilol or Metoprolol European Trial (COMET) found that in patients with heart failure, survival appears to be better with carvedilol than with immediate-release metoprolol." | 4.82 | [Beta-adrenolytics in heart failure--are they all really equal?]. ( Filipiak, KJ; Opolski, G, 2005) |
| "All patients with New York Heart Association class II and III heart failure should receive beta-blocker therapy with bisoprolol, carvedilol, or metoprolol." | 4.81 | Beta-blockers to reduce mortality in patients with systolic dysfunction: a meta-analysis. ( Lee, S; Spencer, A, 2001) |
| "The transdermal formulation of bisoprolol may be useful for the early introduction of β-blockers in patients admitted with cardiac symptoms associated with myocardial ischemia or heart failure." | 4.02 | An attempt at administering a transdermal formulation of bisoprolol in patients with acute cardiac symptoms. ( Horiuchi, N; Kobayashi, T; Kobayashi, Y; Nakamura, S; Nakanishi, H; Naruhashi, K; Nozaki, A; Okugawa, H, 2021) |
| "To the best of our knowledge, there is no study that has conducted a review investigating the clinical efficacy and safety of bisoprolol combined with trimetazidine on chronic heart failure (CHF) patients with chronic obstructive pulmonary disease (COPD)." | 4.02 | Effects of trimetazidine in combination with bisoprolol in patients with chronic heart failure and concomitant chronic obstructive pulmonary disease: A protocol for systematic review and meta-analysis. ( Fu, B; Ma, S; Zhang, X, 2021) |
| "To analyze the application effect of bisoprolol combined with sacubitril valsartan sodium tablets in the cardiac rehabilitation of patients with acute myocardial infarction combined with left heart failure after percutaneous coronary intervention (PCI)." | 4.02 | Study on the application effect of bisoprolol combined with sacubitril valsartan sodium tablets in the cardiac rehabilitation of patients with acute myocardial infarction combined with left heart failure after percutaneous coronary intervention (PCI). ( Chen, C; Li, Y; Peng, Y; Wu, X, 2021) |
| "Although bisoprolol has been established to prevent heart failure (HF), finding the optimal dose remains a challenge." | 3.96 | Association between bisoprolol plasma concentration and worsening of heart failure: (CVI ARO 6). ( Arita, T; Kano, H; Kato, Y; Matsuno, S; Nagashima, K; Oikawa, Y; Otsuka, T; Sagara, K; Semba, H; Suzuki, S; Tanabe, G; Uejima, T; Yagi, N; Yajima, J; Yamashita, T, 2020) |
| "The study aimed to investigate the effects of the sodium-glucose co-transporter 2 (SGLT2) inhibitor empagliflozin on chronic heart failure (HF) in normoglycemic rats." | 3.96 | Comparative efficacy of empagliflozin and drugs of baseline therapy in post-infarct heart failure in normoglycemic rats. ( Ivkin, D; Karpov, A; Kaschina, E; Krasnova, M; Kulikov, A; Okovityi, S; Smirnov, A, 2020) |
| "Although bisoprolol is used widely to treat patients with heart failure (HF), little information is available regarding the association between the dose of bisoprolol administered and the bisoprolol plasma concentration (Bis-PC) in real-world clinical practice." | 3.96 | Association Between Dose and Plasma Concentration of Bisoprolol in Patients with Heart Failure (CVI ARO 6). ( Arita, T; Kano, H; Kato, Y; Matsuno, S; Nagashima, K; Oikawa, Y; Otsuka, T; Sagara, K; Semba, H; Suzuki, S; Tanabe, G; Uejima, T; Yagi, N; Yajima, J; Yamashita, T, 2020) |
| "Clinical guidelines suggest that for patients with heart failure and concurrent chronic obstructive pulmonary disease (COPD), metoprolol/bisoprolol/nebivolol should be preferred over carvedilol." | 3.91 | Beta-blocker choice and exchangeability in patients with heart failure and chronic obstructive pulmonary disease: an Italian register-based cohort study. ( Andersen, M; Capuano, A; Jensen, MT; Kragholm, K; Mascolo, A; Pagliaro, C; Rafaniello, C; Rasmussen, DB; Rossi, F; Sessa, M; Sportiello, L; Tari, GM, 2019) |
| "The work was aimed at studying the relationship between the efficiency of bisoprolol and the polymorphism of β1- and β2-adrenergic receptors (β-AR) genes in patients with heart failure." | 3.91 | [POLYMORPHISM OF THE BETA1- AND BETA2-ADRENORECEPTOR GENES AND BISOPROLOL EFFICIENCY IN PATIENTS WITH HEART FAILURE]. ( Bondar, T; Galchinskaya, V; Isayeva, G; Lozyk, T; Pyvovar, S; Rudyk, I, 2019) |
| "The evidence-based beta-blockers carvedilol, bisoprolol, and metoprolol succinate reduce mortality and hospitalizations among patients with heart failure with reduced ejection fraction (HFrEF)." | 3.91 | Low Utilization of Beta-Blockers Among Medicare Beneficiaries Hospitalized for Heart Failure With Reduced Ejection Fraction. ( Brown, TM; Chen, L; Durant, RW; Kilgore, ML; Levitan, EB; Loop, MS; Safford, MM; van Dyke, MK, 2019) |
| "Whether the reduction of heart rate with ivabradine (IVA) could affect sympathetic activation and cardiac innervation in heart failure (HF) remains unknown." | 3.91 | Modulation of Sympathetic Activity and Innervation With Chronic Ivabradine and β-Blocker Therapies: Analysis of Hypertensive Rats With Heart Failure. ( Akiyama, T; Iwanaga, Y; Kakehi, K; Miyazaki, S; Shimizu, S; Sonobe, T; Watanabe, H; Yamamoto, H, 2019) |
| "Clinical efficacy and adverse effects of the β-blocking agents, carvedilol, bisoprolol, and metoprolol were analyzed theoretically, and then compared quantitatively, for the purpose of determining their proper use for chronic heart failure." | 3.85 | Analysis of Clinical Efficacy and Adverse Effects of β-Blocking Agents Used Clinically for Chronic Heart Failure. ( Fujito, K; Kimura, K; Takayanagi, R; Yamada, Y, 2017) |
| "Heart failure is a highly prevalent cardiovascular complication among patients receiving long-term hemodialysis, but the benefits of carvedilol, bisoprolol, and metoprolol controlled release/extended release on the outcomes of these patients remain unclear." | 3.83 | Prognostic Benefits of Carvedilol, Bisoprolol, and Metoprolol Controlled Release/Extended Release in Hemodialysis Patients with Heart Failure: A 10-Year Cohort. ( Chen, TH; Hong, CY; Sue, YM; Tang, CH; Wang, CC, 2016) |
| "Bisoprolol, an antagonist of β1-adrenergic receptors, is effective in reducing the morbidity and mortality in patients with heart failure (HF)." | 3.83 | β1-Adrenergic blocker bisoprolol reverses down-regulated ion channels in sinoatrial node of heart failure rats. ( Du, Y; Han, K; Huang, X; Ma, A; Wang, T; Wu, G; Xi, Y; Zhang, J, 2016) |
| "The objective of this study was to establish the benefit of bisoprolol up-titration toward recommended dosage targets, versus lower-dose maintenance, in heart failure (HF) patients with systolic dysfunction." | 3.83 | Beneficial Effect on Surrogate Markers of Heart Failure with Bisoprolol Up-Titration to Recommended Targets in Korean Patients with Heart Failure and Left Ventricular Systolic Dysfunction. ( Cha, TJ; Choi, DJ; Choi, SW; Han, SW; Hwang, KK; Jeon, H; Kim, HJ; Kim, JH; Kim, SH; Kim, YJ; Ryu, KH; Shim, WJ; Shin, MS; Yoo, BS, 2016) |
| "The influence of beta-blocker therapy (bisoprolol or carvedilol) (bB) on the prognosis of heart failure (HF) patients with diabetes mellitus (DM) is uncertain." | 3.81 | Beta-blocker therapy and prognosis of heart failure patients with new-onset diabetes mellitus. ( Andrey, JL; Aranda, RM; Garcia-Egido, A; Gomez, F; López-Sáez, JB; Pedrosa, MJ; Puerto, JL; Rosety, M, 2015) |
| "To identify the prevalence and characteristics of recently hospitalized chronic heart failure (CHF) patients in community care who meet the indication for ivabradine." | 3.81 | Characterizing patients with chronic heart failure in community care after hospitalization: a potential role for ivabradine. ( Charles, H; Cochrane, L; Elder, DH; Lang, CC; Mohan, M, 2015) |
| "Data were retrospectively collected from 23 patients with HF [age 57±18 years, left ventricular ejection fraction (LVEF) 33±15%] who could not increase the dosage of carvedilol because of dizziness or hypotension, defined as systolic blood pressure<90 mmHg." | 3.79 | Switching from carvedilol to bisoprolol ameliorates adverse effects in heart failure patients with dizziness or hypotension. ( Asano, Y; Ichibori, Y; Kanzaki, M; Komuro, I; Minamiguchi, H; Mizote, I; Ohtani, T; Sakata, Y; Taniguchi, T, 2013) |
| "Eight weeks from surgically induced myocardial infarction, heart failure rats were randomized to receive bisoprolol (B) or vehicle." | 3.79 | Vascular endothelial growth factor blockade prevents the beneficial effects of β-blocker therapy on cardiac function, angiogenesis, and remodeling in heart failure. ( Agresta, A; Cannavo, A; de Lucia, C; Femminella, GD; Ferrara, N; Koch, WJ; Komici, K; Leosco, D; Liccardo, D; Pagano, G; Parisi, V; Perrone Filardi, P; Rapacciuolo, A; Rengo, G; Scala, O; Trimarco, B; Zincarelli, C, 2013) |
| "In experimental PH, treatment with bisoprolol delays progression toward right heart failure, and partially preserves RV systolic and diastolic function." | 3.78 | Bisoprolol delays progression towards right heart failure in experimental pulmonary hypertension. ( Bogaards, SJ; de Man, FS; Handoko, ML; Paulus, WJ; Postmus, PE; Schalij, I; van Ballegoij, JJ; van der Velden, J; Vonk-Noordegraaf, A; Westerhof, N, 2012) |
| " We investigated pulmonary protein and amino acid metabolism, the biochemical basis of the remodeling process, in individuals with chronic heart failure receiving or not receiving β-blocker therapy with bisoprolol (BIS)." | 3.78 | Lung anabolic activity in patients with chronic heart failure: potential implications for clinical practice. ( Aquilani, R; Baiardi, P; Bongiorno, AI; Boschi, F; Dossena, M; Febo, O; Iadarola, P; La Rovere, MT; Pastoris, O; Verri, M; Viglio, S, 2012) |
| " We present a case where carvedilol was replaced with bisoprolol resulting in acute urinary retention." | 3.77 | Carvedilol for the treatment of benign prostatic hypertrophy in patients with heart failure? ( Lindenfeld, J; Page, RL; Rohrer, CK; Shakar, SF, 2011) |
| "Although carvedilol and bisoprolol are effective medicines for the treatment of patients with heart failure (HF), only a few reports have compared their effects." | 3.76 | Comparative effects of carvedilol vs bisoprolol for severe congestive heart failure. ( Hachiya, H; Haraguchi, G; Hirao, K; Inagaki, H; Isobe, M; Kawabata, M; Kimura, S; Konishi, M, 2010) |
| "At present only bisoprolol, metoprolol succinate, nebivolol, and carvedilol are considered to be beta adrenoblockers with proven efficacy relative to course and prognosis of chronic heart failure (CHF)." | 3.76 | [Clinical, hemodynamic and neurohumoral effects of switching patients with chronic heart failure from not recommended -adrenoblockers to bisoprolol in ambulatory practice]. ( Ageev, FT; Ovchinnikov, AG; Seredenina, EM; Zhubrina, ES, 2010) |
| "This retrospective cohort study using administrative claims data included veterans 65 years and older receiving bisoprolol, carvedilol, or metoprolol succinate for which prescribing physicians indicated treatment was for heart failure." | 3.75 | The effectiveness of collaborative medicine reviews in delaying time to next hospitalization for patients with heart failure in the practice setting: results of a cohort study. ( Barratt, JD; Gilbert, AL; Killer, G; Peck, R; Pratt, N; Ramsay, E; Roughead, EE; Ryan, P, 2009) |
| "To assess the effects of bisoprolol on exercise capacity and ventricular function in patients with heart failure." | 3.74 | Effects of bisoprolol on cardiac function and exercise in patients with heart failure. ( Bacal, F; Bocchi, EA; Cruz, Fd; Ferreira, SM; Guimarães, GV; Issa, VS; Rezende, MV, 2007) |
| "Bisoprolol treatment in patients with chronic heart failure was effectively and safely carried out by primary care physicians." | 3.73 | Effects of bisoprolol treatment for chronic heart failure initiated and followed up by primary care physicians. ( Schuchert, A, 2005) |
| "The purpose of this study was to investigate the relation between the Arg389Gly polymorphism of the beta(1)-AR gene and chronic heart failure (CHF) and to evaluate the effect of this polymorphism on clinical response to beta-adrenoceptor blockade (bisoprolol) in patients with CHF." | 3.73 | [Beta1-adrenergic receptor (Arg389Gly) polymorphism and response to bisoprolol in patients with chronic heart failure]. ( Deng, B; Lou, M; Song, HM; Wang, HB; Yu, WP, 2006) |
| "We hypothesized that abnormal oxidative stress in chronic heart failure (CHF) could be related to endothelial damage and platelet activation, and that the vasodilating beta-blocker carvedilol would have beneficial effects on these processes compared with a selective non-vasodilating cardioselective beta-blocker, bisoprolol." | 3.72 | Neither carvedilol nor bisoprolol in maximally tolerated doses has any specific advantage in lowering chronic heart failure oxidant stress: implications for beta-blocker selection. ( Blann, AD; Chin, BS; Gibbs, CR; Lip, GY, 2003) |
| "This is the first study in Spain to show that bisoprolol can be used effectively at the maximum recommended doses, for the outpatient treatment of heart failure." | 3.72 | [Use of bisoprolol in heart failure. The BISOCOR observational study]. ( Alegría Ezquerra, E; Anguita Sánchez, M; Espinosa Caliani, JS; García Saavedra, V; González-Juanatey, JR; Pérez Ojeda, G; Ruiz Ros, JA, 2003) |
| "The Carvedilol or Metoprolol European Trial (COMET; Lancet 2003; 362:7-13) found that in patients with heart failure, survival appears to be better with carvedilol than with immediate-release metoprolol tartrate." | 3.72 | In heart failure, all beta-blockers are not necessarily equal. ( Francis, GS; Militello, M; Tang, WH, 2003) |
| "To elucidate effect of beta-blocker bisoprolol on hibernating myocardium in patients with congestive heart failure (CHF) of ischaemic etiology without concomitant use of angiotensin converting enzyme inhibitors." | 3.72 | [Effect of beta-Blocker Bisoprolol on Function of Hibernating Myocardium in Patients With Chronic Heart Failure of Ischemic Etiology]. ( Ivanenko, VV; Lopatin, IuM; Riazantseva, NV; Tarasov, DL, 2004) |
| "To determine tolerability and symptom changes associated with the introduction of bisoprolol treatment in older patients with heart failure." | 3.71 | Beta blockers in older persons with heart failure: tolerability and impact on quality of life. ( Baxter, AJ; Gray, CS; Hildreth, A; Karimova, G; O'Connell, JE; Spensley, A, 2002) |
| "This study considers the cost-effectiveness of bisoprolol in heart failure patients as an adjunctive therapy to usual treatment." | 3.71 | A cost-effectiveness analysis of bisoprolol for heart failure. ( Varney, S, 2001) |
| "The beneficial effects of the beta-blocker bisoprolol on mortality and rate of hospitalisation as well as its safety in patients with chronic heart failure has been proven." | 3.71 | Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure. ( Erdmann, E; Lechat, P; Verkenne, P; Wiemann, H, 2001) |
| "To investigate the cost effectiveness of adding the beta-blocker bisoprolol to standard treatment in patients with congestive heart failure (CHF)." | 3.71 | Cost effectiveness of bisoprolol in the treatment of chronic congestive heart failure in Sweden: analysis using data from the Cardiac Insufficiency Bisoprolol Study II trial. ( Ekman, M; Jönsson, B; Zethraeus, N, 2001) |
| "The cardioprotective effects of bisoprolol were studied in a rat model of severe heart failure induced by autoimmune myocarditis." | 3.71 | Bisoprolol improves survival in rats with heart failure. ( Aizawa, Y; Fuse, K; Hanawa, H; Hasegawa, G; Inoue, M; Ito, M; Kato, K; Kodama, M; Ma, M; Naito, M; Nakazawa, M; Ohta, Y; Wahed, MI; Watanabe, K, 2001) |
| "The cost-effectiveness of adding the beta blocker bisoprolol to standard treatment in patients with congestive heart failure was investigated, based on data from the Cardiac Insufficiency Bisoprolol Study II (CIBIS II)." | 3.71 | [Cost-effectiveness of bisoprolol in chronic heart failure]. ( Dahlström, U; Ekman, M; Höglund, C; Zethraeus, N, 2002) |
| "Clinical studies conducted with carvedilol suggest that beta-adrenoceptor antagonism is an effective therapeutic approach to the treatment of heart failure." | 3.70 | In vitro and in vivo characterization of intrinsic sympathomimetic activity in normal and heart failure rats. ( Aiyar, N; Disa, J; Mitchell, MP; Naselsky, DP; Ohlstein, EH; Ruffolo, RR; Stadel, JM; Storer, BL; Willette, RN; Yue, TL, 1999) |
| "The Cardiac Insufficiency Bisoprolol Study (CIBIS) demonstrates that, for patients with heart failure of different aetiologies, administration of the beta 1-adrenoceptor blocker bisoprolol as an adjuvant to the standard therapy leads to a significant avoidance of hospital admissions." | 3.70 | Economic evaluation of the Cardiac Insufficiency Bisoprolol Study for the Federal Republic of Germany. ( Brecht, JG; Paschen, B; Schädlich, PK, 1998) |
| " Recently completed mortality studies with beta-blockers (BB) in chronic heart failure CIBIS II and MERIT HF confirmed the conclusions of pilot studies with carvedilol that in stabilized chronic heart failure BB reduces the mortality rate as well as the need of hospital admission on account of deteriorating heart failure." | 3.70 | [Beta-blockers in the treatment of chronic heart failure. How should results of clinical studies be introduced into clinical practice]. ( Spinar, J; Vítovec, J, 2000) |
| "Chronic obstructive pulmonary disease (COPD) is associated with significant morbidity, mortality and healthcare costs." | 3.11 | Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial (BICS). ( Abbas, H; Briggs, A; Campbell, K; Chaudhuri, R; Choudhury, G; Cotton, S; Dawson, D; De Soyza, A; Devereux, G; Fielding, S; Gompertz, S; Haughney, J; Lang, CC; Lee, AJ; Lipworth, BJ; MacLennan, G; MacNee, W; McCormack, K; McMeekin, N; Mills, NL; Morice, A; Norrie, J; Petrie, MC; Price, D; Short, P; Vestbo, J; Walker, P; Wedzicha, J; Wilson, A, 2022) |
| "Bisoprolol was associated with a lower heart rate (17 beats per minute, p=0." | 2.82 | Bisoprolol in idiopathic pulmonary arterial hypertension: an explorative study. ( Allaart, CP; Bogaard, HJ; de Boer, K; de Man, FS; Handoko, ML; Harms, HJ; Heymans, MW; Marcus, JT; Raijmakers, PG; van Campen, JS; van de Veerdonk, MC; van der Bruggen, CE; Vonk Noordegraaf, A, 2016) |
| "Bisoprolol was started at 1." | 2.76 | Comparison of effectiveness of carvedilol versus bisoprolol for prevention of postdischarge atrial fibrillation after coronary artery bypass grafting in patients with heart failure. ( Arisi, G; Caminiti, G; Iellamo, F; Madonna, M; Marazzi, G; Massaro, R; Righi, D; Rosano, GM; Volterrani, M, 2011) |
| " We also assessed the relations between dose levels and baseline variables or adverse events." | 2.76 | Influence of order and type of drug (bisoprolol vs. enalapril) on outcome and adverse events in patients with chronic heart failure: a post hoc analysis of the CIBIS-III trial. ( Follath, F; Funck-Brentano, C; Goulder, M; van de Ven, LL; van Veldhuisen, DJ; Willenheimer, R, 2011) |
| "Chronic obstructive pulmonary disease (COPD) frequently coexists in patients with chronic heart failure (CHF) and is a key factor for beta blocker underprescription and underdosing." | 2.76 | Differences between bisoprolol and carvedilol in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized trial. ( Kovacic, D; Lainscak, M; Podbregar, M; Rozman, J; von Haehling, S, 2011) |
| "In subjects with COPD, forced expiratory volume in 1 s was lowest with carvedilol and highest with bisoprolol (carvedilol 1." | 2.75 | Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. ( Coleman, CF; Elsik, M; Hayward, CS; Jabbour, A; Keogh, AM; Kotlyar, E; Krum, H; Macdonald, PS; Mellemkjaer, S, 2010) |
| "Heart failure (HF) and chronic obstructive pulmonary disease (COPD) frequently coexist." | 2.74 | Bisoprolol in patients with heart failure and moderate to severe chronic obstructive pulmonary disease: a randomized controlled trial. ( Carter, R; Chalmers, GW; Dunn, FG; Hawkins, NM; MacDonald, MR; McMurray, JJ; Petrie, MC, 2009) |
| "Beta-blocker treatment of stable heart failure in primary care." | 2.74 | Beta-blocker treatment of stable heart failure in primary care. ( Barroso, A; Bernáldez, MJ; Domingo, M; Domíngueza, M; Pie, M; Sancho, F; Simó, M; Verdú Rotellar, JM, 2009) |
| "Whether all patients with congestive heart failure (CHF) need to reach the target dose of beta-blocker to obtain a benefit in terms of survival remains uncertain." | 2.71 | Bisoprolol dose-response relationship in patients with congestive heart failure: a subgroup analysis in the cardiac insufficiency bisoprolol study(CIBIS II). ( Funck-Brentano, C; Jaillon, P; Lechat, P; Mary-Krause, M; Simon, T, 2003) |
| "Beta-blockers substantially improve survival in patients with chronic heart failure (HF) with left ventricular systolic dysfunction, but concerns about cardiovascular adverse effects may deter physicians from prescribing this therapy." | 2.71 | Adverse effects of beta-blocker therapy for patients with heart failure: a quantitative overview of randomized trials. ( Coffey, CS; Curtis, JP; Foody, JM; Hebert, PR; Ko, DT; Krumholz, HM; Sedrakyan, A, 2004) |
| "10, NYHA III-IV 29%) to treatment with either bisoprolol or carvedilol, in order to assess and compare the maximally achievable number of patients on treatment with these BB and the maximally achieved dosage during a minimum of 2 months attendance at our out patient heart failure clinic." | 2.71 | Tolerability of beta-blocker initiation and titration with bisoprolol and carvedilol in congestive heart failure -- a randomized comparison. ( Atar, D; Galatius, S; Gustafsson, F; Hildebrandt, PR, 2004) |
| " The dosage of beta-blockers were increased gradually to target or the tolerant dosages (bisoprolol 10 mg qd, carvedilol 25 mg bid) during 3 months in 36 patients." | 2.71 | [Beneficial neurohormonal profiles of beta-blockades in chronic left heart failure]. ( Bian, WY; Duan, B; Jia, X; Li, W; Li, YS; Wang, F; Wang, L; Xu, ZM, 2005) |
| "Bisoprolol-first treatment was noninferior to enalapril-first treatment if the upper limit of the 95% confidence interval (CI) for the absolute between-group difference was <5%, corresponding to a hazard ratio (HR) of 1." | 2.71 | Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. ( Erdmann, E; Follath, F; Krum, H; Lechat, P; Ponikowski, P; Silke, B; Skene, A; van de Ven, L; van Veldhuisen, DJ; Verkenne, P; Willenheimer, R, 2005) |
| "The bisoprolol daily dose was 5 mg once daily." | 2.68 | Effects of bisoprolol on heart rate variability in heart failure. ( Boissel, JP; Copie, X; Fillette, F; Guize, L; Hetzel, M; Jaillon, P; Le Heuzey, JY; Lechat, P; Pousset, F; Remme, W, 1996) |
| "The base of treatment of heart failure is the blockade of the neuro-hormonal system, which includes the use of angiotensin converting enzyme inhibitors (angiotensin receptor blockers in case of angiotensin converting enzyme inhibitors intolerance), beta receptor blockers and mineralocorticoid receptor antagonists." | 2.49 | [Epidemiology and treatment of chronic heart failure; use of bisoprolol]. ( Nagy, V, 2013) |
| "β-blockers are an important treatment of heart failure (HF) and are useful in reducing the progression of the syndrome." | 2.48 | β-blockers in stage B: a precursor of heart failure. ( Francis, GS; Sarraf, M, 2012) |
| "Metoprolol was significantly superior to carvedilol (P = 0." | 2.48 | β-Blockers in heart failure: benefits of β-blockers according to varying male proportions of study patients. ( Cheng, XJ; He, YM; Li, X; Qian, YX; Xu, HF; Yang, XJ; Zhao, X, 2012) |
| "Bisoprolol fumarate is a highly selective beta-1 receptor blocker." | 2.44 | Bisoprolol in the treatment of chronic heart failure. ( de Groote, P; Ennezat, PV; Mouquet, F, 2007) |
| "The heart failure is one of the pathologies with major social and economic impact in the western world." | 2.44 | [Chronic heart failure and sudden death: the message of CIBIS-III]. ( Dequarti, MC; Poggio, L; Vanoli, E, 2007) |
| "Heart failure is a serious disorder associated with substantial morbidity and mortality." | 2.42 | Role of beta-blocker therapy in heart failure and atrial fibrillation. ( Fung, JW; Kum, LC; Sanderson, JE; Yip, GW; Yu, CM, 2003) |
| " We analyze the problems with the trial design of COMET from the standpoint of comparing 2 therapeutic agents at different positions on a common dose-response curve, and discuss the theoretical reasons why postjunctional adrenergic receptor blockade that is in addition to beta1-receptor antagonism will likely produce only minimal or no incremental benefit in chronic heart failure." | 2.42 | Selective versus nonselective beta-blockade for heart failure therapy: are there lessons to be learned from the COMET trial? ( Adams, KF; Bristow, MR; Feldman, AM; Goldstein, S, 2003) |
| " Results from the recently published trials are summarized to emphasize the proper selection and dosage of beta blocker therapy to optimize the care of this high risk population." | 2.42 | The effects of beta blockers on morbidity and mortality in heart failure. ( Jafri, SM, 2004) |
| "Bisoprolol is a highly selective beta(1)-adrenoceptor antagonist." | 2.41 | Bisoprolol: a review of its use in chronic heart failure. ( Keating, GM; McGavin, JK, 2002) |
| " To date, controlled clinical trials performed in more than 13,000 patients with chronic heart failure have consistently shown that the long term administration of beta-blockers is associated with significant improvement in left ventricular function, clinical symptoms, and survival." | 2.41 | [Role of beta-blockers in the treatment of chronic heart heart failure]. ( Czuriga, I; Edes, I, 2001) |
| "Emphysema was induced in male Wistar rats by four weekly pulmonary instillations of elastase (4UI) and exacerbation by a single dose of lipopolysaccharides (LPS)." | 1.91 | Elevated Blood Pressure Occurs without Endothelial Dysfunction in a Rat Model of Pulmonary Emphysema. ( Alburquerque, L; Bideaux, P; Bourdin, A; Cazorla, O; Charrabi, A; Desplanche, E; Gouzi, F; Grillet, PE; Virsolvy, A; Wynands, Q, 2023) |
| "Patients with bilateral primary aldosteronism (PA) generally are treated with antihypertensive drugs, but optimal treatment for patients with complications due to refractory hypertension has not been established." | 1.91 | Unilateral adrenalectomy for a drug-resistant bilateral primary aldosteronism with heart failure: pathophysiology and surgical indication. ( Akaihata, H; Hata, J; Honda-Takinami, R; Hoshi, S; Kataoka, M; Kojima, Y; Matsuoka, K; Ogawa, S; Onagi, A; Sato, Y; Tanji, R, 2023) |
| "Although liver cirrhosis complicated with chylothorax is rare, several case reports have shown all patients with chylothorax caused by liver cirrhosis were transudative." | 1.72 | [Transudative chylothorax complicated with liver cirrhosis due to primary biliary cholangitis:case report]. ( Higashizawa, T; Hisatake, Y; Kitagawa, K; Kondo, M; Noda, M; Okamura, Y; Sekine, C; Sunaga, S; Teramoto, K, 2022) |
| " Careful monitoring is recommended for possible new symptoms, such as emergence/increase of shortness of breath, cough or changes in dosing of other drugs (for example, increased frequency of using short-acting bronchodilators)." | 1.62 | [Possibilities and limitations of the use of beta-blockers in patients with cardiovascular disease and chronic obstructive pulmonary disease]. ( Karoli, NA; Rebrov, AP, 2021) |
| "Carvedilol was prescribed in 7 331 patients treated for HF (9." | 1.62 | Beta-blockers utilization in heart failure patients: Sub-analysis of a nation-wide population-based study in the Czech Republic. ( Aiglova, R; Danek, J; Gloger, V; Lazarova, M; Pavlu, L; Precek, J; Schee, A; Skala, T; Taborsky, M; Vicha, M, 2021) |
| " The primary outcome was the change in equivalent dosing of ramipril and bisoprolol at 6-months." | 1.62 | Impact of the COVID-19 pandemic on the management of chronic heart failure. ( Gierula, J; Jagger, J; McGinlay, M; Nouri, B; Straw, S; Witte, KK, 2021) |
| "However, orthostatic hypotension (OH) is sometimes caused by BBs." | 1.56 | Bisoprolol transdermal patch improves orthostatic hypotension in patients with chronic heart failure and hypertension. ( Dobashi, S; Fujii, T; Hisatake, S; Ikeda, T; Kabuki, T; Kiuchi, S; Oka, T; Sano, T, 2020) |
| "Thyroid storm is a life-threatening disorder that remains a therapeutic challenge." | 1.46 | Switching Therapy from Intravenous Landiolol to Transdermal Bisoprolol in a Patient with Thyroid Storm Complicated by Decompensated Heart Failure and Gastrointestinal Dysfunction. ( Fujita, M; Godo, S; Kawazoe, Y; Kudo, D; Kushimoto, S; Nomura, R; Ozaki, H; Shimokawa, H, 2017) |
| "Bisoprolol was found to reduce mortality and CHF exacerbation compared to carvedilol and metoprolol." | 1.46 | The evaluation of β-adrenoceptor blocking agents in patients with COPD and congestive heart failure: a nationwide study. ( Chen, CY; Huang, YB; Kuo, CC; Liao, KM; Lin, TY, 2017) |
| "A randomised, open-label, two-period, crossover, single-dose, relative bioavailability study was conducted in fasted healthy Caucasian volunteers." | 1.46 | Bioequivalence study of 2.5 mg film-coated bisoprolol tablets in healthy volunteers. ( Bielak, A; Buś-Kwaśnik, K; Ksycińska, H; Leś, A; Płatek, AE; Raszek, J; Rudzki, PJ; Serafin-Byczak, K; Szymański, FM; Wybraniec, A; Łazowski, T, 2017) |
| "The long-term use of β-blockers has been shown to improve clinical outcomes among patients with heart failure (HF)." | 1.46 | Older adults with heart failure treated with carvedilol, bisoprolol, or metoprolol tartrate: risk of mortality. ( Bouvier, M; de Denus, S; Deblois, D; Dorais, M; Dubé, MP; Haibe-Kains, B; Jenna, S; Leduc, R; Perreault, S; Rouleau, JL; Tardif, JC; White, M; White-Guay, B, 2017) |
| " After adjustment for age, sex, comorbidities, and severity of HF and COPD, bisoprolol use showed a dose-response survival benefit [low dose: adjusted hazard ratio (HR) = 0." | 1.43 | Carvedilol, Bisoprolol, and Metoprolol Use in Patients With Coexistent Heart Failure and Chronic Obstructive Pulmonary Disease. ( Chang, YS; Chen, TJ; Chou, KT; Hu, YW; Hung, MH; Lee, FY; Liu, CJ; Ou, SM; Perng, DW; Su, VY; Yang, KY, 2016) |
| "Chronic obstructive pulmonary disease (COPD) is present in approximately one-third of all congestive heart failure (CHF) patients, and is a key cause of underprescription and underdosing of β-blockers, largely owing to concerns about precipitating respiratory deterioration." | 1.42 | Impact of β-blocker selectivity on long-term outcomes in congestive heart failure patients with chronic obstructive pulmonary disease. ( Asai, K; Furuse, E; Kubota, Y; Murai, K; Nakamura, S; Shimizu, W; Tsukada, YT, 2015) |
| "Literature data relevant to the decision to allow a waiver of in vivo bioequivalence (BE) testing for the approval of immediate-release (IR) solid oral dosage forms containing bisoprolol as the sole active pharmaceutical ingredient (API) are reviewed." | 1.40 | Biowaiver monograph for immediate-release solid oral dosage forms: bisoprolol fumarate. ( Abrahamsson, B; Charoo, NA; Cristofoletti, R; Dressman, J; Groot, DW; Kopp, S; Langguth, P; Lian, LY; Polli, J; Shah, VP; Shamsher, AA, 2014) |
| "Treatment with bisoprolol slowed the heart rate, and treatment with losartan lowered mean arterial pressure, confirming adequate dosing, but none of the treatments improved RV function or arrested the progression of RV hypertrophy and failure compared with vehicle." | 1.40 | Effects of bisoprolol and losartan treatment in the hypertrophic and failing right heart. ( Andersen, A; Andersen, S; Bogaard, HJ; de Man, FS; Holmboe, S; Nielsen, JM; Nielsen-Kudsk, JE; Ringgaard, S; Schultz, JG; Vildbrad, MD; Vonk-Noordegraaf, A, 2014) |
| "Treatment with bisoprolol reversed, to varying degrees, the expression of 10 of the 46 miRNAs whose expression was differentially expressed in the heart failure model." | 1.39 | Regulation by bisoprolol for cardiac microRNA expression in a rat volume-overload heart failure model. ( Chen, C; Geng, T; Jin, T; Li, S; Li, X; Ma, A; Sun, C; Wang, T; Yan, H; Zhang, J; Zhang, X, 2013) |
| "Bisoprolol treatment ameliorated HF-related adverse cardiac remodelling and reduced plasma catecholamine levels, compared with HF/C rats." | 1.38 | Blockade of β-adrenoceptors restores the GRK2-mediated adrenal α(2) -adrenoceptor-catecholamine production axis in heart failure. ( Cannavo, A; de Lucia, C; Femminella, G; Ferrara, N; Gargiulo, P; Koch, W; Leosco, D; Liccardo, D; Lymperopoulos, A; Pagano, G; Perrone Filardi, P; Rengo, G; Zincarelli, C, 2012) |
| "Skeletal muscle atrophy and decreased expression of slow fibers contribute to exercise capacity limitation in Chronic Heart Failure (CHF)." | 1.36 | Skeletal muscle proteins oxidation in chronic right heart failure in rats: can different beta-blockers prevent it to the same degree? ( Angelini, A; Betto, DD; Dalla Libera, L; Evangelista, S; Germinario, E; Gobbo, V; Ravara, B; Vescovo, G, 2010) |
| "In patients with cardiac failure due to systemic right ventricular dysfunction, β-blockers improve New York Heart Association class, quality of life, and systemic right ventricular ejection fraction assessed by radionuclide ventriculography." | 1.36 | Interest of β-blockers in patients with right ventricular systemic dysfunction. ( Bouallal, R; Foucher-Hossein, C; Francart, C; Godart, F; Lions, C; Richard, A, 2010) |
| "Bisoprolol has anti-arrhythmic effects, but its direct effect on I(Na) in cardiac cells remains unclear." | 1.34 | Bisoprolol inhibits sodium current in ventricular myocytes of rats with diastolic heart failure. ( Deng, CY; Kuang, SJ; Tang, HF; Wu, SL; Zhang, WC, 2007) |
| "Heart failure is characterized by limited exercise tolerance and by a skeletal muscle myopathy with atrophy and shift toward fast fibres." | 1.33 | Skeletal muscle myofibrillar protein oxidation in heart failure and the protective effect of Carvedilol. ( Angelini, A; Dalla Libera, L; Danieli Betto, D; Germinario, E; Gobbo, V; Ravara, B; Vescovo, G, 2005) |
| "Treatment with bisoprolol prevented the progression of cardiac dysfunction in TO-2 hamsters." | 1.33 | Attenuation of oxidative stress and cardiac dysfunction by bisoprolol in an animal model of dilated cardiomyopathy. ( Hashimoto, K; Ichihara, G; Ichihara, S; Iwase, M; Kanazawa, H; Kato, Y; Matsushita, A; Oikawa, S; Yamada, Y; Yokota, M, 2006) |
| "Chronic heart failure is associated with high mortality and morbidity." | 1.31 | [Adaptation of guidelines for the treatment of chronic heart failure in a specialized heart failure clinic]. ( Frick, M; Gouya, G; Hügel, H; Pachinger, O; Pölzl, G; Ulmer, H, 2002) |
| "Bisoprolol was administered orally at doses of 1." | 1.29 | [Clinical effects of bisoprolol in congestive heart failure due to dilated cardiomyopathy]. ( Li, L; Li, Z, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.33) | 18.7374 |
| 1990's | 34 (11.33) | 18.2507 |
| 2000's | 137 (45.67) | 29.6817 |
| 2010's | 99 (33.00) | 24.3611 |
| 2020's | 29 (9.67) | 2.80 |
| Authors | Studies |
|---|---|
| Karoli, NA | 1 |
| Rebrov, AP | 1 |
| Yokota, T | 1 |
| Koiwa, H | 1 |
| Matsushima, S | 1 |
| Tsujinaga, S | 1 |
| Naya, M | 1 |
| Morisaki, H | 1 |
| Morisaki, T | 1 |
| Rovai, S | 1 |
| Contini, M | 5 |
| Sciomer, S | 5 |
| Vignati, C | 3 |
| Agostoni, P | 5 |
| Sunaga, S | 1 |
| Okamura, Y | 1 |
| Kondo, M | 1 |
| Kitagawa, K | 1 |
| Noda, M | 1 |
| Hisatake, Y | 1 |
| Teramoto, K | 1 |
| Higashizawa, T | 1 |
| Sekine, C | 1 |
| Cotton, S | 1 |
| Devereux, G | 1 |
| Abbas, H | 1 |
| Briggs, A | 1 |
| Campbell, K | 1 |
| Chaudhuri, R | 1 |
| Choudhury, G | 1 |
| Dawson, D | 1 |
| De Soyza, A | 1 |
| Fielding, S | 1 |
| Gompertz, S | 1 |
| Haughney, J | 1 |
| Lang, CC | 2 |
| Lee, AJ | 1 |
| MacLennan, G | 1 |
| MacNee, W | 1 |
| McCormack, K | 1 |
| McMeekin, N | 1 |
| Mills, NL | 1 |
| Morice, A | 1 |
| Norrie, J | 1 |
| Petrie, MC | 2 |
| Price, D | 1 |
| Short, P | 1 |
| Vestbo, J | 1 |
| Walker, P | 1 |
| Wedzicha, J | 1 |
| Wilson, A | 1 |
| Lipworth, BJ | 1 |
| Sharma, K | 1 |
| Desai, H | 1 |
| Sharm, N | 1 |
| Laddha, M | 1 |
| Hansora, K | 1 |
| Vazirani, P | 1 |
| Dunlay, SM | 1 |
| Killian, JM | 1 |
| Roger, VL | 1 |
| Schulte, PJ | 1 |
| Blecker, SB | 1 |
| Savitz, ST | 1 |
| Redfield, MM | 1 |
| Schranz, D | 1 |
| Wang, Y | 1 |
| Desplanche, E | 1 |
| Grillet, PE | 1 |
| Wynands, Q | 1 |
| Bideaux, P | 1 |
| Alburquerque, L | 1 |
| Charrabi, A | 1 |
| Bourdin, A | 1 |
| Cazorla, O | 1 |
| Gouzi, F | 1 |
| Virsolvy, A | 1 |
| Rahm, AK | 1 |
| Hackbarth, J | 1 |
| Müller, ME | 1 |
| Pfeiffer, J | 1 |
| Gampp, H | 1 |
| Petersenn, F | 1 |
| Rivinius, R | 1 |
| Frey, N | 1 |
| Lugenbiel, P | 1 |
| Thomas, D | 1 |
| Hoshi, S | 1 |
| Onagi, A | 1 |
| Tanji, R | 1 |
| Honda-Takinami, R | 1 |
| Matsuoka, K | 1 |
| Hata, J | 1 |
| Sato, Y | 1 |
| Akaihata, H | 1 |
| Kataoka, M | 1 |
| Ogawa, S | 1 |
| Kojima, Y | 1 |
| Sessa, M | 2 |
| Mascolo, A | 2 |
| Rasmussen, DB | 1 |
| Kragholm, K | 1 |
| Jensen, MT | 1 |
| Sportiello, L | 1 |
| Rafaniello, C | 1 |
| Tari, GM | 1 |
| Pagliaro, C | 1 |
| Andersen, M | 1 |
| Rossi, F | 2 |
| Capuano, A | 2 |
| Toyoda, S | 2 |
| Haruyama, A | 2 |
| Inami, S | 2 |
| Arikawa, T | 2 |
| Saito, F | 1 |
| Watanabe, R | 1 |
| Sakuma, M | 2 |
| Abe, S | 2 |
| Nakajima, T | 1 |
| Tanaka, A | 2 |
| Node, K | 2 |
| Inoue, T | 2 |
| Pyvovar, S | 1 |
| Rudyk, I | 1 |
| Isayeva, G | 1 |
| Lozyk, T | 1 |
| Galchinskaya, V | 1 |
| Bondar, T | 1 |
| Kiuchi, S | 1 |
| Hisatake, S | 1 |
| Kabuki, T | 1 |
| Oka, T | 1 |
| Dobashi, S | 1 |
| Fujii, T | 1 |
| Sano, T | 1 |
| Ikeda, T | 1 |
| Arita, T | 2 |
| Suzuki, S | 2 |
| Kato, Y | 3 |
| Kano, H | 2 |
| Yajima, J | 2 |
| Matsuno, S | 2 |
| Otsuka, T | 2 |
| Semba, H | 2 |
| Uejima, T | 2 |
| Oikawa, Y | 2 |
| Nagashima, K | 2 |
| Yagi, N | 2 |
| Sagara, K | 2 |
| Tanabe, G | 2 |
| Yamashita, T | 2 |
| Krasnova, M | 1 |
| Kulikov, A | 1 |
| Okovityi, S | 1 |
| Ivkin, D | 1 |
| Karpov, A | 1 |
| Kaschina, E | 2 |
| Smirnov, A | 1 |
| Zhou, H | 1 |
| Sim, JJ | 1 |
| Shi, J | 1 |
| Shaw, SF | 1 |
| Lee, MS | 1 |
| Neyer, JR | 1 |
| Kovesdy, CP | 1 |
| Kalantar-Zadeh, K | 1 |
| Jacobsen, SJ | 1 |
| Nozaki, A | 1 |
| Kobayashi, T | 1 |
| Naruhashi, K | 1 |
| Okugawa, H | 1 |
| Horiuchi, N | 1 |
| Nakanishi, H | 1 |
| Kobayashi, Y | 1 |
| Nakamura, S | 2 |
| Taborsky, M | 1 |
| Aiglova, R | 1 |
| Lazarova, M | 1 |
| Pavlu, L | 1 |
| Danek, J | 1 |
| Precek, J | 1 |
| Schee, A | 1 |
| Gloger, V | 1 |
| Vicha, M | 1 |
| Skala, T | 1 |
| Kotecha, D | 2 |
| Bunting, KV | 1 |
| Gill, SK | 1 |
| Mehta, S | 2 |
| Stanbury, M | 2 |
| Jones, JC | 1 |
| Haynes, S | 1 |
| Calvert, MJ | 1 |
| Deeks, JJ | 2 |
| Steeds, RP | 2 |
| Strauss, VY | 1 |
| Rahimi, K | 1 |
| Camm, AJ | 1 |
| Griffith, M | 2 |
| Lip, GYH | 1 |
| Townend, JN | 2 |
| Kirchhof, P | 2 |
| Steurer, J | 1 |
| Zhang, X | 2 |
| Ma, S | 1 |
| Fu, B | 1 |
| McGranaghan, P | 1 |
| Saxena, A | 1 |
| Düngen, HD | 13 |
| Rubens, M | 1 |
| Appunni, S | 1 |
| Salami, J | 1 |
| Veledar, E | 1 |
| Lacour, P | 1 |
| Blaschke, F | 1 |
| Obradovic, D | 2 |
| Loncar, G | 4 |
| Tahirovic, E | 9 |
| Edelmann, F | 9 |
| Pieske, B | 3 |
| Trippel, TD | 3 |
| Chen, C | 2 |
| Wu, X | 1 |
| Li, Y | 2 |
| Peng, Y | 1 |
| AlHabeeb, W | 1 |
| Mrabeti, S | 1 |
| Abdelsalam, AAI | 1 |
| McGinlay, M | 1 |
| Straw, S | 1 |
| Jagger, J | 1 |
| Nouri, B | 1 |
| Gierula, J | 1 |
| Witte, KK | 2 |
| Koraćević, G | 1 |
| Stojanović, M | 1 |
| Kostić, T | 1 |
| Lović, D | 1 |
| Zdravković, M | 2 |
| Koraćević, M | 1 |
| Pavlović, D | 1 |
| Mićić, S | 1 |
| Chavanon, ML | 1 |
| Inkrot, S | 9 |
| Zelenak, C | 1 |
| Stanojevic, D | 3 |
| Apostolovic, S | 10 |
| Sljivic, A | 1 |
| Ristic, AD | 1 |
| Matic, D | 1 |
| Veskovic, J | 1 |
| Lainscak, M | 11 |
| Herrmann-Lingen, C | 4 |
| Fröhlich, H | 1 |
| Torres, L | 1 |
| Täger, T | 1 |
| Schellberg, D | 1 |
| Corletto, A | 1 |
| Kazmi, S | 1 |
| Goode, K | 1 |
| Grundtvig, M | 1 |
| Hole, T | 1 |
| Katus, HA | 1 |
| Cleland, JGF | 1 |
| Atar, D | 2 |
| Clark, AL | 2 |
| Agewall, S | 1 |
| Frankenstein, L | 1 |
| Mulder, BA | 1 |
| Damman, K | 1 |
| Van Veldhuisen, DJ | 10 |
| Van Gelder, IC | 1 |
| Rienstra, M | 1 |
| Takayanagi, R | 1 |
| Fujito, K | 1 |
| Kimura, K | 1 |
| Yamada, Y | 2 |
| Calvert, M | 1 |
| Lip, GY | 3 |
| Slinn, G | 1 |
| Momomura, SI | 2 |
| Saito, Y | 2 |
| Yasumura, Y | 1 |
| Yamamoto, K | 1 |
| Sakata, Y | 2 |
| Daimon, M | 1 |
| Kinugawa, K | 1 |
| Okamoto, H | 1 |
| Dohi, N | 1 |
| Komuro, I | 3 |
| Godo, S | 1 |
| Kawazoe, Y | 1 |
| Ozaki, H | 1 |
| Fujita, M | 1 |
| Kudo, D | 1 |
| Nomura, R | 1 |
| Shimokawa, H | 1 |
| Kushimoto, S | 1 |
| Liao, KM | 1 |
| Lin, TY | 2 |
| Huang, YB | 2 |
| Kuo, CC | 1 |
| Chen, CY | 2 |
| Polhemus, DJ | 1 |
| Trivedi, RK | 1 |
| Gao, J | 1 |
| Li, Z | 2 |
| Scarborough, AL | 1 |
| Goodchild, TT | 1 |
| Varner, KJ | 1 |
| Xia, H | 1 |
| Smart, FW | 1 |
| Kapusta, DR | 1 |
| Lefer, DJ | 1 |
| Mortensen, RN | 1 |
| Andersen, MP | 1 |
| Rosano, GMC | 1 |
| Gislason, G | 1 |
| Enghusen-Poulsen, H | 1 |
| Torp-Pedersen, C | 1 |
| Choi, SW | 2 |
| Han, S | 1 |
| Shim, WJ | 2 |
| Choi, DJ | 5 |
| Kim, YJ | 2 |
| Yoo, BS | 4 |
| Hwang, KK | 2 |
| Jeon, HK | 2 |
| Shin, MS | 2 |
| Ryu, KH | 2 |
| Baek, SH | 4 |
| Ingram, A | 1 |
| Valente, M | 1 |
| Choi, KH | 1 |
| Lee, GY | 1 |
| Choi, JO | 1 |
| Jeon, ES | 3 |
| Lee, HY | 3 |
| Lee, SE | 1 |
| Kim, JJ | 3 |
| Chae, SC | 2 |
| Kang, SM | 3 |
| Kim, KH | 2 |
| Cho, MC | 2 |
| Park, HY | 1 |
| Oh, BH | 2 |
| Loop, MS | 1 |
| van Dyke, MK | 1 |
| Chen, L | 1 |
| Safford, MM | 1 |
| Kilgore, ML | 1 |
| Brown, TM | 1 |
| Durant, RW | 1 |
| Levitan, EB | 1 |
| Park, JJ | 1 |
| Park, HA | 1 |
| Cho, HJ | 1 |
| Kakehi, K | 1 |
| Iwanaga, Y | 1 |
| Watanabe, H | 1 |
| Sonobe, T | 1 |
| Akiyama, T | 1 |
| Shimizu, S | 1 |
| Yamamoto, H | 1 |
| Miyazaki, S | 1 |
| Mueller, DN | 1 |
| Wilck, N | 1 |
| Riemekasten, G | 1 |
| Dragun, D | 1 |
| Busjahn, A | 1 |
| Heidecke, H | 1 |
| Junker, J | 1 |
| Dechend, R | 1 |
| Tsutsui, H | 1 |
| Masuyama, T | 1 |
| Murohara, T | 1 |
| Kinugawa, S | 1 |
| Apostolo, A | 4 |
| Cattadori, G | 4 |
| Paolillo, S | 1 |
| Iorio, A | 1 |
| Bertella, E | 1 |
| Salvioni, E | 3 |
| Alimento, M | 2 |
| Farina, S | 2 |
| Palermo, P | 4 |
| Loguercio, M | 1 |
| Mantegazza, V | 1 |
| Karsten, M | 1 |
| Magrì, D | 2 |
| Fiorentini, C | 3 |
| Taniguchi, T | 1 |
| Ohtani, T | 1 |
| Mizote, I | 1 |
| Kanzaki, M | 1 |
| Ichibori, Y | 1 |
| Minamiguchi, H | 1 |
| Asano, Y | 1 |
| Hori, M | 1 |
| Nagai, R | 1 |
| Izumi, T | 1 |
| Matsuzaki, M | 1 |
| Díez-Manglano, J | 1 |
| Li, X | 3 |
| Wang, T | 3 |
| Sun, C | 1 |
| Jin, T | 1 |
| Yan, H | 1 |
| Zhang, J | 3 |
| Geng, T | 1 |
| Ma, A | 3 |
| Li, S | 1 |
| Ni, Y | 1 |
| Zhuo, X | 1 |
| Song, B | 1 |
| Wei, F | 1 |
| Bai, H | 1 |
| Wang, X | 1 |
| Yang, D | 1 |
| Gao, L | 1 |
| Gelbrich, G | 9 |
| Jankovic-Tomasevic, R | 1 |
| Pavlovic, M | 2 |
| Djordjevic-Radojkovic, D | 1 |
| Salinger-Martinovic, S | 1 |
| Putnikovic, B | 4 |
| Radovanovic, S | 1 |
| Waagstein, F | 7 |
| Tomasevic, M | 1 |
| Musial-Bright, L | 2 |
| Springer, J | 1 |
| Tschirner, A | 1 |
| Haghikia, A | 1 |
| von Haehling, S | 4 |
| Lal, H | 1 |
| Grzesiak, A | 1 |
| Palus, S | 1 |
| Pötsch, M | 1 |
| von Websky, K | 1 |
| Hocher, B | 1 |
| Latouche, C | 1 |
| Jaisser, F | 1 |
| Morawietz, L | 1 |
| Coats, AJ | 1 |
| Beadle, J | 1 |
| Argiles, JM | 1 |
| Thum, T | 1 |
| Földes, G | 1 |
| Doehner, W | 3 |
| Hilfiker-Kleiner, D | 1 |
| Force, T | 1 |
| Anker, SD | 7 |
| Rengo, G | 2 |
| Cannavo, A | 2 |
| Liccardo, D | 2 |
| Zincarelli, C | 2 |
| de Lucia, C | 2 |
| Pagano, G | 2 |
| Komici, K | 1 |
| Parisi, V | 1 |
| Scala, O | 1 |
| Agresta, A | 1 |
| Rapacciuolo, A | 2 |
| Perrone Filardi, P | 2 |
| Ferrara, N | 2 |
| Koch, WJ | 1 |
| Trimarco, B | 1 |
| Femminella, GD | 1 |
| Leosco, D | 2 |
| Nagy, V | 1 |
| Riccioni, G | 1 |
| Masciocco, L | 1 |
| Benvenuto, A | 1 |
| Saracino, P | 1 |
| De Viti, D | 1 |
| Massari, F | 1 |
| Meliota, G | 1 |
| Buta, F | 1 |
| Speziale, G | 1 |
| Charoo, NA | 1 |
| Shamsher, AA | 1 |
| Lian, LY | 1 |
| Abrahamsson, B | 1 |
| Cristofoletti, R | 1 |
| Groot, DW | 1 |
| Kopp, S | 1 |
| Langguth, P | 1 |
| Polli, J | 1 |
| Shah, VP | 1 |
| Dressman, J | 1 |
| Constantinescu, AA | 1 |
| Caliskan, K | 1 |
| Manintveld, OC | 1 |
| van Domburg, R | 1 |
| Jewbali, L | 1 |
| Balk, AH | 1 |
| Sekularac, N | 1 |
| Störk, S | 1 |
| Tscholl, V | 1 |
| Krackhardt, F | 2 |
| Andersen, S | 1 |
| Schultz, JG | 1 |
| Andersen, A | 1 |
| Ringgaard, S | 1 |
| Nielsen, JM | 1 |
| Holmboe, S | 1 |
| Vildbrad, MD | 1 |
| de Man, FS | 3 |
| Bogaard, HJ | 2 |
| Vonk-Noordegraaf, A | 2 |
| Nielsen-Kudsk, JE | 1 |
| Cho, MJ | 1 |
| Lim, RK | 1 |
| Jung Kwak, M | 1 |
| Park, KH | 1 |
| Kim, HY | 1 |
| Kim, YM | 1 |
| Lee, HD | 1 |
| Javed, O | 1 |
| Koo, K | 1 |
| El-Omar, O | 1 |
| Allen, S | 1 |
| Squires, A | 1 |
| El-Omar, M | 1 |
| Palmisano, P | 1 |
| Ammendola, E | 1 |
| D'Onofrio, A | 1 |
| Accogli, M | 1 |
| Calò, L | 1 |
| Ruocco, A | 1 |
| Del Giorno, G | 1 |
| Bianchi, V | 1 |
| Malacrida, M | 1 |
| Valsecchi, S | 1 |
| Gronda, E | 2 |
| Boivin, V | 1 |
| Beyersdorf, N | 1 |
| Palm, D | 1 |
| Nikolaev, VO | 1 |
| Schlipp, A | 1 |
| Müller, J | 1 |
| Schmidt, D | 1 |
| Kocoski, V | 1 |
| Kerkau, T | 1 |
| Hünig, T | 1 |
| Ertl, G | 1 |
| Lohse, MJ | 1 |
| Jahns, R | 1 |
| Garcia-Egido, A | 1 |
| Andrey, JL | 1 |
| Puerto, JL | 1 |
| Aranda, RM | 1 |
| Pedrosa, MJ | 1 |
| López-Sáez, JB | 1 |
| Rosety, M | 1 |
| Gomez, F | 1 |
| Kubota, Y | 1 |
| Asai, K | 1 |
| Furuse, E | 1 |
| Murai, K | 1 |
| Tsukada, YT | 1 |
| Shimizu, W | 1 |
| Elder, DH | 1 |
| Mohan, M | 1 |
| Cochrane, L | 1 |
| Charles, H | 1 |
| Pasternak, B | 1 |
| Mattsson, A | 1 |
| Svanström, H | 1 |
| Hviid, A | 1 |
| Dekleva, M | 2 |
| Lazic, JS | 1 |
| Soldatovic, I | 1 |
| Arandjelovic, A | 1 |
| Cvijanovic, D | 1 |
| Jackson, MW | 1 |
| Taylor, RJ | 1 |
| Tang, CH | 1 |
| Wang, CC | 1 |
| Chen, TH | 1 |
| Hong, CY | 1 |
| Sue, YM | 1 |
| Su, VY | 1 |
| Chang, YS | 1 |
| Hu, YW | 1 |
| Hung, MH | 1 |
| Ou, SM | 1 |
| Lee, FY | 1 |
| Chou, KT | 1 |
| Yang, KY | 1 |
| Perng, DW | 1 |
| Chen, TJ | 1 |
| Liu, CJ | 1 |
| Chung, WJ | 1 |
| Seo, HS | 1 |
| Shin, JH | 1 |
| Lim, SC | 1 |
| Déniel, A | 1 |
| Fedrizzi, S | 1 |
| Lelong-Boulouard, V | 1 |
| Coquerel, A | 1 |
| Alexandre, J | 1 |
| Du, Y | 1 |
| Xi, Y | 1 |
| Wu, G | 1 |
| Han, K | 1 |
| Huang, X | 1 |
| Cvan Trobec, K | 1 |
| Grabnar, I | 1 |
| Kerec Kos, M | 1 |
| Vovk, T | 1 |
| Trontelj, J | 1 |
| Rosano, G | 1 |
| Han, SW | 1 |
| Kim, HJ | 1 |
| Kim, SH | 1 |
| Cha, TJ | 1 |
| Kim, JH | 1 |
| Jeon, H | 1 |
| Fi, Z | 1 |
| Szentes, V | 1 |
| Miró, Ò | 1 |
| Müller, C | 1 |
| Martín-Sánchez, FJ | 1 |
| Bueno, H | 1 |
| Mebazaa, A | 1 |
| Herrero, P | 1 |
| Jacob, J | 1 |
| Gil, V | 1 |
| Escoda, R | 1 |
| Llorens, P | 1 |
| van Campen, JS | 1 |
| de Boer, K | 1 |
| van de Veerdonk, MC | 1 |
| van der Bruggen, CE | 1 |
| Allaart, CP | 1 |
| Raijmakers, PG | 1 |
| Heymans, MW | 1 |
| Marcus, JT | 1 |
| Harms, HJ | 1 |
| Handoko, ML | 2 |
| Vonk Noordegraaf, A | 1 |
| Buś-Kwaśnik, K | 1 |
| Rudzki, PJ | 1 |
| Ksycińska, H | 1 |
| Leś, A | 1 |
| Serafin-Byczak, K | 1 |
| Raszek, J | 1 |
| Bielak, A | 1 |
| Wybraniec, A | 1 |
| Płatek, AE | 1 |
| Szymański, FM | 1 |
| Łazowski, T | 1 |
| Campean, R | 1 |
| Hasun, M | 1 |
| Stöllberger, C | 1 |
| Bucher, J | 1 |
| Finsterer, J | 1 |
| Schnack, C | 1 |
| Weidinger, F | 1 |
| Amano, H | 1 |
| Perreault, S | 1 |
| de Denus, S | 1 |
| White, M | 1 |
| White-Guay, B | 1 |
| Bouvier, M | 1 |
| Dorais, M | 1 |
| Dubé, MP | 1 |
| Rouleau, JL | 1 |
| Tardif, JC | 1 |
| Jenna, S | 1 |
| Haibe-Kains, B | 1 |
| Leduc, R | 1 |
| Deblois, D | 1 |
| Kanorsky, SG | 1 |
| Borisenko, YV | 1 |
| Dobre, D | 1 |
| Goulder, MA | 1 |
| Krum, H | 10 |
| Willenheimer, R | 8 |
| Wachter, R | 3 |
| Eschenhagen, T | 3 |
| Follath, F | 8 |
| Rauchhaus, M | 1 |
| Haverkamp, W | 3 |
| Osterziel, KJ | 1 |
| Dietz, R | 5 |
| Aygul, N | 1 |
| Ozdemir, K | 1 |
| Duzenli, MA | 1 |
| Aygul, MU | 1 |
| Remme, WJ | 5 |
| Bernjak, A | 1 |
| Clarkson, PB | 1 |
| McClintock, PV | 1 |
| Stefanovska, A | 1 |
| Tang, FK | 1 |
| Hua, N | 1 |
| Lu, H | 1 |
| Xiao, J | 1 |
| Tang, XZ | 1 |
| Qi, Z | 1 |
| Dalla Libera, L | 2 |
| Ravara, B | 2 |
| Gobbo, V | 2 |
| Betto, DD | 1 |
| Germinario, E | 2 |
| Angelini, A | 2 |
| Evangelista, S | 1 |
| Vescovo, G | 2 |
| Hawkins, NM | 1 |
| MacDonald, MR | 1 |
| Chalmers, GW | 1 |
| Carter, R | 1 |
| Dunn, FG | 1 |
| McMurray, JJ | 4 |
| van de Ven, LL | 2 |
| Goulder, M | 3 |
| Zilahi, Z | 1 |
| Meyer, WR | 2 |
| Sal'nikov, EV | 1 |
| Adams, KF | 2 |
| Giles, TD | 1 |
| Shaw, SM | 1 |
| Coppinger, T | 1 |
| Waywell, C | 1 |
| Dunne, L | 1 |
| Archer, LD | 1 |
| Critchley, WR | 1 |
| Yonan, N | 1 |
| Fildes, JE | 1 |
| Williams, SG | 1 |
| Verdú Rotellar, JM | 1 |
| Barroso, A | 1 |
| Bernáldez, MJ | 1 |
| Domíngueza, M | 1 |
| Pie, M | 1 |
| Sancho, F | 1 |
| Simó, M | 1 |
| Domingo, M | 1 |
| Roughead, EE | 1 |
| Barratt, JD | 1 |
| Ramsay, E | 1 |
| Pratt, N | 1 |
| Ryan, P | 1 |
| Peck, R | 1 |
| Killer, G | 1 |
| Gilbert, AL | 1 |
| Targoński, R | 1 |
| Sadowski, J | 1 |
| Szydło, K | 1 |
| Zhubrina, ES | 2 |
| Ovchinnikov, AG | 2 |
| Seredenina, EM | 2 |
| Patrusheva, IF | 1 |
| Blankova, ZN | 1 |
| Kuz'mina, AE | 1 |
| Kheĭmets, GI | 1 |
| Ageev, FT | 2 |
| Castagno, D | 2 |
| Jhund, PS | 1 |
| Lewsey, JD | 1 |
| Erdmann, E | 8 |
| Zannad, F | 2 |
| Lopez-Sendon, JL | 2 |
| Lechat, P | 18 |
| Höglund, C | 3 |
| Mareev, V | 2 |
| Sadowski, Z | 2 |
| Seabra-Gomes, RJ | 2 |
| Dargie, HJ | 2 |
| Konishi, M | 1 |
| Haraguchi, G | 1 |
| Kimura, S | 1 |
| Inagaki, H | 1 |
| Kawabata, M | 1 |
| Hachiya, H | 1 |
| Hirao, K | 1 |
| Isobe, M | 1 |
| Jabbour, A | 1 |
| Macdonald, PS | 1 |
| Keogh, AM | 1 |
| Kotlyar, E | 1 |
| Mellemkjaer, S | 1 |
| Coleman, CF | 1 |
| Elsik, M | 1 |
| Hayward, CS | 1 |
| Bouallal, R | 1 |
| Godart, F | 1 |
| Francart, C | 1 |
| Richard, A | 1 |
| Foucher-Hossein, C | 3 |
| Lions, C | 1 |
| Funck-Brentano, C | 7 |
| Vanoli, E | 3 |
| Silke, B | 3 |
| Ponikowski, P | 4 |
| Meyer, W | 2 |
| Cauti, FM | 1 |
| Magini, A | 1 |
| Bussotti, M | 3 |
| Berna, G | 1 |
| Antonioli, L | 1 |
| Schina, M | 1 |
| Marazzi, G | 1 |
| Iellamo, F | 1 |
| Volterrani, M | 1 |
| Caminiti, G | 1 |
| Madonna, M | 1 |
| Arisi, G | 1 |
| Massaro, R | 1 |
| Righi, D | 1 |
| Rosano, GM | 1 |
| Yanagisawa, S | 1 |
| Suzuki, N | 1 |
| Tanaka, T | 1 |
| Gallanagh, S | 1 |
| Wilson, B | 1 |
| Töpper, A | 1 |
| Mehrhof, F | 1 |
| Prettin, C | 1 |
| Neskovic, AN | 4 |
| Krotin, M | 1 |
| Sakac, D | 1 |
| Rau, T | 3 |
| Pituskin, E | 1 |
| Haykowsky, M | 1 |
| Mackey, JR | 1 |
| Thompson, RB | 1 |
| Ezekowitz, J | 1 |
| Koshman, S | 1 |
| Oudit, G | 1 |
| Chow, K | 1 |
| Pagano, JJ | 1 |
| Paterson, I | 1 |
| Shilov, AM | 1 |
| Dulaeva, MS | 1 |
| Rohrer, CK | 1 |
| Page, RL | 1 |
| Shakar, SF | 1 |
| Lindenfeld, J | 1 |
| Podbregar, M | 3 |
| Kovacic, D | 2 |
| Rozman, J | 1 |
| Loeffler, M | 1 |
| van Ballegoij, JJ | 1 |
| Schalij, I | 1 |
| Bogaards, SJ | 1 |
| Postmus, PE | 1 |
| van der Velden, J | 1 |
| Westerhof, N | 1 |
| Paulus, WJ | 1 |
| Spoladore, R | 1 |
| Fragasso, G | 1 |
| Perseghin, G | 1 |
| De Cobelli, F | 1 |
| Esposito, A | 1 |
| Maranta, F | 1 |
| Calori, G | 1 |
| Locatelli, M | 1 |
| Lattuada, G | 1 |
| Scifo, P | 1 |
| Del Maschio, A | 1 |
| Margonato, A | 1 |
| Sarraf, M | 1 |
| Francis, GS | 2 |
| He, YM | 1 |
| Yang, XJ | 1 |
| Zhao, X | 1 |
| Cheng, XJ | 1 |
| Xu, HF | 1 |
| Qian, YX | 1 |
| Lymperopoulos, A | 1 |
| Femminella, G | 1 |
| Gargiulo, P | 1 |
| Koch, W | 1 |
| Aquilani, R | 1 |
| La Rovere, MT | 1 |
| Febo, O | 1 |
| Baiardi, P | 1 |
| Boschi, F | 1 |
| Iadarola, P | 1 |
| Viglio, S | 1 |
| Dossena, M | 1 |
| Bongiorno, AI | 1 |
| Pastoris, O | 1 |
| Verri, M | 1 |
| Dimković, S | 1 |
| Stiefelhagen, P | 1 |
| Mascioli, G | 1 |
| Padeletti, L | 1 |
| Sassone, B | 1 |
| Zecchin, M | 1 |
| Lucca, E | 1 |
| Sacchi, S | 1 |
| Boggian, G | 1 |
| Tondo, AL | 1 |
| Belvito, C | 1 |
| Bakhtadze, N | 1 |
| Borrelli, A | 1 |
| Sinagra, G | 3 |
| Stankovic, I | 1 |
| Minushkina, LO | 1 |
| Hirsh, BJ | 1 |
| Mignatti, A | 1 |
| Garan, AR | 1 |
| Uriel, N | 1 |
| Colombo, P | 1 |
| Sims, DB | 1 |
| Jorde, UP | 1 |
| Kassner, A | 1 |
| Toischer, K | 1 |
| Bohms, B | 1 |
| Kolkhof, P | 1 |
| Abraham, G | 1 |
| Hasenfuβ, G | 1 |
| Morshuis, M | 1 |
| Schulte Eistrup, S | 1 |
| El-Banayosy, A | 1 |
| Gummert, J | 1 |
| Milting, H | 1 |
| Nikolic, VN | 1 |
| Jevtovic-Stoimenov, T | 1 |
| Velickovic-Radovanović, R | 1 |
| Ilic, S | 1 |
| Deljanin-Ilic, M | 1 |
| Marinkovic, D | 1 |
| Zivanovic, S | 1 |
| Stefanovic, N | 1 |
| Pesic, S | 1 |
| Zecevic, DR | 1 |
| Milovanovic, JR | 1 |
| Jankovic, SM | 1 |
| Incrot, S | 1 |
| Suzic Lazic, J | 1 |
| Pavlovic Kleut, M | 1 |
| Sawant, RD | 1 |
| Freeman, LJ | 1 |
| Stanley, KP | 1 |
| McKelvey, A | 1 |
| Scherer, M | 1 |
| Lashki, DJ | 1 |
| Neskovic, A | 1 |
| Bobadilla, RV | 1 |
| Baxter, AJ | 1 |
| Spensley, A | 1 |
| Hildreth, A | 1 |
| Karimova, G | 1 |
| O'Connell, JE | 1 |
| Gray, CS | 1 |
| Rollins, G | 1 |
| McGavin, JK | 1 |
| Keating, GM | 1 |
| Pölzl, G | 1 |
| Gouya, G | 1 |
| Hügel, H | 1 |
| Frick, M | 1 |
| Ulmer, H | 1 |
| Pachinger, O | 1 |
| Voga, G | 1 |
| Simon, T | 2 |
| Mary-Krause, M | 2 |
| Jaillon, P | 5 |
| Chin, BS | 2 |
| Langford, NJ | 1 |
| Nuttall, SL | 1 |
| Gibbs, CR | 2 |
| Blann, AD | 2 |
| Inoko, M | 1 |
| Nohara, R | 1 |
| Bouzamondo, A | 1 |
| Hulot, JS | 1 |
| Sanchez, P | 1 |
| Sallach, JA | 1 |
| Goldstein, S | 3 |
| Ol'binskaia, LI | 1 |
| Ignatenko, SB | 1 |
| Böhm, M | 1 |
| Maack, C | 1 |
| Wehrlen-Grandjean, M | 1 |
| González-Juanatey, JR | 1 |
| Alegría Ezquerra, E | 1 |
| García Saavedra, V | 1 |
| Pérez Ojeda, G | 1 |
| Ruiz Ros, JA | 1 |
| Espinosa Caliani, JS | 1 |
| Anguita Sánchez, M | 1 |
| Schrickel, J | 1 |
| Bielik, H | 1 |
| Yang, A | 1 |
| Schwab, JO | 1 |
| Shlevkov, N | 1 |
| Schimpf, R | 1 |
| Lüderitz, B | 1 |
| Lewalter, T | 1 |
| Belenkov, IuN | 3 |
| Skvortsov, AA | 3 |
| Mareev, VIu | 3 |
| Nasonova, SN | 3 |
| Sychev, AV | 3 |
| Narusov, OIu | 1 |
| Baklanova, NA | 3 |
| Masenko, VP | 3 |
| Bolger, AP | 2 |
| Al-Nasser, F | 1 |
| Terzi, S | 1 |
| Dayi, SU | 1 |
| Akbulut, T | 1 |
| Dağ, O | 1 |
| Köse, H | 1 |
| Satiroğlu, O | 1 |
| Sayar, N | 1 |
| Bilsel, T | 1 |
| Aksoy, S | 1 |
| Yeşilçimen, K | 1 |
| Tang, WH | 1 |
| Militello, M | 1 |
| Lechat, PP | 1 |
| Fung, JW | 1 |
| Yu, CM | 1 |
| Kum, LC | 1 |
| Yip, GW | 1 |
| Sanderson, JE | 1 |
| Tereshchenko, SN | 2 |
| Bulanova, NA | 1 |
| Kositsyna, IV | 1 |
| Morozova, MN | 2 |
| Uteshev, IuA | 2 |
| Patel, MR | 1 |
| Gattis, W | 1 |
| Bristow, MR | 2 |
| Feldman, AM | 1 |
| Hare, D | 1 |
| Van De Ven, L | 2 |
| Verkenne, P | 4 |
| Ko, DT | 1 |
| Hebert, PR | 1 |
| Coffey, CS | 1 |
| Curtis, JP | 1 |
| Foody, JM | 1 |
| Sedrakyan, A | 1 |
| Krumholz, HM | 2 |
| Di Lenarda, A | 1 |
| Sabbadini, G | 1 |
| Galatius, S | 1 |
| Gustafsson, F | 2 |
| Hildebrandt, PR | 1 |
| Ivanenko, VV | 1 |
| Riazantseva, NV | 1 |
| Tarasov, DL | 1 |
| Lopatin, IuM | 1 |
| de Groote, P | 4 |
| Delour, P | 2 |
| Lamblin, N | 3 |
| Dagorn, J | 2 |
| Verkindère, C | 2 |
| Tison, E | 1 |
| Millaire, A | 1 |
| Bauters, C | 3 |
| Jafri, SM | 1 |
| Fedorova, TA | 1 |
| Il'ina, IuV | 1 |
| Sotnikova, TI | 1 |
| Rybakova, MK | 1 |
| Sauls, JL | 1 |
| Rone, T | 1 |
| Murakami, T | 1 |
| Genth-Zotz, S | 1 |
| Kalra, PR | 1 |
| Kemp, M | 1 |
| Adcock, IM | 1 |
| Poole-Wilson, PA | 2 |
| Belousov, IuB | 1 |
| Upnitskiĭ, AA | 1 |
| Khanina, NIu | 1 |
| Danieli Betto, D | 1 |
| Díez Manglano, J | 1 |
| Helbecque, N | 1 |
| Hermant, X | 1 |
| Mc Fadden, E | 1 |
| Amouyel, P | 1 |
| Dallongeville, J | 1 |
| Schuchert, A | 1 |
| Thackray, S | 1 |
| Nikitin, NP | 1 |
| Cleland, JG | 1 |
| Kowey, PR | 1 |
| Wang, F | 2 |
| Xu, ZM | 1 |
| Wang, L | 1 |
| Bian, WY | 1 |
| Jia, X | 1 |
| Duan, B | 1 |
| Li, W | 1 |
| Li, YS | 1 |
| McMurray, J | 1 |
| Cohen-Solal, A | 1 |
| Eichhorn, E | 1 |
| Erhardt, L | 1 |
| Hobbs, FD | 1 |
| Maggioni, A | 1 |
| McKelvie, RS | 1 |
| Piña, IL | 1 |
| Soler-Soler, J | 1 |
| Swedberg, K | 1 |
| Skene, A | 1 |
| Dickstein, K | 1 |
| Di Stasi, F | 1 |
| Scalone, L | 1 |
| De Portu, S | 1 |
| Menditto, E | 1 |
| Mantovani, LG | 1 |
| Urrutia, A | 1 |
| Lupón, J | 1 |
| Altimir, S | 1 |
| González, B | 1 |
| Herreros, J | 1 |
| Díez, C | 1 |
| Coll, R | 1 |
| Valle, V | 1 |
| Rey-Joly, C | 1 |
| Filipiak, KJ | 1 |
| Opolski, G | 1 |
| Bailey, M | 1 |
| Dargie, H | 2 |
| Anker, S | 1 |
| Ichihara, S | 1 |
| Ichihara, G | 1 |
| Kanazawa, H | 1 |
| Hashimoto, K | 1 |
| Matsushita, A | 1 |
| Oikawa, S | 1 |
| Yokota, M | 1 |
| Iwase, M | 1 |
| Arbolishvili, GN | 2 |
| Yu, WP | 1 |
| Lou, M | 1 |
| Deng, B | 1 |
| Song, HM | 1 |
| Wang, HB | 1 |
| Chuich, NG | 1 |
| Kochetov, AG | 1 |
| Issa, VS | 1 |
| Guimarães, GV | 1 |
| Rezende, MV | 1 |
| Cruz, Fd | 1 |
| Ferreira, SM | 1 |
| Bacal, F | 1 |
| Bocchi, EA | 1 |
| Kawano, S | 1 |
| Norozi, K | 1 |
| Bahlmann, J | 1 |
| Raab, B | 1 |
| Alpers, V | 1 |
| Arnhold, JO | 1 |
| Kuehne, T | 1 |
| Klimes, K | 1 |
| Zoege, M | 1 |
| Geyer, S | 1 |
| Wessel, A | 1 |
| Buchhorn, R | 1 |
| Shaddy, RE | 1 |
| Tang, HF | 1 |
| Wu, SL | 1 |
| Deng, CY | 1 |
| Zhang, WC | 1 |
| Kuang, SJ | 1 |
| Marinsek, M | 1 |
| Gobec, L | 1 |
| Tomcsányi, J | 1 |
| Wettstein, A | 1 |
| Toldy-Schedel, E | 1 |
| Somlói, M | 1 |
| Mouquet, F | 2 |
| Hennebert, O | 1 |
| Le Tourneau, T | 1 |
| Li, N | 1 |
| Jiang, W | 1 |
| Huang, J | 1 |
| Xu, Z | 1 |
| Hua, L | 1 |
| Hua, C | 1 |
| Huang, Y | 1 |
| Wu, Y | 1 |
| Li, F | 1 |
| Ennezat, PV | 1 |
| Rosenberg, J | 1 |
| Dequarti, MC | 1 |
| Poggio, L | 1 |
| Aronson, JK | 1 |
| Pousset, F | 2 |
| Copie, X | 2 |
| Boissel, JP | 2 |
| Hetzel, M | 2 |
| Fillette, F | 1 |
| Remme, W | 1 |
| Guize, L | 2 |
| Le Heuzey, JY | 3 |
| Li, L | 1 |
| Escolano, S | 1 |
| Golmard, JL | 1 |
| Lardoux, H | 2 |
| Witchitz, S | 1 |
| Henneman, JA | 1 |
| Maisch, B | 1 |
| Mallet, A | 1 |
| Schädlich, PK | 2 |
| Paschen, B | 3 |
| Brecht, JG | 2 |
| Boccanelli, A | 1 |
| Camerini, F | 1 |
| Gavazzi, A | 1 |
| Maggioni, AP | 1 |
| Opasich, C | 1 |
| Rapezzi, C | 1 |
| Scherillo, M | 1 |
| Tavazzi, L | 2 |
| Kulbertus, H | 2 |
| Piérard, L | 1 |
| McMenemy, MC | 1 |
| Andréjak, M | 1 |
| Slama, M | 1 |
| Willette, RN | 1 |
| Aiyar, N | 1 |
| Yue, TL | 1 |
| Mitchell, MP | 1 |
| Disa, J | 1 |
| Storer, BL | 1 |
| Naselsky, DP | 1 |
| Stadel, JM | 1 |
| Ohlstein, EH | 1 |
| Ruffolo, RR | 1 |
| Anthonio, RL | 1 |
| Brouwer, J | 1 |
| Haaksma, J | 1 |
| van der Ven, L | 1 |
| Crijns, HJ | 1 |
| van Gilst, WH | 1 |
| Drummond, GA | 1 |
| Squire, IB | 1 |
| Johnson, S | 1 |
| Newton, W | 1 |
| Mahé, I | 1 |
| Carson, PE | 1 |
| vom Dahl, J | 1 |
| Schotten, U | 1 |
| Sasse, A | 1 |
| Liedholm, H | 1 |
| Linné, AB | 1 |
| Merlo, J | 1 |
| Kendall, MJ | 1 |
| Malek, M | 1 |
| Witkowska, M | 1 |
| Ritzmann, P | 1 |
| Lancar, R | 2 |
| Soubrié, C | 1 |
| Song, J | 1 |
| White, CM | 1 |
| Davis, M | 1 |
| Suwa, M | 1 |
| Ito, T | 2 |
| Kobashi, A | 1 |
| Yagi, H | 1 |
| Terasaki, F | 1 |
| Hirota, Y | 1 |
| Kawamura, K | 1 |
| Garlichs, C | 1 |
| Daniel, WG | 1 |
| Reddy, P | 1 |
| Dunn, AB | 1 |
| Drummond, G | 1 |
| Gottlieb, SS | 1 |
| LeJemtel, TH | 1 |
| Frantz, RP | 1 |
| Whorlow, SL | 1 |
| Vítovec, J | 1 |
| Spinar, J | 1 |
| Ertle, G | 1 |
| Movahed, A | 1 |
| Chavey, WE | 1 |
| Hart, SM | 1 |
| Peng, DQ | 1 |
| Zhao, SP | 1 |
| Chen, Y | 1 |
| Li, XP | 1 |
| Szucs, TD | 1 |
| Schwenkglenks, M | 1 |
| Gregory, D | 1 |
| Udelson, JE | 1 |
| Konstam, MA | 1 |
| Varney, S | 1 |
| Lee, S | 1 |
| Spencer, A | 1 |
| Coutinho, J | 1 |
| Wiemann, H | 1 |
| Czuriga, I | 1 |
| Edes, I | 1 |
| Ekman, M | 2 |
| Zethraeus, N | 2 |
| Jönsson, B | 1 |
| Hansen, S | 1 |
| Hohnloser, SH | 1 |
| Sleiman, OI | 1 |
| Murin, J | 1 |
| Ghanem, WM | 1 |
| Watanabe, K | 1 |
| Ohta, Y | 1 |
| Inoue, M | 1 |
| Ma, M | 1 |
| Wahed, MI | 1 |
| Nakazawa, M | 1 |
| Hasegawa, G | 1 |
| Naito, M | 1 |
| Fuse, K | 1 |
| Ito, M | 1 |
| Kato, K | 1 |
| Hanawa, H | 1 |
| Kodama, M | 1 |
| Aizawa, Y | 1 |
| Wald, DS | 1 |
| More, RS | 1 |
| Martin, M | 1 |
| Hughes, L | 1 |
| Reid, CJ | 1 |
| Leizorovicz, A | 1 |
| Cucherat, M | 1 |
| Bugnard, F | 1 |
| Dahlström, U | 1 |
| Richardt, G | 1 |
| Richardt, D | 1 |
| Adler, S | 1 |
| Kraatz, E | 1 |
| Nötzold, A | 1 |
| Kurz, T | 1 |
| Ogawa, T | 1 |
| Hieda, N | 1 |
| Sugiyama, S | 1 |
| Satake, T | 1 |
| Ozawa, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Improving Outcomes in Atrial Fibrillation Patients Aided by Implantable Cardiac Monitor: Evaluation of Chronic Beta-blocker Use Versus As-needed Pharmacological Rate Control[NCT05745337] | Phase 1 | 20 participants (Anticipated) | Interventional | 2023-02-06 | Recruiting | ||
| Left Atrium Reservoir Function Modulation in Patients With Atrial Fibrillation: A Randomized Digoxin Versus Beta Blocker Study[NCT05540600] | Phase 3 | 30 participants (Anticipated) | Interventional | 2022-09-12 | Recruiting | ||
| Evaluating Different Rate Control Therapies in Permanent Atrial Fibrillation: A Prospective, Randomised, Open-label, Blinded Endpoint Feasibility Pilot Comparing Digoxin and Beta-blockers as Initial Rate Control Therapy[NCT02391337] | Phase 4 | 161 participants (Actual) | Interventional | 2016-12-20 | Completed | ||
| Phase I Open Label, Randomized, Controlled, Dose-Escalation Study to Evaluate Safety and Immunogenicity of VPM1002 in Comparison With BCG in Healthy Male Volunteers Stratified for History of BCG-Vaccination[NCT00749034] | Phase 1 | 80 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| Registry (Prospective Cohort) for Heart Failure in Korea (KorAHF)[NCT01389843] | 5,625 participants (Actual) | Observational | 2011-03-31 | Completed | |||
| Bisoprolol Plasma Residual Concentrations for the Optimization of Drug Management in Heart Failure With Mild to Reduced Ejection Fraction[NCT03644446] | 81 participants (Anticipated) | Observational [Patient Registry] | 2017-11-02 | Recruiting | |||
| Beta-blocker Therapy in Idiopathic Pulmonary Arterial Hypertension[NCT01246037] | Phase 1/Phase 2 | 30 participants (Anticipated) | Interventional | 2011-02-28 | Active, not recruiting | ||
| Cardioselective Beta-Blockade Using Bisoprolol in Patients With Chronic Heart Failure (CHF) and Coexistent Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) With or Without Significant Reversibility.[NCT00702156] | Phase 2 | 27 participants (Actual) | Interventional | 2005-03-31 | Terminated (stopped due to Inadequate patient recruitment) | ||
| Cross Cultural Adaptation of Functional Status Questionnaire (FSQ) in Urdu Language in CABG Patients[NCT05023083] | 70 participants (Actual) | Observational [Patient Registry] | 2021-05-23 | Completed | |||
| A Prospective Study to See if Cardiac Effects of Herceptin Can be Prevented With Standard Heart Medications[NCT01016886] | Phase 1/Phase 2 | 99 participants (Actual) | Interventional | 2010-09-30 | Active, not recruiting | ||
| Multi-Disciplinary Rehabilitation Program in Recently Hospitalized Patients With Preserved Ejection Fraction Heart Failure[NCT01914315] | 1,100 participants (Anticipated) | Interventional | 2013-10-31 | Recruiting | |||
| Molecular Mechanisms of Volume Overload-Aim 1(SCCOR in Cardiac Dysfunction and Disease)[NCT01052428] | Phase 2/Phase 3 | 38 participants (Actual) | Interventional | 2004-08-31 | Completed | ||
| An Open Label, Pharmacogenetic Study of Bisoprolol Treatment in Patients With Uncontrolled Essential Hypertension (BRAVE)[NCT02398929] | Phase 4 | 100 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
| Reverse Remodeling is Associated With Hemodynamic Improvement and Stabilization in Outpatients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan: an Echocardiographic Study[NCT04397302] | 652 participants (Actual) | Observational [Patient Registry] | 2019-01-13 | Completed | |||
| Long Term Study on the Possible Beneficial Effects of Catheterised Renal Denervation in Patients With Heart Failure and Left Ventricular Systolic Dysfunction Who Are Already on Standard Medical Therapy.[NCT01870310] | 50 participants (Anticipated) | Interventional | 2012-06-30 | Recruiting | |||
| A Multicenter,Randomized, Double Blind, Double Dummy, Parallel Group Study to Compare Effects of Coreg CR and Coreg IR on Left Ventricular End Systolic Volume Index in Subjects With Stable Chronic Heart Failure[NCT00323037] | Phase 3 | 318 participants (Actual) | Interventional | 2006-03-31 | Completed | ||
| Collaborative Systematic Overview of Randomised Controlled Trials of Beta-Blockers in the Treatment of Heart Failure[NCT00832442] | 18,240 participants (Anticipated) | Observational | 2008-08-31 | Enrolling by invitation | |||
| The PACE-MI Registry Study - Outcomes of Beta-blocker Therapy After Myocardial Infarction (OBTAIN)[NCT00430612] | 7,057 participants (Actual) | Observational [Patient Registry] | 2009-05-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
24 hour ambulatory heart-rate. (NCT02391337)
Timeframe: Within 12 months
| Intervention | bpm (Mean) |
|---|---|
| Beta-blocker | 73.7 |
| Digoxin | 78.9 |
B-type natriuretic peptide (BNP) at 6 months. (NCT02391337)
Timeframe: 6 months
| Intervention | ng/L (Median) |
|---|---|
| Beta-blocker | 1209 |
| Digoxin | 1057.5 |
Number of Participants with hospital admissions for cardiovascular events. (NCT02391337)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Beta-blocker | 12 |
| Digoxin | 2 |
Composite functional status measures- 6 minute walking distance at 12 months. (NCT02391337)
Timeframe: 12 months
| Intervention | metres (Median) |
|---|---|
| Beta-blocker | 329 |
| Digoxin | 366 |
"The above parameters will be measured using echocardiography and diastolic indices.~E/e' - the ratio between early mitral inflow velocity and mitral annular early diastolic velocity." (NCT02391337)
Timeframe: 12 months
| Intervention | Ratio of E/e' (Mean) |
|---|---|
| Beta-blocker | 10.8 |
| Digoxin | 10.8 |
Number of participants requiring drug discontinuation due to adverse reactions. (NCT02391337)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Beta-blocker | 9 |
| Digoxin | 2 |
A composite of adverse clinical events (NCT02391337)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Beta-blocker | 19 |
| Digoxin | 11 |
The above parameters will be measured using echocardiography and diastolic indices (NCT02391337)
Timeframe: 12 months
| Intervention | percentage of ejection fraction (Mean) |
|---|---|
| Beta-blocker | 59.8 |
| Digoxin | 59.7 |
Number of Participants with Unplanned Hospital Admissions. (NCT02391337)
Timeframe: During the 12 month follow-up period.
| Intervention | Participants (Count of Participants) |
|---|---|
| Beta-blocker | 19 |
| Digoxin | 11 |
"As assessed using the EQ-5D-5L summary index questionnaires at both 6 and 12 months.~The range for summary index is from -0.594=worst score to 1=best score" (NCT02391337)
Timeframe: 12 months
| Intervention | units on a scale (Mean) |
|---|---|
| Beta-blocker | 0.62 |
| Digoxin | 0.66 |
As assessed using the AFEQT overall score at 12 months. The range for AFEQT overall score is from 0= complete disability to 100=no disability. (NCT02391337)
Timeframe: 12 months
| Intervention | score on a scale (Mean) |
|---|---|
| Beta-blocker | 68.1 |
| Digoxin | 75.6 |
"Patient-reported outcomes as assessed by the SF-36 questionnaire physical component score.~The physical component score ranges from 0-100 where higher value indicates better outcome." (NCT02391337)
Timeframe: Primary outcome at 6 months timepoint.
| Intervention | score on a scale (Mean) |
|---|---|
| Beta-blocker | 29.7 |
| Digoxin | 31.9 |
As assessed using the SF-36 version 2 global and specific scores at 12 months. All domains presented are between 0 to 100 scale where the higher score indicates better outcomes. (NCT02391337)
Timeframe: 12 months
| Intervention | score on a scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Physical Component Summary | Mental Component Summary | Physical Function Domain Score | Role Limitation Due to Physical Domain score | Role Limitation Due to Emotional Problems Domain score | Social Functioning Domain Score | Mental Health Domain | Energy/Vitality Domain Score | Pain Score | General Health Perception Domain Score | |
| Beta-blocker | 29.4 | 51.3 | 27.5 | 32 | 40.7 | 43.3 | 51.8 | 42 | 41.9 | 39.6 |
| Digoxin | 32.5 | 53.6 | 31.5 | 37 | 45.2 | 45.6 | 51.3 | 47.1 | 40.5 | 42.8 |
Convenience, compliance and cross-over data (NCT02391337)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Death71940422 | Death71940423 | Lost to follow-up71940422 | Lost to follow-up71940423 | Withdrawn consent71940422 | Withdrawn consent71940423 | |||||||
| yes | No | |||||||||||
| Beta-blocker | 7 | |||||||||||
| Digoxin | 4 | |||||||||||
| Beta-blocker | 73 | |||||||||||
| Digoxin | 77 | |||||||||||
| Beta-blocker | 0 | |||||||||||
| Digoxin | 2 | |||||||||||
| Beta-blocker | 80 | |||||||||||
| Beta-blocker | 1 | |||||||||||
| Beta-blocker | 79 | |||||||||||
| Digoxin | 79 | |||||||||||
Left Ventricular Ejection Fraction Is a calculation of heart pump function determined from the volume after complete filling minus the volume after complete contraction divided by the volume after complete filling. A value of 55% or greater is normal. (NCT01052428)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | percent (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=19,19) | Month 3 (n=1,0) | Month 6 (n=17,19) | Month 9 (n=1,1) | Month 12 (n=14,15) | Month 15 (n=3,2) | Month 18 (n=14,18) | Month 21 (n=5,0) | Month 24 (n=16,18) | |
| Placebo | 62.62 | 63.90 | 63.80 | 41.90 | 61.70 | 44.70 | 60.95 | 53.79 | 59.95 |
| Toprol XL | 62.09 | NA | 61.29 | 54.81 | 62.77 | 68.47 | 62.05 | NA | 63.02 |
Left Ventricular End Diastolic Volume Indexed to Body Surface Area: As an indicator of heart size, the blood volume of the heart is related to the body size. The end diastolic volume is the blood volume of the heart at the end of filling, just before contraction. The relation of heart blood volume to body size is more accurate in determining pathology because larger people require a larger heart blood volume. The values that are too high or too low indicate a diseased myocardium. (NCT01052428)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | ml/m^2 (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=19,19) | Month 3 (n=1,0) | Month 6 (n=17,19) | Month 9 (n=1,0) | Month 12 (n=14,15) | Month 15 (n=3,2) | Month 18 (n=14,18) | Month 21 (n=5,0) | Month 24 (n=16,18) | |
| Placebo | 91.66 | 90.93 | 90.84 | 70.56 | 88.99 | 82.73 | 90.16 | 85.75 | 87.31 |
| Toprol XL | 95.74 | NA | 95.24 | NA | 95.71 | 98.16 | 97.6 | NA | 95.16 |
Left Ventricular End Systolic Volume Indexed to Body Surface Area As an indicator of heart size, the blood volume of the heart is related to the body size. The end systolic volume is the blood volume of the heart at the end of contraction and is an index of the pump function of the heart. This relation to body size is more accurate in determining pathology because larger people require a larger heart blood volume. The values that are too high or too low indicate a diseased myocardium. (NCT01052428)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | ml/m^2 (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=19,19) | Month 3 (n=1,0) | Month 6 (n=17,19) | Month 9 (n=1,0) | Month 12 (n=14,15) | Month 15 (n=3,2) | Month 18 (n=14,18) | Month 21 (n=5,0) | Month 24 (n=16,18) | |
| Placebo | 34.01 | 32.83 | 32.53 | 40.99 | 33.70 | 47.25 | 34.99 | 39.97 | 34.47 |
| Toprol XL | 35.98 | NA | 36.53 | NA | 35.89 | 30.97 | 36.72 | NA | 35.13 |
Left Ventricular End-diastolic Mass Indexed to Left Ventricular End-diastolic Volume As an indicator of heart muscle mass and heart blood volume, the mass indexed to end diastolic volume determines whether there is an adequate amount of heart muscle to pump the heart blood volume obtained from a three-dimensional analysis. The values that are too high or too low indicate a diseased myocardium. (NCT01052428)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | g/ml (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=19,19) | Month 3 (n=1,0) | Month 6 (n=17,19) | Month 9 (n=1,1) | Month 12 (n=14,15) | Month 15 (n=3,2) | Month 18 (n=14,18) | Month 21 (n=5,0) | Month 24 (n=16,18) | |
| Placebo | 0.61 | 0.53 | 0.62 | 0.67 | 0.65 | 0.65 | 0.65 | 0.61 | 0.64 |
| Toprol XL | 0.61 | NA | 0.6 | 0.53 | 0.60 | 0.55 | 0.59 | NA | 0.62 |
Left Ventricular End-Diastolic Radius to Wall Thickness As an indicator of heart muscle mass and heart volume chamber diameter, the end-diastolic radius indexed to end diastolic wall thickness determines whether there is an adequate amount of heart muscle to pump the heart blood volume obtained from a two-dimensional analysis. The values that are too high or too low indicate a diseased myocardium. (NCT01052428)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | unitless (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=19,19) | Month 3 (n=1,0) | Month 6 (n=17,19) | Month 9 (n=1,1) | Month 12 (n=14,15) | Month 15 (n=3,2) | Month 18 (n=14,18) | Month 21 (n=5,0) | Month 24 (n=16,18) | |
| Placebo | 4.76 | 5.02 | 4.51 | 4.15 | 4.46 | 4.61 | 4.43 | 4.72 | 4.52 |
| Toprol XL | 4.69 | NA | 4.85 | 5.74 | 4.79 | 5.02 | 4.77 | NA | 4.59 |
Peak Early Filling Rate The peak early filling rate of change is calculated from the slope of the volume during the early filling of the heart with respect to time. The higher values indicate a very healthy heart muscle and lower values are indicative of a very stiff muscle. (NCT01052428)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | EDV/sec (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=19,19) | Month 3 (n=1,0) | Month 6 (n=17,19) | Month 9 (n=1,0) | Month 12 (n=14,15) | Month 15 (n=3,2) | Month 18 (n=14,18) | Month 21 (n=5,0) | Month 24 (n=16,18) | |
| Placebo | 2.27 | 2.58 | 2.38 | 1.56 | 2.26 | 1.83 | 1.95 | 1.73 | 2.17 |
| Toprol XL | 2.12 | NA | 2.08 | NA | 2.24 | 2.28 | 2.26 | NA | 2.25 |
Systolic Longitudinal Strain. By identifying two points on the heart, the strain is the difference between the distance between these two points at the end of filling of the heart and the end of contraction divided by the length at the end of filling. Thus, the measure is like the ejection fraction, however the strain is more localized to a specified segment in the heart muscle. The higher values indicate a healthy heart. (NCT01052428)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | percent/%Systolic interval (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=19,19) | Month 3 (n=1,0) | Month 6 (n=17,19) | Month 9 (n=1,0) | Month 12 (n=14,15) | Month 15 (n=3,2) | Month 18 (n=14,18) | Month 21 (n=5,0) | Month 24 (n=16,18) | |
| Placebo | 87.94 | 115.07 | 45.90 | 37.2 | 87.85 | 52.95 | 88.11 | 67.53 | 79.94 |
| Toprol XL | 82.55 | NA | 78.68 | NA | 80.04 | 88.34 | 79.29 | NA | 85.18 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | -0.88 |
| Carvedilol Controlled Release | -0.86 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | 24.00 |
| Carvedilol Controlled Release | 53.37 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | -0.20 |
| Carvedilol Controlled Release | -0.45 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | -0.33 |
| Carvedilol Controlled Release | -0.36 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | -0.76 |
| Carvedilol Controlled Release | -0.83 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | .08 |
| Carvedilol Controlled Release | .05 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | .08 |
| Carvedilol Controlled Release | .08 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | -36.61 |
| Carvedilol Controlled Release | -42.22 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | -18.29 |
| Carvedilol Controlled Release | -20.57 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | -36.61 |
| Carvedilol Controlled Release | -43.00 |
Maintenance Visit 3 minus Baseline. Maintenance Visit 3 occurred 24 weeks after entry into the maintenance period. The maintenance period started after completion of a titration period of variable duration. (NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | mL/m^2 (Mean) |
|---|---|
| Coreg Immediate Release | -18.36 |
| Coreg Controlled Release | -20.81 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | 9.5 |
| Carvedilol Controlled Release | -9.29 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | .07 |
| Carvedilol Controlled Release | .05 |
SAEs experienced (NCT00323037)
Timeframe: 24 weeks after entry into the maintenance phase (after unblinding)
| Intervention | number of SAEs (Number) |
|---|---|
| Carvedilol Immediate Release | 40 |
| Carvedilol Controlled Release | 35 |
(NCT00323037)
Timeframe: Up to 32 weeks (titration and maintenance phases)
| Intervention | subjects in each treatment group (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Study Entry (10mg Coreg CR, 3.125mg Coreg IR) | Maintenance Entry (10mg Coreg CR, 3.125mg Coreg IR) | End of Study (10mg Coreg CR, 3.125mg Coreg IR) | Study Entry (20mg Coreg CR, 6.25mg Coreg IR) | Maintenance Entry (20mg Coreg CR, 6.25mg Coreg IR) | End of Study (20mg Coreg CR, 6.25mg Coreg IR) | Study Entry (40mg Coreg CR, 12.5mg Coreg IR) | Maintenance Entry (40mg Coreg CR, 12.5mg Coreg IR) | End of Study (40mg Coreg CR, 12.5mg Coreg IR) | Study Entry (80mg Coreg CR, 25mg Coreg IR) | Maintenance Entry (80mg Coreg CR, 25mg Coreg IR) | End of Study (80mg Coreg CR, 25mg Coreg IR) | |
| Carvedilol Controlled Release | 83 | 0 | 4 | 39 | 9 | 16 | 27 | 16 | 22 | 4 | 114 | 111 |
| Carvedilol Immediate Release | 79 | 0 | 7 | 61 | 13 | 16 | 21 | 12 | 21 | 4 | 116 | 121 |
(NCT00323037)
Timeframe: Up to 32 weeks (titration and maintenance phases)
| Intervention | participants in each treatment group (Number) | ||
|---|---|---|---|
| Hospitalization for Heart Failure | Hospitalization Due to Any Cause | Hospitalization or Death | |
| Carvedilol Controlled Release | 6 | 29 | 29 |
| Carvedilol Immediate Release | 6 | 31 | 32 |
51 reviews available for bisoprolol and Heart Failure
| Article | Year |
|---|---|
Therapeutic Properties of Highly Selective β-blockers With or Without Additional Vasodilator Properties: Focus on Bisoprolol and Nebivolol in Patients With Cardiovascular Disease.
Topics: Adrenergic beta-Antagonists; Benzopyrans; Bisoprolol; Cardiovascular Diseases; Ethanolamines; Heart | 2022 |
Genetic Variation of Hepatic Enzymes Influence on β-Blocker Dose in Patients With Reduced Ejection Fraction Heart Failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carvedilol; Cytochrome P-450 CYP2D6; Genetic Variation; Hea | 2020 |
[Epidemiology and treatment of chronic heart failure; use of bisoprolol].
Topics: Adrenergic beta-1 Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Bisoprolol; Chroni | 2013 |
Effects of beta-blockers for congestive heart failure in pediatric and congenital heart disease patients: a meta-analysis of published studies.
Topics: Adrenergic beta-Antagonists; Age Factors; Bisoprolol; Carbazoles; Carvedilol; Child; Heart Defects, | 2015 |
[The benefits of carvedilol therapy in the treatment of patients with high cardiovascular risk].
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Antihypertensive Agents; Bisoprolol; Carbazoles; Cardi | 2016 |
Beta-blockers in heart failure: how far have we progressed?
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Bisoprolol; Carbazoles; Carvedilol; Contraindi | 2002 |
Use of beta-blockers for heart failure in patients with diabetes mellitus.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Bisoprolol; Carbazoles; Carvedilol; Diabetes C | 2002 |
β-blockers in stage B: a precursor of heart failure.
Topics: Adrenergic beta-Antagonists; Animals; Benzazepines; Bisoprolol; Carbazoles; Cardiovascular System; C | 2012 |
β-Blockers in heart failure: benefits of β-blockers according to varying male proportions of study patients.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Bisoprolol; Carbazoles; Carvedilol; China; Hea | 2012 |
[Bisoprolol: opportunities in the treatment of hypertension].
Topics: Adrenergic beta-1 Receptor Antagonists; Biological Availability; Bisoprolol; Comorbidity; Coronary D | 2012 |
Bisoprolol: a review of its use in chronic heart failure.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Bisoprolol; Cost-Benefit Analys | 2002 |
[Use of beta-blockers in heart failure].
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Clinical Trials as Topic; Contraind | 2003 |
Beta-blocker benefit according to severity of heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Chronic Disease; Heart Failure; Hos | 2003 |
Use of beta-blockers in congestive heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; F | 2003 |
Beta-blockers for chronic heart failure: surviving longer but feeling better?
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Exercise Test; Exercise Tolerance; | 2003 |
Role of beta-blocker therapy in heart failure and atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Atrial Fibrillation; Bisoprolol; Exercise Tolerance; Heart Failure; Hum | 2003 |
[Chronic heart failure and atrial fibrilation: aspects of management].
Topics: Acute Disease; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmi | 2003 |
Selective versus nonselective beta-blockade for heart failure therapy: are there lessons to be learned from the COMET trial?
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; E | 2003 |
The effects of beta blockers on morbidity and mortality in heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; | 2004 |
Emerging trends in the management of heart failure: Beta blocker therapy.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Bisoprolol; Carbazoles; Carve | 2005 |
[Beta blockers for therapy of chronic heart failure].
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Chronic Disease; Clinical Trials as | 2005 |
[Congestive heart failure in Spain: cost-effectiveness and cost-benefit analyses of treatment with beta-blockers].
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Cost-Benefit Analysis; Heart Failur | 2005 |
A review of carvedilol arrhythmia data in clinical trials.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bisoprolol; Ca | 2005 |
[Beta-adrenolytics in heart failure--are they all really equal?].
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; | 2005 |
[Beta blockers: characteristics, mechanisms of action, pharmacokinetics, indication, contraindication, clinical data, and side effects].
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Clinical Trials as Topic; Contraind | 2007 |
Bisoprolol in the treatment of chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Bisoprolol; Chronic Dis | 2007 |
Beta blockers or angiotensin-converting-enzyme inhibitor/angiotensin receptor blocker: what should be first?
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Bisoprolol; Carbazoles; Carve | 2007 |
Bisoprolol for congestive heart failure.
Topics: Animals; Bisoprolol; Heart Failure; Humans; Randomized Controlled Trials as Topic | 2008 |
[Chronic heart failure and sudden death: the message of CIBIS-III].
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents | 2007 |
[Adrenergic betablockers and heart failure].
Topics: Adrenergic beta-Antagonists; Bisoprolol; Cardiomyopathy, Dilated; Heart Failure; Humans; Metoprolol; | 1995 |
[Beta blockers in heart failure. Experiences and recommendations for clinical use. ANMCO-Area Heart Failure].
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Carbazoles; Carvedilol; Controlled Clinical Trials as | 1998 |
Beta-blocker therapy in heart failure: pathophysiology and clinical results.
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Carbazoles; Carvedilol; Clinical Trials as Topic; Exe | 1999 |
[Drug therapy of chronic heart failure: when are beta receptor blockers indicated?].
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Antihypertensive Agents; Bisoprolol; Carbazoles | 1999 |
Major beta blocker mortality trials in chronic heart failure: a critical review.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Bisoprolol; Carbazoles; Carvedilol; Female; He | 1999 |
Beta-adrenoceptor blockers in heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; | 1999 |
beta-adrenergic receptor blockade in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Chronic Disease; Heart Failure; Hea | 2000 |
The effect of beta-blockers on health-related quality of life in patients with heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Clinical Trials as Topic; Health St | 2000 |
The impact of beta-blockade on mortality rates in patients with congestive heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Heart Failure; Humans; Meta-Analysi | 2000 |
Review of the Cardiac Insufficiency Bisoprolol Study II (CIBIS-II).
Topics: Adrenergic beta-Antagonists; Bisoprolol; Clinical Trials as Topic; Heart Failure; Humans; Survival A | 1999 |
Beta blockade in patients with congestive heart failure. Why, who, and how.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Contraindications; Heart Failure; H | 2000 |
Meta-analysis of effect of beta-blocker therapy on mortality in patients with New York Heart Association class IV chronic congestive heart failure.
Topics: Adrenergic beta-Antagonists; Benzopyrans; Bisoprolol; Carbazoles; Carvedilol; Ethanolamines; Heart F | 2000 |
Beta blockers and congestive heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Heart Failure; Humans; Meta-Analysi | 2000 |
The importance of beta blockers in the treatment of heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Contraindications; Drug Administrat | 2000 |
Influence of beta-blockers on mortality in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Chronic Disease; Heart Failure; Hum | 2000 |
Economic impact of beta blockade in heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Clinical Trials as Topic; Cost-Bene | 2001 |
Beta-blockers to reduce mortality in patients with systolic dysfunction: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Heart Failure; Hemodynamics; Humans | 2001 |
[Adrenergic beta inhibitors in heart insufficiency: which and when?].
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; | 2001 |
Beta-blockade treatment in heart failure: the cardiac insufficiency bisoprolol study (CIBIS) project. CIBIS Committees and Investigators. Cardiac Insufficiency Bisoprolol Study.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Cardiotonic Agents; Heart Failure; Humans; Multicenter Stud | 1990 |
[Role of beta-blockers in the treatment of chronic heart heart failure].
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Chronic Disease; Controlled Clinica | 2001 |
Beta-blockers in heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; | 2001 |
Bisoprolol for the treatment of chronic heart failure: a meta-analysis on individual data of two placebo-controlled studies--CIBIS and CIBIS II. Cardiac Insufficiency Bisoprolol Study.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Female; Heart Failure; Hospitalization; Humans; Male; Middl | 2002 |
85 trials available for bisoprolol and Heart Failure
| Article | Year |
|---|---|
Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial (BICS).
Topics: Adrenal Cortex Hormones; Adrenergic beta-Antagonists; Adult; Anti-Bacterial Agents; Bisoprolol; Dise | 2022 |
The Efficacy and Safety of Bisoprolol in the Treatment of Myocardial Infarction with Cardiac Insufficiency.
Topics: Bisoprolol; Heart Failure; Humans; Meta-Analysis as Topic; Myocardial Infarction; Stroke Volume; Ven | 2022 |
Effects of carvedilol vs bisoprolol on inflammation and oxidative stress in patients with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Anti-Inflammatory Agents; Bisoprolol; C-Reactive Protein; | 2020 |
Effect of Digoxin vs Bisoprolol for Heart Rate Control in Atrial Fibrillation on Patient-Reported Quality of Life: The RATE-AF Randomized Clinical Trial.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibr | 2020 |
Effect of Digoxin vs Bisoprolol for Heart Rate Control in Atrial Fibrillation on Patient-Reported Quality of Life: The RATE-AF Randomized Clinical Trial.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibr | 2020 |
Effect of Digoxin vs Bisoprolol for Heart Rate Control in Atrial Fibrillation on Patient-Reported Quality of Life: The RATE-AF Randomized Clinical Trial.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibr | 2020 |
Effect of Digoxin vs Bisoprolol for Heart Rate Control in Atrial Fibrillation on Patient-Reported Quality of Life: The RATE-AF Randomized Clinical Trial.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibr | 2020 |
Effect of Digoxin vs Bisoprolol for Heart Rate Control in Atrial Fibrillation on Patient-Reported Quality of Life: The RATE-AF Randomized Clinical Trial.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibr | 2020 |
Effect of Digoxin vs Bisoprolol for Heart Rate Control in Atrial Fibrillation on Patient-Reported Quality of Life: The RATE-AF Randomized Clinical Trial.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibr | 2020 |
Effect of Digoxin vs Bisoprolol for Heart Rate Control in Atrial Fibrillation on Patient-Reported Quality of Life: The RATE-AF Randomized Clinical Trial.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibr | 2020 |
Effect of Digoxin vs Bisoprolol for Heart Rate Control in Atrial Fibrillation on Patient-Reported Quality of Life: The RATE-AF Randomized Clinical Trial.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibr | 2020 |
Effect of Digoxin vs Bisoprolol for Heart Rate Control in Atrial Fibrillation on Patient-Reported Quality of Life: The RATE-AF Randomized Clinical Trial.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibr | 2020 |
Regional differences in health-related quality of life in elderly heart failure patients: results from the CIBIS-ELD trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Aged; Bisoprolol; C | 2017 |
Heart rate and outcome in heart failure with reduced ejection fraction: Differences between atrial fibrillation and sinus rhythm-A CIBIS II analysis.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Atrial Fibrillation; Bisoprolol; Double-Blind Method; | 2017 |
A review of rate control in atrial fibrillation, and the rationale and protocol for the RATE-AF trial.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Bisoprolo | 2017 |
Efficacy and Safety of Switching From Oral Bisoprolol to Transdermal Patch in Japanese Patients With Chronic Heart Failure.
Topics: Administration, Oral; Aged; Antihypertensive Agents; Asian People; Bisoprolol; Chronic Disease; Fema | 2017 |
Relationship between heart failure, concurrent chronic obstructive pulmonary disease and beta-blocker use: a Danish nationwide cohort study.
Topics: Adrenergic beta-1 Receptor Agonists; Aged; Bisoprolol; Carvedilol; Cause of Death; Comorbidity; Denm | 2018 |
Anti-ß1-Adrenoreceptor auto-Antibodies in elderly heart failure patients.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Autoantibodies; Biomarkers; Bisoprolol; Carved | 2019 |
Tolerability, Efficacy, and Safety of Bisoprolol vs. Carvedilol in Japanese Patients With Heart Failure and Reduced Ejection Fraction - The CIBIS-J Trial.
Topics: Adult; Aged; Aged, 80 and over; Bisoprolol; Carvedilol; Heart Failure; Heart Rate; Humans; Japan; Mi | 2019 |
Multiparametric comparison of CARvedilol, vs. NEbivolol, vs. BIsoprolol in moderate heart failure: the CARNEBI trial.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Benzopyrans; Bisoprolol; Ca | 2013 |
Efficacy and safety of bisoprolol fumarate compared with carvedilol in Japanese patients with chronic heart failure: results of the randomized, controlled, double-blind, Multistep Administration of bisoprolol IN Chronic Heart Failure II (MAIN-CHF II) stud
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Carbazoles; Carvedilol; Chronic Disease; Disease-Free | 2014 |
Regional differences among female patients with heart failure from the Cardiac Insufficiency BIsoprolol Study in ELDerly (CIBIS-ELD).
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Aged; Bisoprolol; C | 2014 |
Ivabradine improves quality of life in subjects with chronic heart failure compared to treatment with β-blockers: results of a multicentric observational APULIA study.
Topics: Adrenergic beta-Antagonists; Aged; Benzazepines; Bisoprolol; Blood Pressure; Carbazoles; Carvedilol; | 2013 |
Heart rate following short-term beta-blocker titration predicts all-cause mortality in elderly chronic heart failure patients: insights from the CIBIS-ELD trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Bisoprolol; Carbazoles; Carvedilol; Chronic Di | 2014 |
Evaluation of synergistic effects of resynchronization therapy and a β-blocker up-titration strategy based on a predefined patient-management program: the RESTORE study.
Topics: Adrenergic beta-1 Receptor Antagonists; Bisoprolol; Carbazoles; Cardiac Resynchronization Therapy; C | 2015 |
Improvement of Ventricular-Arterial Coupling in Elderly Patients with Heart Failure After Beta Blocker Therapy: Results from the CIBIS-ELD Trial.
Topics: Adrenergic beta-Antagonists; Aged; Arteries; Bisoprolol; Double-Blind Method; Echocardiography, Dopp | 2015 |
Bisoprolol pharmacokinetics and body composition in patients with chronic heart failure: a longitudinal study.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Aged, 80 and over; Bisoprolol; Body Composition; Chron | 2016 |
Bisoprolol in idiopathic pulmonary arterial hypertension: an explorative study.
Topics: Adult; Aged; Antihypertensive Agents; Bisoprolol; Cross-Over Studies; Double-Blind Method; Exercise; | 2016 |
Protective effects of bisoprolol against myocardial injury and pulmonary dysfunction in patients with chronic heart failure.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Bisoprolol; Cardiotonic Agents; Chronic Disease; Femal | 2017 |
[Comparative Evaluation of -blockers and If-Channel Inhibitor in Patients With Chronic Heart Failure and Preserved Left Ventricular Ejection Fraction].
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Benzazepines; Bisoprolol; Cardiovascular Agents; Exerc | 2016 |
Clinical effects of initial 6 months monotherapy with bisoprolol versus enalapril in the treatment of patients with mild to moderate chronic heart failure. Data from the CIBIS III Trial.
Topics: Aged; Antihypertensive Agents; Bisoprolol; Blood Pressure; Bradycardia; Chronic Disease; Cough; Drug | 2008 |
Bisoprolol vs. carvedilol in elderly patients with heart failure: rationale and design of the CIBIS-ELD trial.
Topics: Adrenergic beta-Antagonists; Age Distribution; Aged; Bisoprolol; Carbazoles; Carvedilol; Double-Blin | 2008 |
The comparative effects of long-term carvedilol versus bisoprolol therapy on QT dispersion in patients with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Carbazoles; Carvedilol; Chronic Disease; Electrocardi | 2009 |
[Effects of bisoprolol on serum interleukin-6 and tumor necrosis factor-alpha level in patients with congestive heart failure].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Female; Heart Failure; Huma | 2008 |
Bisoprolol in patients with heart failure and moderate to severe chronic obstructive pulmonary disease: a randomized controlled trial.
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Blood Gas Analysis; Comorbidity; Double-Blind Method; | 2009 |
The effect of treatment with bisoprolol-first versus enalapril-first on cardiac structure and function in heart failure.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Bisoprolol; | 2010 |
Beta-blocker treatment of stable heart failure in primary care.
Topics: Adrenergic alpha-Antagonists; Aged; Bisoprolol; Carbazoles; Carvedilol; Female; Heart Failure; Human | 2009 |
[Optimization of use of beta-adrenoblockers in the treatment of chronic heart failure in the outpatient setting].
Topics: Adrenergic beta-Antagonists; Aged; Ambulatory Care; Benzopyrans; Bisoprolol; Chronic Disease; Ethano | 2009 |
Improved survival with bisoprolol in patients with heart failure and renal impairment: an analysis of the cardiac insufficiency bisoprolol study II (CIBIS-II) trial.
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Double-Blind Method; Female; Heart Failure; Humans; M | 2010 |
Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Carbazoles; Carvedilol; Chr | 2010 |
Effect on mode of death of heart failure treatment started with bisoprolol followed by Enalapril, compared to the opposite order: results of the randomized CIBIS III trial.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Bisoprolol; Chronic Dis | 2011 |
Comparison of effectiveness of carvedilol versus bisoprolol for prevention of postdischarge atrial fibrillation after coronary artery bypass grafting in patients with heart failure.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Bisoprolol; Carbazoles | 2011 |
Evaluation of the functional status questionnaire in heart failure: a sub-study of the second cardiac insufficiency bisoprolol survival study (CIBIS-II).
Topics: Bisoprolol; Double-Blind Method; Female; Heart Failure; Humans; Interpersonal Relations; Male; Middl | 2011 |
Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial.
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Carbazoles; Carvedilol; Dose-Response Relationship, D | 2011 |
Influence of order and type of drug (bisoprolol vs. enalapril) on outcome and adverse events in patients with chronic heart failure: a post hoc analysis of the CIBIS-III trial.
Topics: Adrenergic beta-Antagonists; Aged; Analysis of Variance; Angiotensin Receptor Antagonists; Angiotens | 2011 |
Rationale and design of the Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research Trial (MANTICORE 101--Breast): a randomized, placebo-controlled trial to determine if conventional heart failure pharmacotherapy can prevent trastuzu
Topics: Adrenergic beta-1 Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antibodies, Monocl | 2011 |
Differences between bisoprolol and carvedilol in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized trial.
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Bisoprolol; Carbazoles; Carvedilol; Chro | 2011 |
Is target dose the treatment target? Uptitrating beta-blockers for heart failure in the elderly.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Bisoprolol; Blood Pressure; Carbazoles; Carved | 2012 |
Impact of the β1-adrenoceptor Arg389Gly polymorphism on heart-rate responses to bisoprolol and carvedilol in heart-failure patients.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Atrial Fibrillation; Bisoprolol; Carbazoles; Carvedilo | 2012 |
Electrocardiographic criteria of true left bundle branch block: a simple sign to predict a better clinical and instrumental response to CRT.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Bisoprolol; Bundle-Branch Block; Cardiac Resynchro | 2012 |
Sinus rhythm versus atrial fibrillation in elderly patients with chronic heart failure--insight from the Cardiac Insufficiency Bisoprolol Study in Elderly.
Topics: Aged; Atrial Fibrillation; Bisoprolol; Double-Blind Method; Female; Follow-Up Studies; Heart Failure | 2012 |
Effect of β-blocker cessation on chronotropic incompetence and exercise tolerance in patients with advanced heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Analysis of Variance; Biomarkers; Bisoprolol; Carbazoles; Carved | 2012 |
Population pharmacokinetics of bisoprolol in patients with chronic heart failure.
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Chronic Disease; | 2013 |
Beta blockers therapy is associated with improved left ventricular systolic function and sustained exercise capacity in elderly patients with heart failure. CIBIS-ELD sub-study.
Topics: Adrenergic beta-Antagonists; Aged; Aging; Bisoprolol; Blood Pressure; Carbazoles; Carvedilol; Exerci | 2012 |
Determinants of change in quality of life in the Cardiac Insufficiency Bisoprolol Study in Elderly (CIBIS-ELD).
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Aged, 80 and over; Bisoprolol; Carbazoles; Carvedilol; | 2013 |
Effect of selective and nonselective beta-blockers on resting energy production rate and total body substrate utilization in chronic heart failure.
Topics: Adipose Tissue; Adrenergic beta-Antagonists; Aged; Basal Metabolism; Bisoprolol; Blood Pressure; Bod | 2002 |
Bisoprolol dose-response relationship in patients with congestive heart failure: a subgroup analysis in the cardiac insufficiency bisoprolol study(CIBIS II).
Topics: Adrenergic beta-Antagonists; Bisoprolol; Death, Sudden, Cardiac; Dose-Response Relationship, Drug; D | 2003 |
Beta-blocker benefit according to severity of heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Chronic Disease; Heart Failure; Hos | 2003 |
Effect of bisoprolol on perioperative complications in chronic heart failure after surgery (Cardiac Insufficiency Bisoprolol Study II (CIBIS II)).
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Data Interpretation, Statis | 2003 |
[Clinical, hemodynamic and neurohumoral effects of long-term therapy of patients with severe chronic heart failure with beta-adrenoblocker bisoprolol].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Bisoprolol; Blood Pressure; Echocardiography; Female; Foll | 2003 |
[Assessment of the efficacy of bisoprolol administration by cardiopulmonary exercise testing in patients with heart failure].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Bisoprolol; Diuretics; Drug A | 2003 |
Comparison of treatment initiation with bisoprolol vs. enalapril in chronic heart failure patients: rationale and design of CIBIS-III.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Bisoprolol; Blood Press | 2004 |
Adverse effects of beta-blocker therapy for patients with heart failure: a quantitative overview of randomized trials.
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Bradycardia; Carbazoles; Carvedilol; Dizziness; Fatig | 2004 |
Tolerability of beta-blocker initiation and titration with bisoprolol and carvedilol in congestive heart failure -- a randomized comparison.
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Carbazoles; Carvedilol; Drug Administration Schedule; | 2004 |
Effects of bisoprolol in patients with stable congestive heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Female; Heart Failure; Humans; Male; Middle Aged | 2004 |
[Potentialities of cytoprotection in the treatment of chronic heart failure in patients with coronary heart disease].
Topics: Aged; Aged, 80 and over; Bisoprolol; Chronic Disease; Female; Heart Failure; Hemodynamics; Humans; M | 2004 |
[Effect of long-term therapy with contemporary drugs on diastolic cardiac function in patients with chronic heart failure].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Bisoprolol; Carbazoles; Carve | 2005 |
[Beneficial neurohormonal profiles of beta-blockades in chronic left heart failure].
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Carbazoles; Car | 2005 |
Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III.
Topics: Adrenergic beta-Antagonists; Age of Onset; Aged; Angiotensin-Converting Enzyme Inhibitors; Bisoprolo | 2005 |
Impact of statin therapy on clinical outcomes in chronic heart failure patients according to beta-blocker use: results of CIBIS II.
Topics: Adrenergic beta-Antagonists; Analysis of Variance; Bisoprolol; Cause of Death; Chi-Square Distributi | 2007 |
[Is triple combination of different neurohormonal modulators recommended for treatment of mild-to-moderate congestive heart failure patients? (Results of SADKO-CHF study). Part 2].
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2006 |
[Is triple combination of different neurohormonal modulators recommended for treatment of mild-to-moderate congestive heart failure patients? (Results of Sadko-CHF study)].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Conve | 2006 |
[Effect of bisoprolol and sotalol on clinical status of patients with proximal form of atrial fibrillation and chronic heart failure].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atrial Fibrillation; Bisoprolol; Exercise Test; Female; He | 2007 |
Lung function with carvedilol and bisoprolol in chronic heart failure: is beta selectivity relevant?
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Carbazoles; Carvedilol; Chronic Disease; Cross-Over S | 2007 |
A prospective, randomized, double-blind, placebo controlled trial of beta-blockade in patients who have undergone surgical correction of tetralogy of Fallot.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Bisoprolol; Double-Blind Method; Drug Administration | 2007 |
Effect of selective and non-selective beta-blockers on body weight, insulin resistance and leptin concentration in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Blood Glucose; Body Weight; Carbazoles; Carvedilol; C | 2008 |
Switching beta-blocker therapy in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Chronic Disease; Heart Failure; Humans; Metoprolol | 2008 |
The effects of beta-blockers in patients with stable chronic heart failure. Predictors of left ventricular ejection fraction improvement and impact on prognosis.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Chronic Disease; Female; Heart Fail | 2007 |
Does NT-proBNP remain a sensitive biomarker for chronic heart failure after administration of a beta-blocker?
Topics: Adrenergic beta-Antagonists; Biomarkers; Bisoprolol; Carbazoles; Carvedilol; Female; Heart Failure; | 2007 |
Effects of bisoprolol on heart rate variability in heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Female; Heart Failure; Heart Rate; Hemodynamics; Huma | 1996 |
Effects of beta-blockade with bisoprolol on heart rate variability in advanced heart failure: analysis of scatterplots of R-R intervals at selected heart rates.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Double-Blind Method; Female; Heart Failure; Heart Rate; Hum | 1996 |
Prognostic value of bisoprolol-induced hemodynamic effects in heart failure during the Cardiac Insufficiency BIsoprolol Study (CIBIS).
Topics: Adrenergic beta-Antagonists; Analysis of Variance; Bisoprolol; Blood Pressure; Double-Blind Method; | 1997 |
[Cost effectiveness of bisoprolol in heart failure. Economic evaluation of the Cardiac Insufficiency Bisoprolol Study (CIBIS) for Germany].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Bisoprolol; Cost-Benefit Analysis; Double-Blind Method; Fe | 1997 |
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou | 1999 |
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou | 1999 |
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou | 1999 |
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou | 1999 |
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou | 1999 |
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou | 1999 |
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou | 1999 |
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou | 1999 |
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou | 1999 |
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou | 1999 |
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou | 1999 |
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou | 1999 |
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou | 1999 |
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou | 1999 |
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou | 1999 |
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou | 1999 |
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou | 1999 |
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou | 1999 |
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou | 1999 |
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou | 1999 |
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou | 1999 |
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou | 1999 |
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou | 1999 |
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou | 1999 |
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou | 1999 |
[Clinical trial of the month. The CIBIS-II study].
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzy | 1999 |
Beta-blockers for the treatment of congestive heart failure.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Double-Blind Me | 1999 |
[Heart failure: an indication for beta blockaders].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Bisoprolol; Female; Heart Failure | 1999 |
[Beta-blocker and heart failure: bisoprolol decreases mortality in patients with stable heart failure].
Topics: Adrenergic beta-Antagonists; Bisoprolol; Double-Blind Method; Heart Failure; Humans; Survival Rate | 1999 |
Predictors of medical events in patients enrolled in the cardiac insufficiency bisoprolol study (CIBIS): a study of the interactions between beta-blocker therapy and occurrence of critical events using analysis of competitive risks.
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Female; Heart Failure; Humans; Male; Middle Aged; Pro | 2000 |
Sex differences in the prognosis of congestive heart failure: results from the Cardiac Insufficiency Bisoprolol Study (CIBIS II).
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Bisoprolol; Female; Heart Failure; Human | 2001 |
Effect of bisoprolol on QT dispersion in patients with congestive heart failure--the etiology-dependent response.
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Cardiomyopathy, Dilated; Female; Heart Conduction Sys | 2001 |
[Cost effectiveness of bisoprolol in treatment of heart failure in Germany. An analysis based on the CIBIS-II study].
Topics: Aged; Bisoprolol; Chronic Disease; Cost-Benefit Analysis; Double-Blind Method; Female; Germany; Hear | 2000 |
Predictors of medical events and of their competitive interactions in the Cardiac Insufficiency Bisoprolol Study 2 (CIBIS-2).
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Drug Administration Schedule; Female; Follow-Up Studi | 2001 |
165 other studies available for bisoprolol and Heart Failure
| Article | Year |
|---|---|
[Possibilities and limitations of the use of beta-blockers in patients with cardiovascular disease and chronic obstructive pulmonary disease].
Topics: Adrenergic beta-Antagonists; Bisoprolol; Cardiovascular Diseases; Heart Failure; Humans; Pulmonary D | 2021 |
Loeys-Dietz Cardiomyopathy? Long-term Follow-up After Onset of Acute Decompensated Heart Failure.
Topics: Acute Disease; Bisoprolol; Cardiomegaly; Cardiomyopathies; Cardiovascular Agents; Echocardiography; | 2022 |
The double anaerobic threshold in heart failure.
Topics: Adrenergic beta-Antagonists; Anaerobic Threshold; Bisoprolol; Carvedilol; Exercise Test; Heart Failu | 2022 |
[Transudative chylothorax complicated with liver cirrhosis due to primary biliary cholangitis:case report].
Topics: Aged; Bisoprolol; Carvedilol; Chylothorax; Dyspnea; Female; Heart Failure; Humans; Hypertension, Por | 2022 |
To Evaluate the 'Real World' Clinical Performance of Bisoprolol in Post-Myocardial Infarction with Left Ventricular Dysfunction: Tenacity Study.
Topics: Bisoprolol; Female; Glycated Hemoglobin; Heart Failure; Humans; Lipids; Male; Middle Aged; Myocardia | 2022 |
Guideline-Directed Medical Therapy in Newly Diagnosed Heart Failure With Reduced Ejection Fraction in the Community.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme I | 2022 |
Can Pediatric Heart Failure Therapy Be Improved? Yes It Can, But….
Topics: Adrenergic beta-Antagonists; Angiotensins; Anti-Arrhythmia Agents; Bisoprolol; Cardiotonic Agents; C | 2022 |
Elevated Blood Pressure Occurs without Endothelial Dysfunction in a Rat Model of Pulmonary Emphysema.
Topics: Animals; Bisoprolol; Blood Pressure; Emphysema; Heart Failure; Hypertension; Male; Pulmonary Disease | 2023 |
Differential Effects of the Betablockers Carvedilol, Metoprolol and Bisoprolol on Cardiac K
Topics: Bisoprolol; Carvedilol; Heart; Heart Failure; Humans; Metoprolol; Protein Isoforms | 2023 |
Unilateral adrenalectomy for a drug-resistant bilateral primary aldosteronism with heart failure: pathophysiology and surgical indication.
Topics: Adrenal Glands; Adrenalectomy; Aldosterone; Antihypertensive Agents; Bisoprolol; Eplerenone; Heart F | 2023 |
Beta-blocker choice and exchangeability in patients with heart failure and chronic obstructive pulmonary disease: an Italian register-based cohort study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Atrioventricular Block; Bisoprolol; Carvedilol | 2019 |
[POLYMORPHISM OF THE BETA1- AND BETA2-ADRENORECEPTOR GENES AND BISOPROLOL EFFICIENCY IN PATIENTS WITH HEART FAILURE].
Topics: Adrenergic beta-Antagonists; Bisoprolol; Gene Frequency; Heart Failure; Humans; Patients; Receptors, | 2019 |
Bisoprolol transdermal patch improves orthostatic hypotension in patients with chronic heart failure and hypertension.
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Blood Pressure; Female; Heart Failure; Humans; Hypert | 2020 |
Association between bisoprolol plasma concentration and worsening of heart failure: (CVI ARO 6).
Topics: Aged; Bisoprolol; Female; Heart Failure; Humans; Kidney; Male; Middle Aged; Multivariate Analysis; R | 2020 |
Comparative efficacy of empagliflozin and drugs of baseline therapy in post-infarct heart failure in normoglycemic rats.
Topics: Animals; Benzhydryl Compounds; Bisoprolol; Cardiovascular Agents; Chronic Disease; Disease Models, A | 2020 |
Association Between Dose and Plasma Concentration of Bisoprolol in Patients with Heart Failure (CVI ARO 6).
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Female; Heart Fa | 2020 |
β-Blocker Use and Risk of Mortality in Heart Failure Patients Initiating Maintenance Dialysis.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Atenolol; Bisoprolol; Carvedilol; Cause of Dea | 2021 |
An attempt at administering a transdermal formulation of bisoprolol in patients with acute cardiac symptoms.
Topics: Acute Coronary Syndrome; Acute Disease; Administration, Cutaneous; Adrenergic beta-1 Receptor Antago | 2021 |
Beta-blockers utilization in heart failure patients: Sub-analysis of a nation-wide population-based study in the Czech Republic.
Topics: Adrenergic beta-Antagonists; Betaxolol; Bisoprolol; Carbazoles; Carvedilol; Czech Republic; Heart Fa | 2021 |
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Bisoprolol; Digoxin; Heart Failure; Humans | 2021 |
Effects of trimetazidine in combination with bisoprolol in patients with chronic heart failure and concomitant chronic obstructive pulmonary disease: A protocol for systematic review and meta-analysis.
Topics: Adrenergic beta-1 Receptor Antagonists; Bisoprolol; Chronic Disease; Drug Therapy, Combination; Hear | 2021 |
Performance of a cardiac lipid panel compared to four prognostic scores in chronic heart failure.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Biomarkers; Bisoprolol; Carvedilol; Cluster Analysis; | 2021 |
Study on the application effect of bisoprolol combined with sacubitril valsartan sodium tablets in the cardiac rehabilitation of patients with acute myocardial infarction combined with left heart failure after percutaneous coronary intervention (PCI).
Topics: Aminobutyrates; Biphenyl Compounds; Bisoprolol; Cardiac Rehabilitation; Drug Combinations; Heart Fai | 2021 |
Impact of the COVID-19 pandemic on the management of chronic heart failure.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Bisoprolol; | 2021 |
Contraindications Differ Widely Among Beta Blockers and Ought to be Cited for an Individual Drug, Not for the Entire Class.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carvedilol; Contraindications; Heart Failure; Humans; Nebiv | 2021 |
Bisoprolol compared with carvedilol and metoprolol succinate in the treatment of patients with chronic heart failure.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Aged, 80 and over; Bisoprolol; Carbazoles; Carvedilol; | 2017 |
Analysis of Clinical Efficacy and Adverse Effects of β-Blocking Agents Used Clinically for Chronic Heart Failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Chronic Disease; Forced Expiratory | 2017 |
Switching Therapy from Intravenous Landiolol to Transdermal Bisoprolol in a Patient with Thyroid Storm Complicated by Decompensated Heart Failure and Gastrointestinal Dysfunction.
Topics: Administration, Cutaneous; Administration, Intravenous; Adrenergic beta-Antagonists; Adult; Atrial F | 2017 |
The evaluation of β-adrenoceptor blocking agents in patients with COPD and congestive heart failure: a nationwide study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Bisoprolol; Carbazoles; Carvedilol; Chi-Square | 2017 |
Renal Sympathetic Denervation Protects the Failing Heart Via Inhibition of Neprilysin Activity in the Kidney.
Topics: Aminobutyrates; Angiotensin II; Animals; Biphenyl Compounds; Bisoprolol; Blood Pressure; Drug Combin | 2017 |
Impact of Heart Rate Reduction with Maximal Tolerable Dose of Bisoprolol on Left Ventricular Reverse Remodeling.
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Age Factors; Aged; Bisoprolol; Female; Heart Failure; | 2018 |
Beta Blockers in Heart Failure: More Evidence for an Old Friend.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Friends; Heart Failure; Heart Rate; Humans | 2018 |
The mortality benefit of carvedilol versus bisoprolol in patients with heart failure with reduced ejection fraction.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Aged, 80 and over; Bisoprolol; Carvedilol; Female; Hea | 2019 |
Low Utilization of Beta-Blockers Among Medicare Beneficiaries Hospitalized for Heart Failure With Reduced Ejection Fraction.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Bisoprolol; Carvedilol; Cohort Studies; Drug Prescript | 2019 |
β-Blockers and 1-Year Postdischarge Mortality for Heart Failure and Reduced Ejection Fraction and Slow Discharge Heart Rate.
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Carvedilol; Female; Follow-Up Studies; Heart Failure; | 2019 |
Modulation of Sympathetic Activity and Innervation With Chronic Ivabradine and β-Blocker Therapies: Analysis of Hypertensive Rats With Heart Failure.
Topics: Adrenergic beta-1 Receptor Antagonists; Animals; Bisoprolol; Cardiovascular Agents; Disease Models, | 2019 |
Switching from carvedilol to bisoprolol ameliorates adverse effects in heart failure patients with dizziness or hypotension.
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Carbazoles; Carvedilol; Dizziness; Dose-Response Rela | 2013 |
[Economic analysis of the treatment of heart failure with beta-blockers].
Topics: Adrenergic beta-Antagonists; Benzopyrans; Bisoprolol; Carbazoles; Carvedilol; Clinical Trials as Top | 2013 |
Regulation by bisoprolol for cardiac microRNA expression in a rat volume-overload heart failure model.
Topics: Adrenergic beta-1 Receptor Antagonists; Animals; Bisoprolol; Cardiac Volume; Computational Biology; | 2013 |
Bisoprolol reversed small conductance calcium-activated potassium channel (SK) remodeling in a volume-overload rat model.
Topics: Adrenergic beta-1 Receptor Antagonists; Animals; Apamin; Arteriovenous Fistula; Bisoprolol; Cells, C | 2013 |
Prevention of liver cancer cachexia-induced cardiac wasting and heart failure.
Topics: Adrenergic beta-1 Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Bisoprolo | 2014 |
Vascular endothelial growth factor blockade prevents the beneficial effects of β-blocker therapy on cardiac function, angiogenesis, and remodeling in heart failure.
Topics: Adrenergic beta-1 Receptor Antagonists; Animals; Bisoprolol; Coronary Circulation; Disease Models, A | 2013 |
Biowaiver monograph for immediate-release solid oral dosage forms: bisoprolol fumarate.
Topics: Adrenergic beta-Antagonists; Biological Availability; Biopharmaceutics; Biotransformation; Bisoprolo | 2014 |
Weaning from inotropic support and concomitant beta-blocker therapy in severely ill heart failure patients: take the time in order to improve prognosis.
Topics: Adrenergic beta-Antagonists; Adult; Bisoprolol; Carbazoles; Cardiotonic Agents; Carvedilol; Dobutami | 2014 |
Effects of bisoprolol and losartan treatment in the hypertrophic and failing right heart.
Topics: Adrenergic beta-1 Receptor Antagonists; Angiotensin II Type 1 Receptor Blockers; Animals; Bisoprolol | 2014 |
Clinic and ambulatory heart rates in patients with ischaemic heart disease and/or chronic heart failure taking rate-limiting medications: are they interchangeable?
Topics: Adrenergic beta-1 Receptor Antagonists; Ambulatory Care Facilities; Bisoprolol; Chronic Disease; Ele | 2015 |
Novel receptor-derived cyclopeptides to treat heart failure caused by anti-β1-adrenoceptor antibodies in a human-analogous rat model.
Topics: Animals; Antibodies; B-Lymphocytes; Bisoprolol; CD4-Positive T-Lymphocytes; Disease Models, Animal; | 2015 |
Beta-blocker therapy and prognosis of heart failure patients with new-onset diabetes mellitus.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Bisoprolol; Carbazoles; Carvedilol; Case-Control Stud | 2015 |
Impact of β-blocker selectivity on long-term outcomes in congestive heart failure patients with chronic obstructive pulmonary disease.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Aged, 80 and over; Bisoprolol; Carbazoles; Carvedilol | 2015 |
Characterizing patients with chronic heart failure in community care after hospitalization: a potential role for ivabradine.
Topics: Acute Disease; Aged; Aged, 80 and over; Benzazepines; Bisoprolol; Cardiovascular Agents; Chronic Dis | 2015 |
Comparative effectiveness of bisoprolol and metoprolol succinate in patients with heart failure.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Aged, 80 and over; Bisoprolol; Cohort Studies; Denmark | 2015 |
New-Onset Heart Failure in a Patient With a Pacemaker: An Unusual Cause.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Aortic Valve Stenosis; Atrial Fibrillation; Bisoprolol; Ca | 2016 |
Prognostic Benefits of Carvedilol, Bisoprolol, and Metoprolol Controlled Release/Extended Release in Hemodialysis Patients with Heart Failure: A 10-Year Cohort.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Conve | 2016 |
Carvedilol, Bisoprolol, and Metoprolol Use in Patients With Coexistent Heart Failure and Chronic Obstructive Pulmonary Disease.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Carbazoles; Carvedilol; Con | 2016 |
Impact of the β-1 adrenergic receptor polymorphism on tolerability and efficacy of bisoprolol therapy in Korean heart failure patients: association between β adrenergic receptor polymorphism and bisoprolol therapy in heart failure (ABBA) study.
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Aged; Bisoprolol; Female; Gene Frequency; Genotype; H | 2016 |
Fatal Cardiac Arrest Associated with Concomitant Bisoprolol and Verapamil Overdose.
Topics: Aged, 80 and over; Antihypertensive Agents; Bisoprolol; Calcium Channel Blockers; Drug Overdose; Ech | 2016 |
β1-Adrenergic blocker bisoprolol reverses down-regulated ion channels in sinoatrial node of heart failure rats.
Topics: Adrenergic beta-1 Receptor Antagonists; Animals; Atrial Remodeling; Bisoprolol; Cardiotonic Agents; | 2016 |
Beneficial Effect on Surrogate Markers of Heart Failure with Bisoprolol Up-Titration to Recommended Targets in Korean Patients with Heart Failure and Left Ventricular Systolic Dysfunction.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Biomarkers; Bisoprolol; Blood Pressure; Drug Administr | 2016 |
BETAWIN-AHF study: effect of beta-blocker withdrawal during acute decompensation in patients with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Bisoprolol; Carbazoles; Carvedilol; Chi-Square | 2016 |
Bioequivalence study of 2.5 mg film-coated bisoprolol tablets in healthy volunteers.
Topics: Adolescent; Adult; Biological Availability; Bisoprolol; Chromatography, Liquid; Coronary Disease; Cr | 2017 |
Takotsubo-like syndrome triggered by fludrocortisone overdose for Addison's disease: a case report.
Topics: Addison Disease; Adult; Anti-Inflammatory Agents; Antihypertensive Agents; Biomarkers; Bisoprolol; D | 2016 |
Older adults with heart failure treated with carvedilol, bisoprolol, or metoprolol tartrate: risk of mortality.
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Carbazoles; Carvedilol; Cohort Studies; Databases, Fa | 2017 |
Evaluating the effectiveness of different beta-adrenoceptor blockers in heart failure patients.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Bisoprolol; Carbazoles; Carvedilol; Female; He | 2017 |
Beta-blockade as first-line therapy in the elderly heart failure patient--the proper approach or asking for trouble?
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Bisoprolol; Carbazoles; Carvedilol; Chro | 2008 |
Low-frequency blood flow oscillations in congestive heart failure and after beta1-blockade treatment.
Topics: Acetylcholine; Adrenergic beta-Antagonists; Aged; Bisoprolol; Blood Flow Velocity; Case-Control Stud | 2008 |
Skeletal muscle proteins oxidation in chronic right heart failure in rats: can different beta-blockers prevent it to the same degree?
Topics: Adrenergic beta-Antagonists; Animals; Apoptosis; Benzopyrans; Bisoprolol; Chronic Disease; Ethanolam | 2010 |
Heart rate variability in rats with experimental chronic heart failure and long-term exposure to beta-adrenoblockers.
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Benzopyrans; Bisoprolol; Ethanolamines; Heart Failur | 2009 |
The effect of beta-blockers on the adaptive immune system in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Benzopyrans; Bisoprolol; Carbazoles; Carvedilol; Chronic Disease; | 2009 |
The effectiveness of collaborative medicine reviews in delaying time to next hospitalization for patients with heart failure in the practice setting: results of a cohort study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Australia; Bisoprolol; Carbazoles; Carvedilol; | 2009 |
The effect of an evening dose of a long-acting beta-blocker on the autonomic tone in patients with congestive heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Autonomic Nervous System; Bisoprolol; Diabetes Complications; Dru | 2009 |
[Activity of the autonomic nervous system in patients with congestive heart failure - is it worth evaluating?].
Topics: Adrenergic beta-Antagonists; Autonomic Nervous System; Bisoprolol; Drug Administration Schedule; Ele | 2009 |
Comparative effects of carvedilol vs bisoprolol for severe congestive heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Atrial Fibrillation; Bisoprolol; Carbazoles; C | 2010 |
Interest of β-blockers in patients with right ventricular systemic dysfunction.
Topics: Adrenergic beta-Antagonists; Adult; Bisoprolol; Female; Heart Failure; Humans; Male; Middle Aged; Ox | 2010 |
Chronotropic incompentence and functional capacity in chronic heart failure: no role of β-blockers and β-blocker dose.
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Carbazoles; Carvedilol; Chronic Disease; Dose-Respons | 2012 |
Effects of beta-blockers on ventilation efficiency in heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Echocardiography; Exercise Test; Fe | 2010 |
Which beta-blocker is most effective in heart failure?
Topics: Adrenergic beta-Antagonists; Animals; Benzopyrans; Bisoprolol; Carbazoles; Carvedilol; Clinical Tria | 2010 |
[Clinical, hemodynamic and neurohumoral effects of switching patients with chronic heart failure from not recommended -adrenoblockers to bisoprolol in ambulatory practice].
Topics: Adrenergic beta-Antagonists; Aged; Biomarkers, Pharmacological; Bisoprolol; Depression, Chemical; Dr | 2010 |
Poor tolerance of beta-blockers by elderly patients with heart failure.
Topics: Adrenergic beta-Antagonists; Aged, 80 and over; Angiotensin Receptor Antagonists; Aortic Valve Steno | 2010 |
[Chronic heart failure--speciale of treatment].
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Bisoprolol; Chronic Disease; Drug Therapy, Combination | 2011 |
Carvedilol for the treatment of benign prostatic hypertrophy in patients with heart failure?
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Carbazoles; Carvedilol; Heart Failure; Humans; Male; | 2011 |
Bisoprolol delays progression towards right heart failure in experimental pulmonary hypertension.
Topics: Adrenergic beta-1 Receptor Antagonists; Animals; Antihypertensive Agents; Bisoprolol; Disease Models | 2012 |
Beneficial effects of beta-blockers on left ventricular function and cellular energy reserve in patients with heart failure.
Topics: Adenosine Triphosphate; Adrenergic beta-Antagonists; Aged; Bisoprolol; Carbazoles; Carvedilol; Echoc | 2013 |
Blockade of β-adrenoceptors restores the GRK2-mediated adrenal α(2) -adrenoceptor-catecholamine production axis in heart failure.
Topics: Adrenal Glands; Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Animals; Bisopr | 2012 |
Lung anabolic activity in patients with chronic heart failure: potential implications for clinical practice.
Topics: Adrenergic beta-1 Receptor Antagonists; Airway Remodeling; Amino Acids; Arteries; Bisoprolol; Chroni | 2012 |
[COPD patients with heart failure: no concern about the beta blocker!].
Topics: Adrenergic Agents; Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Comorbidity; Con | 2012 |
Regulation of cyclic adenosine monophosphate release by selective β2-adrenergic receptor stimulation in human terminal failing myocardium before and after ventricular assist device support.
Topics: Adenylyl Cyclases; Adolescent; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Adult; Aged; B | 2012 |
Pregnancy and treatment outcome in a patient with left ventricular non-compaction.
Topics: Adult; Antihypertensive Agents; Bisoprolol; Diuretics; Drug Therapy, Combination; Echocardiography; | 2013 |
[Heart failure. Only every fifth patient is properly treated?].
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Bisoprolol; Drug Therapy, Combination; Germany | 2002 |
Current research on carvedilol in heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; | 2002 |
[Beta blockers in heart failure. Start with low and slowly increase the dosage!].
Topics: Adrenergic beta-Antagonists; Bisoprolol; Clinical Trials as Topic; Drug Administration Schedule; Hea | 2002 |
Beta blockers in older persons with heart failure: tolerability and impact on quality of life.
Topics: Adrenergic beta-Agonists; Aged; Aged, 80 and over; Bisoprolol; Blood Pressure; Cohort Studies; Dose- | 2002 |
Beta-blockers work as well in women as in men.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Bisoprolol; Clinical Trials as Topic; Female; Heart Failur | 2002 |
[Heart failure studies are transferrable to everyday practice. No fear of beta blockers!].
Topics: Adrenergic beta-Antagonists; Bisoprolol; Clinical Trials as Topic; Heart Failure; Heart Rate; Humans | 2002 |
[Adaptation of guidelines for the treatment of chronic heart failure in a specialized heart failure clinic].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2002 |
beta-blockers in heart failure--much more than heart rate reduction.
Topics: Adrenergic beta-Antagonists; Basal Metabolism; Bisoprolol; Carbazoles; Carvedilol; Heart Failure; He | 2002 |
[Every 2nd heart failure patient without beta blocker. "Intolerance" is often a dosage error].
Topics: Adrenergic beta-Antagonists; Bisoprolol; Dose-Response Relationship, Drug; Drug Administration Sched | 2003 |
Anti-oxidative properties of beta-blockers and angiotensin-converting enzyme inhibitors in congestive heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Bisoprolol; | 2003 |
Neither carvedilol nor bisoprolol in maximally tolerated doses has any specific advantage in lowering chronic heart failure oxidant stress: implications for beta-blocker selection.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Biomarkers; Bisoprolol; Carbazoles; Car | 2003 |
[NMR shows how beta blockers change the failing ventricle. Decreased size and better output performance].
Topics: Adrenergic beta-Antagonists; Bisoprolol; Cardiac Volume; Heart Failure; Humans; Magnetic Resonance S | 2003 |
[The use of cardioselective beta-adrenoblocker bisoprolol in patients with chronic heart failure].
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents | 2003 |
[Use of bisoprolol in heart failure. The BISOCOR observational study].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Female; Heart Failure; Huma | 2003 |
Amiodarone-associated "torsade de pointes". Relevance of concomitant cardiovascular medication in a patient with atrial fibrillation and structural heart disease.
Topics: Acetyldigoxins; Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibril | 2003 |
[Longevity promoting beta blocker. Soon in 1st place in heart failure?].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Bisoprolol; Cause of Death; C | 2003 |
[For the first time beta blockers are in direct comparison With carvedilol weak hearts beat longer].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Doubl | 2003 |
[Beta blocker in heart failure. A little is better than nothing].
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Bisoprolol; Dose-Response Relationship, Drug; | 2003 |
In heart failure, all beta-blockers are not necessarily equal.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Clinical Trials as Topic; Cost-Bene | 2003 |
Beta-blocker efficacy according to heart rate and rhythm in patients with heart failure. Commentary on the Cardiac Insufficiency Bisoprolol Study II analysis.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Heart Conduction System; Heart Failure; Heart Rate; Humans; | 2003 |
Which beta-blocker for heart failure?
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Contraindications; Coronary Disease | 2004 |
"Bisoprolol dose-response relationship in patients with congestive heart failure: a subgroup analysis in the cardiac insufficiency bisoprolol study(CIBIS II)," by Simon T.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Dose-Response Relationship, Drug; Heart Failure; Humans; Tr | 2004 |
Do pharmacological differences among beta-blockers affect their clinical efficacy in heart failure?
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; | 2004 |
[Effect of beta-Blocker Bisoprolol on Function of Hibernating Myocardium in Patients With Chronic Heart Failure of Ischemic Etiology].
Topics: Adrenergic beta-Antagonists; Bisoprolol; Heart Failure; Humans; Myocardium; Quality of Life | 2004 |
Effect of noradrenaline and isoproterenol on lipopolysaccharide-induced tumor necrosis factor-alpha production in whole blood from patients with chronic heart failure and the role of beta-adrenergic receptors.
Topics: Adrenergic beta-Antagonists; Adult; Bisoprolol; Cardiovascular Agents; Female; Heart Failure; Humans | 2005 |
Skeletal muscle myofibrillar protein oxidation in heart failure and the protective effect of Carvedilol.
Topics: Adrenergic beta-Antagonists; Animals; Antioxidants; Bisoprolol; Carbazoles; Carvedilol; Heart Failur | 2005 |
Association between beta-1 and beta-2 adrenergic receptor gene polymorphisms and the response to beta-blockade in patients with stable congestive heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Alleles; Angiography; Bisoprolol; Carbazoles; Carvedilol; Codon; | 2005 |
Effects of bisoprolol treatment for chronic heart failure initiated and followed up by primary care physicians.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Blood Pressure; | 2005 |
The effects of long-term beta-blockade on the ventilatory responses to exercise in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Carbazoles; Carvedilol; Exercise Test; Heart Failure; | 2005 |
Beta-blocker treatment before angiotensin-converting enzyme inhibitor therapy in newly diagnosed heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Bisoprolol; Carbazoles; Carve | 2005 |
Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2005 |
[Beginning therapy of heart failure with beta blockers. Do these patients survive longer?].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Bisoprolol; Death, Sudden, Ca | 2005 |
Comment on "Clinical trials update from the European Society of Cardiology meeting 2005: CIBIS-III, by JGF Cleland and others".
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Bisoprolol; Enalapril; Heart | 2006 |
Clinical trials update from the European Society of Cardiology Meeting 2005: CIBIS-III. Response to correspondence from R. Willenheimer et al.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Bisoprolol; Enalapril; Heart | 2006 |
Cost-effectiveness analysis of bisoprolol treatment for heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Cost-Benefit Analysis; Heart Failure; Humans | 2005 |
[Use of betablockers in elderly patients with congestive heart failure].
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aged, 80 and over; Antihypertensive Agents; Bisoprol | 2006 |
Attenuation of oxidative stress and cardiac dysfunction by bisoprolol in an animal model of dilated cardiomyopathy.
Topics: Aldehydes; Animals; Antioxidants; Bisoprolol; Blood Pressure; Body Weight; Cardiomyopathy, Dilated; | 2006 |
[Beta1-adrenergic receptor (Arg389Gly) polymorphism and response to bisoprolol in patients with chronic heart failure].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Case-Control Studies; Femal | 2006 |
[Risk reduction of acute heart failure with initial administration of beta-blockers].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Bisoprolol; Enalapril; Heart | 2007 |
Effects of bisoprolol on cardiac function and exercise in patients with heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Bisoprolol; Ergometry; Exercise; Female; Follow-Up Studies; Hear | 2007 |
Paediatric heart failure trials...and tribulations.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Child; Exercise Tolerance; Heart Failure; Humans; Natriuret | 2007 |
Bisoprolol inhibits sodium current in ventricular myocytes of rats with diastolic heart failure.
Topics: Animals; Anti-Arrhythmia Agents; Aorta, Abdominal; Aortic Coarctation; Arrhythmias, Cardiac; Bisopro | 2007 |
Changing beta-blockers in heart failure: when is a class not a class?
Topics: Adrenergic beta-Antagonists; Atenolol; Bisoprolol; Carbazoles; Carvedilol; Heart; Heart Failure; Hum | 2008 |
[Reports from large clinical trials CIBIS. Effects of beta blockade by bisoprolol on mortality in heart failure].
Topics: Bisoprolol; Heart Failure; Humans; Survival Rate | 1993 |
[Clinical effects of bisoprolol in congestive heart failure due to dilated cardiomyopathy].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Bisoprolol; Cardiomyopathy, Dilated; Depression, Chemical; | 1995 |
[Info-congress. Bisoprolol in congestive heart failure].
Topics: Adrenergic beta-Antagonists; Bisoprolol; Heart Failure; Humans; Multicenter Studies as Topic; Random | 1998 |
Beta-blockers given the go-ahead for treatment of heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Heart Failure; Humans | 1998 |
[Drugs prescribed for chronic heart failure. Current data on their effectiveness].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biso | 1998 |
Beta-blockers for mild to moderate heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Animals; Bisoprolol; Heart Failure; Humans; Ra | 1999 |
In vitro and in vivo characterization of intrinsic sympathomimetic activity in normal and heart failure rats.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animals; Animals, Newborn; Bisoprolol; Carbaz | 1999 |
Economic evaluation of the Cardiac Insufficiency Bisoprolol Study for the Federal Republic of Germany.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Costs and Cost Analysis; Germany; Heart Failure; Humans | 1998 |
Different effects of bisoprolol on heart rate in patients with ischemic or idiopathic dilated cardiomyopathy (a 24-hour Holter substudy of the Cardiac Insufficiency Bisoprolol Study [CIBIS]).
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Bisoprolol; Cardiomyopathy, Dilated; Circadian | 1999 |
The Cardiac Insufficiency Bisoprolol Study II.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Coronary Disease; Heart Failure; Humans | 1999 |
The Cardiac Insufficiency Bisoprolol Study II.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Death, Sudden, Cardiac; Heart Failure; Humans | 1999 |
[Practical advice on the treatment of cardiac insufficiency with beta-blockers. Announcement by the Italian Association of Hospital-based Cardiologists].
Topics: Adrenergic beta-Antagonists; Bisoprolol; Cardiac Output, Low; Drug Administration Schedule; Heart Fa | 1999 |
Pharmacological treatment of systolic heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Heart Failure; Humans; Metoprolol; Research Design | 1999 |
Recent clinical data regarding the use of beta blockers in heart failure: focus on CIBIS II.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Female; Heart Failure; Hospitalization; Humans; Male; Middl | 1999 |
Possible mechanisms of action in the positive effect of beta blockers in heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Death, Sudden, Cardiac; Heart Failure; Humans; Myocardial I | 1999 |
Health economics of heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; France; Germany; Health Care Costs; Heart Failure; Humans; | 1999 |
[The role of beta-adrenergic blocking agents in treatment of heart failure].
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; | 1999 |
Bisoprolol in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2000 |
Myocardial integrated ultrasonic backscatter in patients with dilated cardiomyopathy: prediction of response to beta-blocker therapy.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Biopsy; Bisoprolol; Cardiomyopathy, Dilated; Echocardiogra | 2000 |
[New milestones in the therapy of chronic heart failure with beta blockers].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Bisoprolol; Carbazoles; Cardi | 2000 |
Bisoprolol in heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Bisoprolol; Heart Failu | 2000 |
Beta-blockers for heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Bradycardia; Carbazoles; Carvedilol; Heart Failure; Humans; | 2000 |
[Beta-blockers in the treatment of chronic heart failure. How should results of clinical studies be introduced into clinical practice].
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; | 2000 |
[CIBIS-II Study. Bisoprolol in patients with chronic heart failure].
Topics: Bisoprolol; Chronic Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administrat | 2000 |
[A must in symptomatic heart failure. Added beta blocker improves prognosis].
Topics: Adrenergic beta-Antagonists; Bisoprolol; Drug Therapy, Combination; Heart Failure; Hemodynamics; Hum | 2001 |
[New indications for beta blockers. Cave hypertension focus/heart failure].
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; D | 2000 |
A cost-effectiveness analysis of bisoprolol for heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Cost-Benefit Analysis; Follow-Up St | 2001 |
Reduced costs with bisoprolol treatment for heart failure: an economic analysis of the second Cardiac Insufficiency Bisoprolol Study (CIBIS-II).
Topics: Adrenergic beta-Antagonists; Bisoprolol; Chemotherapy, Adjuvant; Cost-Benefit Analysis; France; Germ | 2001 |
Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Age Distribution; Aged; Aged, 80 and over; Bisoprolol; Cause of Death; | 2001 |
Cost effectiveness of bisoprolol in the treatment of chronic congestive heart failure in Sweden: analysis using data from the Cardiac Insufficiency Bisoprolol Study II trial.
Topics: Aged; Antihypertensive Agents; Bisoprolol; Cost-Benefit Analysis; Health Care Costs; Heart Failure; | 2001 |
Bisoprolol improves survival in rats with heart failure.
Topics: Adrenergic beta-Antagonists; Animals; Bisoprolol; Body Weight; Fibrosis; Heart Failure; Hemodynamics | 2001 |
Can beta blockers be safely initiated at home in patients with heart failure?
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Bisoprolol; Community Health Services; England | 2002 |
[Cost-effectiveness of bisoprolol in chronic heart failure].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Bisoprolol; Controlled Clinical Trials as Topic; Cost of I | 2002 |
Unique effects of carvedilol on noradrenaline release in the human heart.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; H | 2002 |
Cardioprotective and antiarrhythmic effects of beta-blockers, propranolol, bisoprolol, and nipradilol in a canine model of regional ischemia.
Topics: Acetylglucosaminidase; Adrenergic beta-Antagonists; Animals; Arrhythmias, Cardiac; Bisoprolol; Coron | 1989 |